| Cholesterol biosynthesis |
23 |
1.70e-10 |
3.84e-09 |
0.8080 |
NA |
0.805000 |
-0.070100 |
2.30e-11 |
5.61e-01 |
| Unwinding of DNA |
12 |
2.54e-05 |
2.14e-04 |
0.7660 |
NA |
0.727000 |
0.241000 |
1.31e-05 |
1.48e-01 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol |
13 |
3.85e-05 |
2.99e-04 |
0.7210 |
NA |
-0.226000 |
-0.684000 |
1.57e-01 |
1.93e-05 |
| Initial triggering of complement |
13 |
7.58e-05 |
5.33e-04 |
0.7000 |
NA |
0.517000 |
-0.471000 |
1.24e-03 |
3.30e-03 |
| Regulation of Complement cascade |
30 |
1.14e-09 |
2.37e-08 |
0.6780 |
NA |
0.553000 |
-0.392000 |
1.54e-07 |
2.01e-04 |
| Voltage gated Potassium channels |
14 |
1.01e-04 |
6.83e-04 |
0.6630 |
NA |
-0.109000 |
0.654000 |
4.78e-01 |
2.29e-05 |
| Adenylate cyclase inhibitory pathway |
11 |
7.98e-04 |
3.72e-03 |
0.6580 |
NA |
-0.020000 |
0.657000 |
9.08e-01 |
1.59e-04 |
| Calnexin/calreticulin cycle |
26 |
9.81e-08 |
1.44e-06 |
0.6430 |
NA |
-0.640000 |
-0.067600 |
1.64e-08 |
5.51e-01 |
| Insulin receptor recycling |
23 |
1.32e-06 |
1.71e-05 |
0.6280 |
NA |
-0.515000 |
0.360000 |
1.90e-05 |
2.83e-03 |
| ER Quality Control Compartment (ERQC) |
21 |
4.99e-06 |
5.49e-05 |
0.6230 |
NA |
-0.623000 |
0.015800 |
7.81e-07 |
9.00e-01 |
| DNA strand elongation |
32 |
9.14e-09 |
1.56e-07 |
0.6200 |
NA |
0.566000 |
0.254000 |
3.05e-08 |
1.29e-02 |
| Removal of the Flap Intermediate |
14 |
3.01e-04 |
1.72e-03 |
0.6200 |
NA |
0.512000 |
0.349000 |
9.09e-04 |
2.36e-02 |
| Folding of actin by CCT/TriC |
10 |
3.16e-03 |
1.14e-02 |
0.6180 |
NA |
-0.564000 |
-0.254000 |
2.01e-03 |
1.65e-01 |
| Regulation of TLR by endogenous ligand |
13 |
6.35e-04 |
3.09e-03 |
0.6150 |
NA |
0.608000 |
-0.095300 |
1.48e-04 |
5.52e-01 |
| Processive synthesis on the lagging strand |
15 |
2.38e-04 |
1.39e-03 |
0.6080 |
NA |
0.531000 |
0.297000 |
3.74e-04 |
4.67e-02 |
| Leading Strand Synthesis |
14 |
5.09e-04 |
2.60e-03 |
0.6000 |
NA |
0.512000 |
0.313000 |
9.14e-04 |
4.29e-02 |
| Polymerase switching |
14 |
5.09e-04 |
2.60e-03 |
0.6000 |
NA |
0.512000 |
0.313000 |
9.14e-04 |
4.29e-02 |
| Polymerase switching on the C-strand of the telomere |
14 |
5.09e-04 |
2.60e-03 |
0.6000 |
NA |
0.512000 |
0.313000 |
9.14e-04 |
4.29e-02 |
| Complement cascade |
36 |
4.92e-09 |
8.76e-08 |
0.5970 |
NA |
0.462000 |
-0.379000 |
1.65e-06 |
8.37e-05 |
| MET activates RAS signaling |
10 |
5.47e-03 |
1.72e-02 |
0.5910 |
NA |
-0.532000 |
0.257000 |
3.61e-03 |
1.59e-01 |
| Effects of PIP2 hydrolysis |
21 |
1.84e-05 |
1.60e-04 |
0.5900 |
NA |
-0.251000 |
0.534000 |
4.65e-02 |
2.29e-05 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle |
35 |
2.07e-08 |
3.36e-07 |
0.5800 |
NA |
-0.575000 |
-0.080900 |
3.96e-09 |
4.08e-01 |
| ROS and RNS production in phagocytes |
26 |
3.19e-06 |
3.74e-05 |
0.5710 |
NA |
-0.395000 |
0.413000 |
4.89e-04 |
2.68e-04 |
| SRP-dependent cotranslational protein targeting to membrane |
108 |
5.71e-23 |
7.22e-21 |
0.5620 |
NA |
-0.478000 |
-0.295000 |
8.76e-18 |
1.19e-07 |
| Ribosomal scanning and start codon recognition |
57 |
4.01e-12 |
1.15e-10 |
0.5530 |
NA |
-0.412000 |
-0.369000 |
7.45e-08 |
1.45e-06 |
| Regulation of signaling by CBL |
13 |
2.83e-03 |
1.05e-02 |
0.5500 |
NA |
-0.496000 |
0.238000 |
1.96e-03 |
1.38e-01 |
| Translation initiation complex formation |
57 |
1.18e-11 |
3.32e-10 |
0.5420 |
NA |
-0.406000 |
-0.359000 |
1.17e-07 |
2.81e-06 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) |
25 |
1.81e-05 |
1.59e-04 |
0.5390 |
NA |
0.528000 |
0.108000 |
4.80e-06 |
3.50e-01 |
| Diseases associated with N-glycosylation of proteins |
17 |
5.93e-04 |
2.96e-03 |
0.5390 |
NA |
-0.267000 |
-0.468000 |
5.67e-02 |
8.37e-04 |
| Lagging Strand Synthesis |
20 |
1.74e-04 |
1.07e-03 |
0.5360 |
NA |
0.468000 |
0.261000 |
2.89e-04 |
4.30e-02 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S |
58 |
1.29e-11 |
3.55e-10 |
0.5360 |
NA |
-0.389000 |
-0.369000 |
3.10e-07 |
1.15e-06 |
| Uptake and function of anthrax toxins |
11 |
8.91e-03 |
2.56e-02 |
0.5350 |
NA |
-0.532000 |
0.055800 |
2.23e-03 |
7.49e-01 |
| Formation of the ternary complex, and subsequently, the 43S complex |
50 |
4.34e-10 |
9.30e-09 |
0.5350 |
NA |
-0.424000 |
-0.327000 |
2.15e-07 |
6.41e-05 |
| ATF6 (ATF6-alpha) activates chaperone genes |
10 |
1.34e-02 |
3.47e-02 |
0.5350 |
NA |
-0.478000 |
-0.240000 |
8.80e-03 |
1.89e-01 |
| L13a-mediated translational silencing of Ceruloplasmin expression |
108 |
8.64e-21 |
7.80e-19 |
0.5340 |
NA |
-0.401000 |
-0.352000 |
6.24e-13 |
2.53e-10 |
| RUNX3 regulates p14-ARF |
10 |
1.44e-02 |
3.63e-02 |
0.5330 |
NA |
-0.494000 |
0.199000 |
6.81e-03 |
2.75e-01 |
| Viral mRNA Translation |
86 |
1.19e-16 |
5.80e-15 |
0.5330 |
NA |
-0.420000 |
-0.327000 |
1.58e-11 |
1.62e-07 |
| Peptide chain elongation |
86 |
1.25e-16 |
5.88e-15 |
0.5320 |
NA |
-0.418000 |
-0.329000 |
2.05e-11 |
1.31e-07 |
| GTP hydrolysis and joining of the 60S ribosomal subunit |
109 |
7.40e-21 |
7.20e-19 |
0.5320 |
NA |
-0.397000 |
-0.354000 |
7.93e-13 |
1.70e-10 |
| Cytosolic tRNA aminoacylation |
24 |
3.77e-05 |
2.96e-04 |
0.5310 |
NA |
-0.283000 |
-0.449000 |
1.66e-02 |
1.38e-04 |
| Eukaryotic Translation Elongation |
90 |
3.35e-17 |
1.76e-15 |
0.5300 |
NA |
-0.422000 |
-0.320000 |
4.38e-12 |
1.61e-07 |
| Ephrin signaling |
18 |
5.63e-04 |
2.84e-03 |
0.5280 |
NA |
-0.208000 |
0.485000 |
1.27e-01 |
3.67e-04 |
| Resolution of D-loop Structures through Holliday Junction Intermediates |
30 |
3.67e-06 |
4.26e-05 |
0.5270 |
NA |
0.525000 |
0.045700 |
6.30e-07 |
6.65e-01 |
| IRE1alpha activates chaperones |
49 |
1.42e-09 |
2.91e-08 |
0.5270 |
NA |
-0.526000 |
0.034100 |
1.87e-10 |
6.79e-01 |
| Formation of a pool of free 40S subunits |
98 |
1.96e-18 |
1.18e-16 |
0.5260 |
NA |
-0.403000 |
-0.338000 |
5.34e-12 |
7.25e-09 |
| Interaction between L1 and Ankyrins |
21 |
1.72e-04 |
1.07e-03 |
0.5250 |
NA |
0.001030 |
0.525000 |
9.93e-01 |
3.13e-05 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) |
91 |
7.55e-17 |
3.82e-15 |
0.5210 |
NA |
-0.416000 |
-0.314000 |
7.06e-12 |
2.29e-07 |
| Collagen chain trimerization |
18 |
6.47e-04 |
3.10e-03 |
0.5210 |
NA |
0.500000 |
0.146000 |
2.40e-04 |
2.82e-01 |
| Cap-dependent Translation Initiation |
116 |
4.08e-21 |
4.30e-19 |
0.5190 |
NA |
-0.379000 |
-0.354000 |
1.70e-12 |
4.32e-11 |
| Eukaryotic Translation Initiation |
116 |
4.08e-21 |
4.30e-19 |
0.5190 |
NA |
-0.379000 |
-0.354000 |
1.70e-12 |
4.32e-11 |
| AKT phosphorylates targets in the cytosol |
14 |
3.48e-03 |
1.24e-02 |
0.5190 |
NA |
-0.509000 |
-0.102000 |
9.83e-04 |
5.07e-01 |
| HDMs demethylate histones |
22 |
1.64e-04 |
1.02e-03 |
0.5130 |
NA |
-0.406000 |
-0.314000 |
9.92e-04 |
1.08e-02 |
| Generation of second messenger molecules |
15 |
2.93e-03 |
1.09e-02 |
0.5110 |
NA |
-0.272000 |
0.432000 |
6.87e-02 |
3.74e-03 |
| Selenocysteine synthesis |
90 |
5.33e-16 |
2.25e-14 |
0.5100 |
NA |
-0.391000 |
-0.328000 |
1.47e-10 |
7.93e-08 |
| Biotin transport and metabolism |
11 |
1.36e-02 |
3.50e-02 |
0.5090 |
NA |
-0.243000 |
-0.447000 |
1.62e-01 |
1.02e-02 |
| ATF6 (ATF6-alpha) activates chaperones |
12 |
9.34e-03 |
2.60e-02 |
0.5090 |
NA |
-0.433000 |
-0.266000 |
9.38e-03 |
1.10e-01 |
| XBP1(S) activates chaperone genes |
47 |
1.37e-08 |
2.31e-07 |
0.5070 |
NA |
-0.506000 |
0.032600 |
1.89e-09 |
6.99e-01 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS |
14 |
4.62e-03 |
1.53e-02 |
0.5050 |
NA |
0.283000 |
0.418000 |
6.67e-02 |
6.75e-03 |
| Defective EXT2 causes exostoses 2 |
14 |
4.62e-03 |
1.53e-02 |
0.5050 |
NA |
0.283000 |
0.418000 |
6.67e-02 |
6.75e-03 |
| NCAM1 interactions |
21 |
3.19e-04 |
1.80e-03 |
0.5050 |
NA |
0.202000 |
0.463000 |
1.10e-01 |
2.41e-04 |
| Advanced glycosylation endproduct receptor signaling |
10 |
2.16e-02 |
5.03e-02 |
0.5050 |
NA |
-0.448000 |
-0.231000 |
1.41e-02 |
2.05e-01 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) |
111 |
3.94e-19 |
2.77e-17 |
0.5040 |
NA |
-0.375000 |
-0.337000 |
8.36e-12 |
9.05e-10 |
| Nonsense-Mediated Decay (NMD) |
111 |
3.94e-19 |
2.77e-17 |
0.5040 |
NA |
-0.375000 |
-0.337000 |
8.36e-12 |
9.05e-10 |
| Eukaryotic Translation Termination |
89 |
2.02e-15 |
7.29e-14 |
0.5030 |
NA |
-0.398000 |
-0.307000 |
8.27e-11 |
5.54e-07 |
| Cell-extracellular matrix interactions |
13 |
7.47e-03 |
2.22e-02 |
0.5020 |
NA |
-0.442000 |
0.239000 |
5.79e-03 |
1.36e-01 |
| Removal of the Flap Intermediate from the C-strand |
10 |
2.35e-02 |
5.32e-02 |
0.4990 |
NA |
0.384000 |
0.318000 |
3.54e-02 |
8.15e-02 |
| Common Pathway of Fibrin Clot Formation |
16 |
2.83e-03 |
1.05e-02 |
0.4960 |
NA |
0.345000 |
-0.356000 |
1.68e-02 |
1.37e-02 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants |
15 |
4.17e-03 |
1.40e-02 |
0.4950 |
NA |
-0.297000 |
0.396000 |
4.62e-02 |
7.96e-03 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer |
15 |
4.17e-03 |
1.40e-02 |
0.4950 |
NA |
-0.297000 |
0.396000 |
4.62e-02 |
7.96e-03 |
| Resolution of D-Loop Structures |
31 |
1.13e-05 |
1.10e-04 |
0.4950 |
NA |
0.492000 |
0.051500 |
2.09e-06 |
6.20e-01 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation |
16 |
2.79e-03 |
1.05e-02 |
0.4940 |
NA |
-0.457000 |
-0.187000 |
1.54e-03 |
1.95e-01 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane |
22 |
3.19e-04 |
1.80e-03 |
0.4940 |
NA |
-0.494000 |
0.027100 |
6.14e-05 |
8.26e-01 |
| SHC-mediated cascade:FGFR1 |
10 |
2.74e-02 |
5.97e-02 |
0.4910 |
NA |
-0.371000 |
0.322000 |
4.20e-02 |
7.83e-02 |
| Processive synthesis on the C-strand of the telomere |
11 |
1.90e-02 |
4.50e-02 |
0.4890 |
NA |
0.421000 |
0.249000 |
1.56e-02 |
1.53e-01 |
| Striated Muscle Contraction |
22 |
3.64e-04 |
2.00e-03 |
0.4890 |
NA |
0.296000 |
0.389000 |
1.62e-02 |
1.59e-03 |
| NF-kB is activated and signals survival |
12 |
1.34e-02 |
3.47e-02 |
0.4880 |
NA |
-0.431000 |
-0.230000 |
9.80e-03 |
1.67e-01 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 |
11 |
2.00e-02 |
4.70e-02 |
0.4880 |
NA |
-0.406000 |
0.271000 |
1.97e-02 |
1.20e-01 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) |
14 |
6.69e-03 |
2.03e-02 |
0.4870 |
NA |
0.441000 |
0.208000 |
4.28e-03 |
1.78e-01 |
| Methylation |
11 |
2.09e-02 |
4.87e-02 |
0.4860 |
NA |
0.269000 |
-0.404000 |
1.22e-01 |
2.03e-02 |
| PKA activation |
14 |
7.14e-03 |
2.13e-02 |
0.4850 |
NA |
0.016500 |
0.485000 |
9.15e-01 |
1.68e-03 |
| Defective B3GAT3 causes JDSSDHD |
19 |
1.23e-03 |
5.25e-03 |
0.4840 |
NA |
0.201000 |
0.440000 |
1.29e-01 |
8.91e-04 |
| mRNA 3’-end processing |
56 |
3.43e-09 |
6.47e-08 |
0.4820 |
NA |
-0.138000 |
-0.461000 |
7.41e-02 |
2.33e-09 |
| Phase 2 - plateau phase |
11 |
2.26e-02 |
5.22e-02 |
0.4790 |
NA |
0.044300 |
0.477000 |
7.99e-01 |
6.16e-03 |
| Homologous DNA Pairing and Strand Exchange |
40 |
1.04e-06 |
1.37e-05 |
0.4790 |
NA |
0.463000 |
0.122000 |
4.02e-07 |
1.81e-01 |
| Transferrin endocytosis and recycling |
29 |
5.28e-05 |
3.88e-04 |
0.4770 |
NA |
-0.421000 |
0.225000 |
8.70e-05 |
3.63e-02 |
| Potassium Channels |
35 |
6.74e-06 |
7.23e-05 |
0.4770 |
NA |
-0.073900 |
0.471000 |
4.49e-01 |
1.40e-06 |
| WNT ligand biogenesis and trafficking |
15 |
6.22e-03 |
1.90e-02 |
0.4760 |
NA |
-0.175000 |
0.443000 |
2.41e-01 |
2.97e-03 |
| rRNA modification in the nucleus and cytosol |
58 |
3.82e-09 |
7.01e-08 |
0.4720 |
NA |
-0.234000 |
-0.410000 |
2.09e-03 |
6.87e-08 |
| SHC-mediated cascade:FGFR2 |
10 |
3.65e-02 |
7.52e-02 |
0.4710 |
NA |
-0.190000 |
0.431000 |
2.98e-01 |
1.83e-02 |
| Nucleobase biosynthesis |
15 |
7.74e-03 |
2.29e-02 |
0.4660 |
NA |
0.249000 |
-0.394000 |
9.54e-02 |
8.20e-03 |
| DAP12 signaling |
19 |
2.17e-03 |
8.58e-03 |
0.4650 |
NA |
-0.356000 |
0.300000 |
7.25e-03 |
2.37e-02 |
| Selenoamino acid metabolism |
112 |
1.89e-16 |
8.52e-15 |
0.4640 |
NA |
-0.324000 |
-0.332000 |
3.15e-09 |
1.27e-09 |
| Defective B4GALT7 causes EDS, progeroid type |
19 |
2.11e-03 |
8.39e-03 |
0.4640 |
NA |
0.247000 |
0.393000 |
6.20e-02 |
3.05e-03 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation |
10 |
3.99e-02 |
8.07e-02 |
0.4630 |
NA |
-0.062000 |
-0.459000 |
7.34e-01 |
1.19e-02 |
| Formation of Fibrin Clot (Clotting Cascade) |
29 |
9.91e-05 |
6.74e-04 |
0.4620 |
NA |
0.381000 |
-0.261000 |
3.87e-04 |
1.49e-02 |
| Activation of GABAB receptors |
22 |
9.13e-04 |
4.10e-03 |
0.4610 |
NA |
-0.007260 |
0.461000 |
9.53e-01 |
1.83e-04 |
| GABA B receptor activation |
22 |
9.13e-04 |
4.10e-03 |
0.4610 |
NA |
-0.007260 |
0.461000 |
9.53e-01 |
1.83e-04 |
| CASP8 activity is inhibited |
10 |
4.16e-02 |
8.31e-02 |
0.4600 |
NA |
-0.043600 |
-0.458000 |
8.11e-01 |
1.21e-02 |
| Dimerization of procaspase-8 |
10 |
4.16e-02 |
8.31e-02 |
0.4600 |
NA |
-0.043600 |
-0.458000 |
8.11e-01 |
1.21e-02 |
| Regulation by c-FLIP |
10 |
4.16e-02 |
8.31e-02 |
0.4600 |
NA |
-0.043600 |
-0.458000 |
8.11e-01 |
1.21e-02 |
| Presynaptic phase of homologous DNA pairing and strand exchange |
37 |
8.10e-06 |
8.40e-05 |
0.4590 |
NA |
0.436000 |
0.143000 |
4.36e-06 |
1.32e-01 |
| Defects in cobalamin (B12) metabolism |
12 |
2.35e-02 |
5.32e-02 |
0.4580 |
NA |
0.269000 |
-0.370000 |
1.06e-01 |
2.63e-02 |
| rRNA processing in the nucleus and cytosol |
186 |
4.71e-26 |
1.19e-23 |
0.4580 |
NA |
-0.285000 |
-0.358000 |
2.10e-11 |
3.65e-17 |
| Other semaphorin interactions |
12 |
2.41e-02 |
5.41e-02 |
0.4560 |
NA |
-0.116000 |
0.441000 |
4.87e-01 |
8.22e-03 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) |
14 |
1.32e-02 |
3.44e-02 |
0.4530 |
NA |
0.437000 |
0.122000 |
4.67e-03 |
4.29e-01 |
| Metabolism of folate and pterines |
15 |
9.78e-03 |
2.71e-02 |
0.4530 |
NA |
-0.130000 |
-0.434000 |
3.82e-01 |
3.62e-03 |
| The activation of arylsulfatases |
10 |
4.61e-02 |
9.02e-02 |
0.4530 |
NA |
-0.059000 |
-0.449000 |
7.47e-01 |
1.40e-02 |
| Regulation of PTEN mRNA translation |
12 |
2.50e-02 |
5.52e-02 |
0.4520 |
NA |
-0.131000 |
-0.433000 |
4.32e-01 |
9.43e-03 |
| Intraflagellar transport |
37 |
1.14e-05 |
1.10e-04 |
0.4520 |
NA |
0.281000 |
0.354000 |
3.11e-03 |
1.93e-04 |
| Defects in vitamin and cofactor metabolism |
20 |
2.20e-03 |
8.65e-03 |
0.4520 |
NA |
0.011000 |
-0.452000 |
9.32e-01 |
4.68e-04 |
| Mitochondrial tRNA aminoacylation |
21 |
1.66e-03 |
6.75e-03 |
0.4520 |
NA |
0.184000 |
-0.413000 |
1.45e-01 |
1.06e-03 |
| mRNA Splicing - Major Pathway |
174 |
8.93e-24 |
1.41e-21 |
0.4520 |
NA |
-0.203000 |
-0.404000 |
4.10e-06 |
4.12e-20 |
| Major pathway of rRNA processing in the nucleolus and cytosol |
176 |
5.91e-24 |
1.07e-21 |
0.4510 |
NA |
-0.288000 |
-0.347000 |
4.58e-11 |
2.19e-15 |
| SHC-mediated cascade:FGFR4 |
10 |
5.07e-02 |
9.76e-02 |
0.4470 |
NA |
-0.391000 |
0.216000 |
3.21e-02 |
2.37e-01 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol |
21 |
1.86e-03 |
7.46e-03 |
0.4460 |
NA |
-0.101000 |
-0.435000 |
4.23e-01 |
5.62e-04 |
| GABA receptor activation |
26 |
4.35e-04 |
2.28e-03 |
0.4460 |
NA |
0.052000 |
0.442000 |
6.47e-01 |
9.41e-05 |
| Long-term potentiation |
18 |
4.92e-03 |
1.61e-02 |
0.4430 |
NA |
0.224000 |
0.382000 |
1.00e-01 |
5.00e-03 |
| CLEC7A (Dectin-1) induces NFAT activation |
11 |
4.01e-02 |
8.09e-02 |
0.4430 |
NA |
-0.198000 |
0.396000 |
2.55e-01 |
2.30e-02 |
| Tie2 Signaling |
13 |
2.23e-02 |
5.15e-02 |
0.4420 |
NA |
-0.426000 |
0.120000 |
7.87e-03 |
4.54e-01 |
| Inactivation of APC/C via direct inhibition of the APC/C complex |
20 |
2.97e-03 |
1.09e-02 |
0.4420 |
NA |
0.323000 |
-0.302000 |
1.25e-02 |
1.94e-02 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components |
20 |
2.97e-03 |
1.09e-02 |
0.4420 |
NA |
0.323000 |
-0.302000 |
1.25e-02 |
1.94e-02 |
| G-protein mediated events |
40 |
9.18e-06 |
9.29e-05 |
0.4410 |
NA |
-0.106000 |
0.428000 |
2.47e-01 |
2.85e-06 |
| Translation |
286 |
1.52e-36 |
8.99e-34 |
0.4400 |
NA |
-0.273000 |
-0.345000 |
2.13e-15 |
1.04e-23 |
| PLC beta mediated events |
39 |
1.28e-05 |
1.22e-04 |
0.4400 |
NA |
-0.123000 |
0.422000 |
1.84e-01 |
5.02e-06 |
| Scavenging by Class A Receptors |
11 |
4.08e-02 |
8.21e-02 |
0.4400 |
NA |
-0.415000 |
-0.144000 |
1.71e-02 |
4.08e-01 |
| mRNA Splicing |
183 |
1.47e-23 |
2.06e-21 |
0.4380 |
NA |
-0.198000 |
-0.391000 |
3.89e-06 |
7.16e-20 |
| Cargo concentration in the ER |
29 |
2.56e-04 |
1.49e-03 |
0.4370 |
NA |
-0.426000 |
0.094600 |
7.04e-05 |
3.78e-01 |
| Activation of ATR in response to replication stress |
36 |
3.29e-05 |
2.69e-04 |
0.4370 |
NA |
0.396000 |
0.184000 |
3.91e-05 |
5.65e-02 |
| G alpha (z) signalling events |
32 |
1.16e-04 |
7.64e-04 |
0.4350 |
NA |
-0.100000 |
0.424000 |
3.26e-01 |
3.36e-05 |
| RIP-mediated NFkB activation via ZBP1 |
15 |
1.40e-02 |
3.58e-02 |
0.4350 |
NA |
-0.414000 |
-0.132000 |
5.47e-03 |
3.75e-01 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript |
71 |
1.81e-09 |
3.47e-08 |
0.4350 |
NA |
-0.119000 |
-0.418000 |
8.26e-02 |
1.11e-09 |
| Constitutive Signaling by EGFRvIII |
14 |
1.92e-02 |
4.54e-02 |
0.4350 |
NA |
-0.412000 |
0.139000 |
7.65e-03 |
3.66e-01 |
| Signaling by EGFRvIII in Cancer |
14 |
1.92e-02 |
4.54e-02 |
0.4350 |
NA |
-0.412000 |
0.139000 |
7.65e-03 |
3.66e-01 |
| FCERI mediated Ca+2 mobilization |
21 |
2.74e-03 |
1.04e-02 |
0.4340 |
NA |
-0.293000 |
0.320000 |
2.01e-02 |
1.11e-02 |
| Mismatch Repair |
15 |
1.43e-02 |
3.62e-02 |
0.4340 |
NA |
0.407000 |
0.150000 |
6.34e-03 |
3.14e-01 |
| Antimicrobial peptides |
16 |
1.14e-02 |
3.06e-02 |
0.4310 |
NA |
0.337000 |
0.268000 |
1.95e-02 |
6.35e-02 |
| HATs acetylate histones |
88 |
2.44e-11 |
6.42e-10 |
0.4300 |
NA |
-0.190000 |
-0.386000 |
2.05e-03 |
3.93e-10 |
| SHC1 events in EGFR signaling |
10 |
6.34e-02 |
1.14e-01 |
0.4300 |
NA |
-0.388000 |
0.185000 |
3.36e-02 |
3.11e-01 |
| TGF-beta receptor signaling activates SMADs |
32 |
1.41e-04 |
8.99e-04 |
0.4300 |
NA |
-0.417000 |
-0.101000 |
4.38e-05 |
3.21e-01 |
| Caspase activation via Death Receptors in the presence of ligand |
13 |
2.77e-02 |
6.02e-02 |
0.4290 |
NA |
-0.003120 |
-0.429000 |
9.84e-01 |
7.41e-03 |
| MAPK targets/ Nuclear events mediated by MAP kinases |
29 |
3.64e-04 |
2.00e-03 |
0.4280 |
NA |
-0.362000 |
0.228000 |
7.31e-04 |
3.39e-02 |
| Influenza Life Cycle |
140 |
2.09e-17 |
1.15e-15 |
0.4280 |
NA |
-0.327000 |
-0.276000 |
2.37e-11 |
1.81e-08 |
| Synthesis of bile acids and bile salts via 24-hydroxycholesterol |
12 |
3.66e-02 |
7.52e-02 |
0.4280 |
NA |
-0.224000 |
-0.365000 |
1.79e-01 |
2.88e-02 |
| Unfolded Protein Response (UPR) |
87 |
4.60e-11 |
1.14e-09 |
0.4280 |
NA |
-0.426000 |
-0.043000 |
6.85e-12 |
4.88e-01 |
| Phosphorylation of the APC/C |
19 |
5.65e-03 |
1.76e-02 |
0.4280 |
NA |
0.276000 |
-0.327000 |
3.75e-02 |
1.37e-02 |
| ERKs are inactivated |
13 |
2.95e-02 |
6.36e-02 |
0.4260 |
NA |
-0.406000 |
0.129000 |
1.13e-02 |
4.19e-01 |
| Vitamin B5 (pantothenate) metabolism |
16 |
1.32e-02 |
3.44e-02 |
0.4260 |
NA |
0.212000 |
-0.369000 |
1.42e-01 |
1.06e-02 |
| Phase 0 - rapid depolarisation |
25 |
1.19e-03 |
5.15e-03 |
0.4240 |
NA |
0.096800 |
0.412000 |
4.02e-01 |
3.59e-04 |
| Transport of Mature Transcript to Cytoplasm |
80 |
4.59e-10 |
9.67e-09 |
0.4240 |
NA |
-0.116000 |
-0.407000 |
7.21e-02 |
3.05e-10 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 |
19 |
5.94e-03 |
1.83e-02 |
0.4230 |
NA |
0.188000 |
0.380000 |
1.57e-01 |
4.19e-03 |
| RAF-independent MAPK1/3 activation |
21 |
3.67e-03 |
1.29e-02 |
0.4230 |
NA |
-0.312000 |
0.286000 |
1.33e-02 |
2.32e-02 |
| Mitotic Telophase/Cytokinesis |
13 |
3.08e-02 |
6.60e-02 |
0.4230 |
NA |
-0.000964 |
-0.423000 |
9.95e-01 |
8.35e-03 |
| Uptake and actions of bacterial toxins |
24 |
1.68e-03 |
6.82e-03 |
0.4220 |
NA |
-0.359000 |
0.223000 |
2.34e-03 |
5.87e-02 |
| tRNA Aminoacylation |
42 |
1.35e-05 |
1.26e-04 |
0.4220 |
NA |
-0.045400 |
-0.420000 |
6.11e-01 |
2.53e-06 |
| Negative regulation of MET activity |
18 |
8.49e-03 |
2.47e-02 |
0.4210 |
NA |
-0.370000 |
0.202000 |
6.63e-03 |
1.37e-01 |
| RNA Polymerase II Transcription Termination |
65 |
3.10e-08 |
4.90e-07 |
0.4210 |
NA |
-0.129000 |
-0.401000 |
7.30e-02 |
2.27e-08 |
| Defective B3GALTL causes Peters-plus syndrome (PpS) |
21 |
3.69e-03 |
1.29e-02 |
0.4210 |
NA |
0.177000 |
0.382000 |
1.61e-01 |
2.43e-03 |
| RORA activates gene expression |
18 |
8.19e-03 |
2.40e-02 |
0.4210 |
NA |
-0.252000 |
-0.337000 |
6.42e-02 |
1.33e-02 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants |
18 |
8.72e-03 |
2.51e-02 |
0.4200 |
NA |
-0.410000 |
0.089200 |
2.59e-03 |
5.13e-01 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer |
18 |
8.72e-03 |
2.51e-02 |
0.4200 |
NA |
-0.410000 |
0.089200 |
2.59e-03 |
5.13e-01 |
| Lysosome Vesicle Biogenesis |
32 |
2.21e-04 |
1.30e-03 |
0.4200 |
NA |
-0.408000 |
0.097600 |
6.46e-05 |
3.40e-01 |
| N-Glycan antennae elongation |
11 |
5.41e-02 |
1.03e-01 |
0.4190 |
NA |
-0.303000 |
-0.290000 |
8.18e-02 |
9.59e-02 |
| Receptor Mediated Mitophagy |
10 |
7.07e-02 |
1.23e-01 |
0.4190 |
NA |
-0.343000 |
-0.241000 |
6.05e-02 |
1.86e-01 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism |
11 |
5.65e-02 |
1.06e-01 |
0.4190 |
NA |
-0.294000 |
0.298000 |
9.09e-02 |
8.76e-02 |
| Nicotinate metabolism |
19 |
7.01e-03 |
2.12e-02 |
0.4180 |
NA |
0.189000 |
-0.373000 |
1.53e-01 |
4.89e-03 |
| RHO GTPases Activate ROCKs |
19 |
7.13e-03 |
2.13e-02 |
0.4180 |
NA |
-0.228000 |
0.350000 |
8.58e-02 |
8.22e-03 |
| Downregulation of TGF-beta receptor signaling |
26 |
1.11e-03 |
4.82e-03 |
0.4180 |
NA |
-0.409000 |
-0.086500 |
3.11e-04 |
4.45e-01 |
| Unblocking of NMDA receptors, glutamate binding and activation |
15 |
1.96e-02 |
4.61e-02 |
0.4170 |
NA |
0.185000 |
0.374000 |
2.15e-01 |
1.21e-02 |
| Influenza Infection |
151 |
9.24e-18 |
5.32e-16 |
0.4170 |
NA |
-0.333000 |
-0.250000 |
1.59e-12 |
1.20e-07 |
| Processing of Capped Intron-Containing Pre-mRNA |
233 |
8.81e-27 |
2.79e-24 |
0.4160 |
NA |
-0.170000 |
-0.379000 |
8.27e-06 |
1.95e-23 |
| O-glycosylation of TSR domain-containing proteins |
22 |
3.34e-03 |
1.19e-02 |
0.4150 |
NA |
0.165000 |
0.381000 |
1.79e-01 |
1.99e-03 |
| Regulation of TP53 Activity through Acetylation |
30 |
4.51e-04 |
2.34e-03 |
0.4130 |
NA |
-0.383000 |
-0.156000 |
2.85e-04 |
1.39e-01 |
| Influenza Viral RNA Transcription and Replication |
131 |
2.91e-15 |
9.93e-14 |
0.4130 |
NA |
-0.304000 |
-0.279000 |
1.81e-09 |
3.60e-08 |
| Role of LAT2/NTAL/LAB on calcium mobilization |
11 |
6.08e-02 |
1.12e-01 |
0.4130 |
NA |
-0.386000 |
0.148000 |
2.68e-02 |
3.97e-01 |
| rRNA processing |
218 |
8.66e-25 |
1.83e-22 |
0.4130 |
NA |
-0.242000 |
-0.335000 |
8.19e-10 |
1.79e-17 |
| DAP12 interactions |
22 |
3.76e-03 |
1.30e-02 |
0.4130 |
NA |
-0.253000 |
0.326000 |
4.01e-02 |
8.11e-03 |
| Erythropoietin activates RAS |
13 |
3.82e-02 |
7.78e-02 |
0.4100 |
NA |
-0.340000 |
0.230000 |
3.40e-02 |
1.50e-01 |
| ERK/MAPK targets |
21 |
5.26e-03 |
1.68e-02 |
0.4090 |
NA |
-0.332000 |
0.239000 |
8.40e-03 |
5.78e-02 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release |
17 |
1.41e-02 |
3.59e-02 |
0.4080 |
NA |
-0.331000 |
-0.238000 |
1.81e-02 |
8.90e-02 |
| Carboxyterminal post-translational modifications of tubulin |
28 |
9.12e-04 |
4.10e-03 |
0.4070 |
NA |
0.249000 |
0.322000 |
2.25e-02 |
3.15e-03 |
| PKA-mediated phosphorylation of CREB |
15 |
2.47e-02 |
5.47e-02 |
0.4060 |
NA |
0.022500 |
0.405000 |
8.80e-01 |
6.60e-03 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation |
30 |
6.00e-04 |
2.96e-03 |
0.4050 |
NA |
-0.289000 |
-0.285000 |
6.23e-03 |
7.00e-03 |
| Negative regulation of MAPK pathway |
39 |
7.08e-05 |
5.03e-04 |
0.4050 |
NA |
-0.388000 |
0.117000 |
2.76e-05 |
2.08e-01 |
| Activation of the pre-replicative complex |
32 |
3.84e-04 |
2.07e-03 |
0.4040 |
NA |
0.355000 |
0.193000 |
5.12e-04 |
5.83e-02 |
| SUMOylation of transcription cofactors |
43 |
2.65e-05 |
2.21e-04 |
0.4040 |
NA |
-0.228000 |
-0.333000 |
9.57e-03 |
1.60e-04 |
| Miscellaneous transport and binding events |
22 |
5.01e-03 |
1.63e-02 |
0.4020 |
NA |
-0.307000 |
0.260000 |
1.27e-02 |
3.51e-02 |
| Norepinephrine Neurotransmitter Release Cycle |
13 |
4.35e-02 |
8.56e-02 |
0.4020 |
NA |
-0.131000 |
0.380000 |
4.12e-01 |
1.78e-02 |
| Diseases associated with O-glycosylation of proteins |
40 |
6.24e-05 |
4.51e-04 |
0.4020 |
NA |
0.069400 |
0.396000 |
4.48e-01 |
1.49e-05 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) |
10 |
8.89e-02 |
1.50e-01 |
0.4010 |
NA |
0.381000 |
0.125000 |
3.69e-02 |
4.94e-01 |
| TRP channels |
10 |
9.01e-02 |
1.51e-01 |
0.4000 |
NA |
0.084900 |
0.391000 |
6.42e-01 |
3.22e-02 |
| Telomere C-strand (Lagging Strand) Synthesis |
24 |
3.08e-03 |
1.12e-02 |
0.4000 |
NA |
0.359000 |
0.176000 |
2.32e-03 |
1.35e-01 |
| Signaling by Insulin receptor |
56 |
1.59e-06 |
1.98e-05 |
0.4000 |
NA |
-0.382000 |
0.119000 |
7.76e-07 |
1.24e-01 |
| WNT5A-dependent internalization of FZD4 |
14 |
3.57e-02 |
7.39e-02 |
0.4000 |
NA |
-0.243000 |
0.318000 |
1.16e-01 |
3.97e-02 |
| A tetrasaccharide linker sequence is required for GAG synthesis |
24 |
3.20e-03 |
1.15e-02 |
0.3990 |
NA |
0.150000 |
0.370000 |
2.02e-01 |
1.73e-03 |
| Deadenylation of mRNA |
25 |
2.55e-03 |
9.76e-03 |
0.3980 |
NA |
-0.192000 |
-0.349000 |
9.67e-02 |
2.52e-03 |
| Polo-like kinase mediated events |
16 |
2.28e-02 |
5.22e-02 |
0.3980 |
NA |
0.248000 |
-0.311000 |
8.57e-02 |
3.11e-02 |
| Cristae formation |
13 |
4.52e-02 |
8.86e-02 |
0.3980 |
NA |
-0.233000 |
-0.322000 |
1.45e-01 |
4.44e-02 |
| Signaling by EGFR in Cancer |
21 |
7.15e-03 |
2.13e-02 |
0.3970 |
NA |
-0.380000 |
0.113000 |
2.55e-03 |
3.70e-01 |
| TRAF6 mediated NF-kB activation |
20 |
9.01e-03 |
2.56e-02 |
0.3960 |
NA |
-0.371000 |
-0.137000 |
4.05e-03 |
2.89e-01 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known |
36 |
2.13e-04 |
1.26e-03 |
0.3950 |
NA |
-0.150000 |
-0.366000 |
1.19e-01 |
1.46e-04 |
| MECP2 regulates neuronal receptors and channels |
13 |
4.87e-02 |
9.42e-02 |
0.3950 |
NA |
-0.283000 |
0.275000 |
7.69e-02 |
8.60e-02 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell |
45 |
2.65e-05 |
2.21e-04 |
0.3950 |
NA |
0.146000 |
0.367000 |
9.05e-02 |
2.06e-05 |
| Acetylcholine Neurotransmitter Release Cycle |
10 |
9.69e-02 |
1.59e-01 |
0.3950 |
NA |
-0.009070 |
0.395000 |
9.60e-01 |
3.07e-02 |
| Mitochondrial translation initiation |
87 |
1.60e-09 |
3.17e-08 |
0.3940 |
NA |
-0.080800 |
-0.386000 |
1.93e-01 |
4.90e-10 |
| Ion homeostasis |
34 |
3.82e-04 |
2.07e-03 |
0.3940 |
NA |
-0.144000 |
0.367000 |
1.46e-01 |
2.16e-04 |
| Signalling to ERKs |
29 |
1.22e-03 |
5.22e-03 |
0.3940 |
NA |
-0.379000 |
0.108000 |
4.19e-04 |
3.14e-01 |
| p75NTR signals via NF-kB |
15 |
3.11e-02 |
6.64e-02 |
0.3920 |
NA |
-0.357000 |
-0.163000 |
1.67e-02 |
2.76e-01 |
| Nuclear Events (kinase and transcription factor activation) |
24 |
4.11e-03 |
1.39e-02 |
0.3920 |
NA |
-0.354000 |
0.167000 |
2.66e-03 |
1.56e-01 |
| Acyl chain remodelling of PE |
16 |
2.48e-02 |
5.49e-02 |
0.3920 |
NA |
0.290000 |
0.263000 |
4.47e-02 |
6.84e-02 |
| Degradation of cysteine and homocysteine |
12 |
6.38e-02 |
1.15e-01 |
0.3910 |
NA |
0.391000 |
0.013900 |
1.91e-02 |
9.33e-01 |
| Processing of SMDT1 |
15 |
3.26e-02 |
6.93e-02 |
0.3900 |
NA |
-0.091400 |
-0.379000 |
5.40e-01 |
1.11e-02 |
| DAG and IP3 signaling |
31 |
8.87e-04 |
4.03e-03 |
0.3890 |
NA |
-0.042600 |
0.387000 |
6.82e-01 |
1.92e-04 |
| CDC6 association with the ORC:origin complex |
11 |
8.13e-02 |
1.39e-01 |
0.3890 |
NA |
0.249000 |
0.299000 |
1.52e-01 |
8.63e-02 |
| RHO GTPases activate PAKs |
21 |
9.05e-03 |
2.56e-02 |
0.3880 |
NA |
-0.248000 |
0.298000 |
4.91e-02 |
1.81e-02 |
| CD28 dependent PI3K/Akt signaling |
18 |
1.73e-02 |
4.19e-02 |
0.3880 |
NA |
-0.386000 |
-0.032600 |
4.56e-03 |
8.11e-01 |
| Activated NOTCH1 Transmits Signal to the Nucleus |
28 |
1.92e-03 |
7.68e-03 |
0.3870 |
NA |
-0.279000 |
0.268000 |
1.06e-02 |
1.40e-02 |
| Nephrin family interactions |
21 |
9.20e-03 |
2.57e-02 |
0.3870 |
NA |
-0.277000 |
0.270000 |
2.78e-02 |
3.22e-02 |
| Regulation of expression of SLITs and ROBOs |
156 |
6.72e-16 |
2.74e-14 |
0.3870 |
NA |
-0.309000 |
-0.232000 |
2.65e-11 |
5.65e-07 |
| CRMPs in Sema3A signaling |
16 |
2.78e-02 |
6.03e-02 |
0.3860 |
NA |
0.027600 |
0.385000 |
8.48e-01 |
7.60e-03 |
| Mitochondrial translation elongation |
87 |
3.68e-09 |
6.84e-08 |
0.3860 |
NA |
-0.097500 |
-0.374000 |
1.16e-01 |
1.72e-09 |
| Signalling to RAS |
18 |
1.82e-02 |
4.37e-02 |
0.3860 |
NA |
-0.373000 |
0.098800 |
6.16e-03 |
4.68e-01 |
| HDR through Single Strand Annealing (SSA) |
35 |
4.05e-04 |
2.13e-03 |
0.3860 |
NA |
0.372000 |
0.101000 |
1.39e-04 |
3.02e-01 |
| Mitochondrial translation termination |
87 |
3.90e-09 |
7.05e-08 |
0.3850 |
NA |
-0.105000 |
-0.371000 |
9.09e-02 |
2.24e-09 |
| ABC transporters in lipid homeostasis |
15 |
3.51e-02 |
7.29e-02 |
0.3850 |
NA |
0.192000 |
0.334000 |
1.97e-01 |
2.53e-02 |
| FCERI mediated MAPK activation |
24 |
4.96e-03 |
1.62e-02 |
0.3850 |
NA |
-0.345000 |
0.171000 |
3.45e-03 |
1.47e-01 |
| SHC1 events in ERBB4 signaling |
11 |
8.91e-02 |
1.50e-01 |
0.3840 |
NA |
-0.189000 |
0.334000 |
2.77e-01 |
5.52e-02 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion |
14 |
4.59e-02 |
8.99e-02 |
0.3840 |
NA |
-0.063100 |
0.378000 |
6.83e-01 |
1.43e-02 |
| Condensation of Prometaphase Chromosomes |
11 |
9.05e-02 |
1.51e-01 |
0.3830 |
NA |
0.222000 |
-0.312000 |
2.03e-01 |
7.32e-02 |
| Nuclear import of Rev protein |
33 |
7.10e-04 |
3.35e-03 |
0.3830 |
NA |
-0.096500 |
-0.370000 |
3.38e-01 |
2.33e-04 |
| Regulation of necroptotic cell death |
13 |
5.81e-02 |
1.08e-01 |
0.3820 |
NA |
-0.032400 |
-0.381000 |
8.40e-01 |
1.75e-02 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers |
24 |
5.43e-03 |
1.71e-02 |
0.3820 |
NA |
-0.243000 |
0.295000 |
3.94e-02 |
1.25e-02 |
| Loss of function of MECP2 in Rett syndrome |
11 |
9.11e-02 |
1.52e-01 |
0.3820 |
NA |
-0.374000 |
0.077700 |
3.19e-02 |
6.55e-01 |
| Pervasive developmental disorders |
11 |
9.11e-02 |
1.52e-01 |
0.3820 |
NA |
-0.374000 |
0.077700 |
3.19e-02 |
6.55e-01 |
| Dectin-2 family |
13 |
5.93e-02 |
1.10e-01 |
0.3810 |
NA |
-0.138000 |
0.355000 |
3.88e-01 |
2.65e-02 |
| Nuclear Receptor transcription pathway |
42 |
1.08e-04 |
7.16e-04 |
0.3800 |
NA |
-0.317000 |
-0.209000 |
3.72e-04 |
1.89e-02 |
| Activation of gene expression by SREBF (SREBP) |
42 |
1.23e-04 |
7.92e-04 |
0.3790 |
NA |
0.312000 |
-0.216000 |
4.75e-04 |
1.52e-02 |
| Regulation of TP53 Activity through Methylation |
18 |
2.06e-02 |
4.83e-02 |
0.3790 |
NA |
-0.152000 |
-0.347000 |
2.64e-01 |
1.09e-02 |
| Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism |
35 |
5.97e-04 |
2.96e-03 |
0.3770 |
NA |
0.250000 |
-0.283000 |
1.05e-02 |
3.79e-03 |
| InlB-mediated entry of Listeria monocytogenes into host cell |
13 |
6.45e-02 |
1.16e-01 |
0.3760 |
NA |
-0.331000 |
0.178000 |
3.87e-02 |
2.66e-01 |
| CaM pathway |
25 |
5.11e-03 |
1.65e-02 |
0.3750 |
NA |
-0.000443 |
0.375000 |
9.97e-01 |
1.16e-03 |
| Calmodulin induced events |
25 |
5.11e-03 |
1.65e-02 |
0.3750 |
NA |
-0.000443 |
0.375000 |
9.97e-01 |
1.16e-03 |
| Interactions of Rev with host cellular proteins |
36 |
4.96e-04 |
2.56e-03 |
0.3750 |
NA |
-0.079200 |
-0.367000 |
4.11e-01 |
1.40e-04 |
| Assembly Of The HIV Virion |
16 |
3.40e-02 |
7.10e-02 |
0.3750 |
NA |
-0.283000 |
-0.245000 |
4.97e-02 |
8.98e-02 |
| FRS-mediated FGFR1 signaling |
12 |
8.17e-02 |
1.40e-01 |
0.3740 |
NA |
-0.267000 |
0.262000 |
1.09e-01 |
1.17e-01 |
| Post-chaperonin tubulin folding pathway |
20 |
1.48e-02 |
3.72e-02 |
0.3740 |
NA |
0.313000 |
0.205000 |
1.55e-02 |
1.12e-01 |
| Amino acid transport across the plasma membrane |
28 |
2.82e-03 |
1.05e-02 |
0.3740 |
NA |
-0.370000 |
-0.055400 |
7.09e-04 |
6.12e-01 |
| HS-GAG degradation |
20 |
1.50e-02 |
3.75e-02 |
0.3740 |
NA |
0.230000 |
0.295000 |
7.54e-02 |
2.26e-02 |
| Acyl chain remodelling of PS |
12 |
8.06e-02 |
1.38e-01 |
0.3730 |
NA |
0.221000 |
0.301000 |
1.85e-01 |
7.14e-02 |
| PI-3K cascade:FGFR1 |
10 |
1.26e-01 |
1.97e-01 |
0.3730 |
NA |
-0.335000 |
0.164000 |
6.69e-02 |
3.70e-01 |
| Chromatin modifying enzymes |
205 |
3.66e-19 |
2.77e-17 |
0.3730 |
NA |
-0.209000 |
-0.309000 |
2.72e-07 |
2.69e-14 |
| Chromatin organization |
205 |
3.66e-19 |
2.77e-17 |
0.3730 |
NA |
-0.209000 |
-0.309000 |
2.72e-07 |
2.69e-14 |
| NCAM signaling for neurite out-growth |
41 |
1.97e-04 |
1.18e-03 |
0.3730 |
NA |
0.069400 |
0.366000 |
4.42e-01 |
5.02e-05 |
| Glutathione conjugation |
28 |
3.07e-03 |
1.12e-02 |
0.3720 |
NA |
0.343000 |
-0.145000 |
1.69e-03 |
1.85e-01 |
| Signaling by NTRK1 (TRKA) |
68 |
8.03e-07 |
1.08e-05 |
0.3720 |
NA |
-0.356000 |
0.108000 |
3.85e-07 |
1.23e-01 |
| Ca-dependent events |
26 |
4.63e-03 |
1.53e-02 |
0.3720 |
NA |
-0.027800 |
0.371000 |
8.06e-01 |
1.07e-03 |
| FRS-mediated FGFR2 signaling |
12 |
8.42e-02 |
1.43e-01 |
0.3710 |
NA |
-0.116000 |
0.353000 |
4.85e-01 |
3.44e-02 |
| Negative regulation of NMDA receptor-mediated neuronal transmission |
18 |
2.39e-02 |
5.37e-02 |
0.3710 |
NA |
0.170000 |
0.330000 |
2.11e-01 |
1.54e-02 |
| tRNA modification in the nucleus and cytosol |
41 |
2.17e-04 |
1.28e-03 |
0.3710 |
NA |
0.046100 |
-0.368000 |
6.09e-01 |
4.54e-05 |
| Activation of SMO |
13 |
7.05e-02 |
1.23e-01 |
0.3700 |
NA |
-0.130000 |
0.346000 |
4.16e-01 |
3.09e-02 |
| Negative regulation of FGFR4 signaling |
21 |
1.39e-02 |
3.54e-02 |
0.3690 |
NA |
-0.367000 |
0.036900 |
3.59e-03 |
7.70e-01 |
| ZBP1(DAI) mediated induction of type I IFNs |
18 |
2.55e-02 |
5.63e-02 |
0.3690 |
NA |
-0.368000 |
-0.012600 |
6.81e-03 |
9.26e-01 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity |
23 |
9.13e-03 |
2.57e-02 |
0.3680 |
NA |
-0.295000 |
-0.220000 |
1.42e-02 |
6.80e-02 |
| Negative regulation of FGFR1 signaling |
21 |
1.43e-02 |
3.61e-02 |
0.3680 |
NA |
-0.358000 |
0.087300 |
4.57e-03 |
4.89e-01 |
| LDL clearance |
19 |
2.16e-02 |
5.03e-02 |
0.3680 |
NA |
-0.318000 |
0.184000 |
1.63e-02 |
1.65e-01 |
| Activation of RAC1 |
11 |
1.08e-01 |
1.74e-01 |
0.3680 |
NA |
-0.361000 |
0.070800 |
3.82e-02 |
6.84e-01 |
| Mitochondrial translation |
93 |
6.57e-09 |
1.15e-07 |
0.3680 |
NA |
-0.105000 |
-0.353000 |
8.05e-02 |
4.24e-09 |
| PERK regulates gene expression |
29 |
2.79e-03 |
1.05e-02 |
0.3670 |
NA |
-0.283000 |
-0.234000 |
8.41e-03 |
2.92e-02 |
| Metabolism of RNA |
676 |
2.86e-58 |
3.61e-55 |
0.3670 |
NA |
-0.170000 |
-0.325000 |
6.05e-14 |
7.01e-47 |
| Adrenaline,noradrenaline inhibits insulin secretion |
19 |
2.31e-02 |
5.27e-02 |
0.3650 |
NA |
-0.141000 |
0.336000 |
2.87e-01 |
1.12e-02 |
| Cardiac conduction |
77 |
2.53e-07 |
3.67e-06 |
0.3640 |
NA |
-0.087400 |
0.353000 |
1.85e-01 |
8.45e-08 |
| AMER1 mutants destabilize the destruction complex |
14 |
6.20e-02 |
1.12e-01 |
0.3640 |
NA |
-0.357000 |
-0.069600 |
2.08e-02 |
6.52e-01 |
| APC truncation mutants have impaired AXIN binding |
14 |
6.20e-02 |
1.12e-01 |
0.3640 |
NA |
-0.357000 |
-0.069600 |
2.08e-02 |
6.52e-01 |
| AXIN missense mutants destabilize the destruction complex |
14 |
6.20e-02 |
1.12e-01 |
0.3640 |
NA |
-0.357000 |
-0.069600 |
2.08e-02 |
6.52e-01 |
| AXIN mutants destabilize the destruction complex, activating WNT signaling |
14 |
6.20e-02 |
1.12e-01 |
0.3640 |
NA |
-0.357000 |
-0.069600 |
2.08e-02 |
6.52e-01 |
| Truncations of AMER1 destabilize the destruction complex |
14 |
6.20e-02 |
1.12e-01 |
0.3640 |
NA |
-0.357000 |
-0.069600 |
2.08e-02 |
6.52e-01 |
| truncated APC mutants destabilize the destruction complex |
14 |
6.20e-02 |
1.12e-01 |
0.3640 |
NA |
-0.357000 |
-0.069600 |
2.08e-02 |
6.52e-01 |
| Synthesis, secretion, and deacylation of Ghrelin |
10 |
1.39e-01 |
2.14e-01 |
0.3630 |
NA |
-0.349000 |
0.102000 |
5.63e-02 |
5.76e-01 |
| PKA activation in glucagon signalling |
14 |
6.31e-02 |
1.14e-01 |
0.3630 |
NA |
0.028200 |
0.362000 |
8.55e-01 |
1.91e-02 |
| Spry regulation of FGF signaling |
16 |
4.28e-02 |
8.48e-02 |
0.3630 |
NA |
-0.362000 |
0.010300 |
1.21e-02 |
9.43e-01 |
| Prolonged ERK activation events |
10 |
1.40e-01 |
2.16e-01 |
0.3620 |
NA |
-0.350000 |
0.095700 |
5.56e-02 |
6.00e-01 |
| Intrinsic Pathway of Fibrin Clot Formation |
18 |
2.95e-02 |
6.36e-02 |
0.3620 |
NA |
0.243000 |
-0.268000 |
7.39e-02 |
4.86e-02 |
| COPII-mediated vesicle transport |
63 |
4.53e-06 |
5.12e-05 |
0.3620 |
NA |
-0.350000 |
0.091500 |
1.54e-06 |
2.10e-01 |
| Assembly and cell surface presentation of NMDA receptors |
22 |
1.35e-02 |
3.48e-02 |
0.3610 |
NA |
0.186000 |
0.309000 |
1.31e-01 |
1.22e-02 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) |
16 |
4.45e-02 |
8.75e-02 |
0.3600 |
NA |
-0.360000 |
0.007920 |
1.26e-02 |
9.56e-01 |
| SUMOylation of immune response proteins |
11 |
1.16e-01 |
1.85e-01 |
0.3600 |
NA |
-0.288000 |
-0.216000 |
9.79e-02 |
2.15e-01 |
| G-protein activation |
16 |
4.51e-02 |
8.85e-02 |
0.3600 |
NA |
-0.149000 |
0.328000 |
3.03e-01 |
2.31e-02 |
| Nicotinamide salvaging |
10 |
1.45e-01 |
2.21e-01 |
0.3600 |
NA |
0.245000 |
-0.264000 |
1.81e-01 |
1.48e-01 |
| PI-3K cascade:FGFR4 |
10 |
1.45e-01 |
2.21e-01 |
0.3590 |
NA |
-0.355000 |
0.058100 |
5.21e-02 |
7.51e-01 |
| Synthesis of PIPs at the early endosome membrane |
15 |
5.55e-02 |
1.05e-01 |
0.3590 |
NA |
-0.313000 |
0.177000 |
3.59e-02 |
2.36e-01 |
| Class B/2 (Secretin family receptors) |
47 |
1.18e-04 |
7.70e-04 |
0.3580 |
NA |
0.025100 |
0.358000 |
7.66e-01 |
2.22e-05 |
| FRS-mediated FGFR3 signaling |
11 |
1.22e-01 |
1.93e-01 |
0.3580 |
NA |
-0.239000 |
0.267000 |
1.70e-01 |
1.25e-01 |
| Hh mutants that don’t undergo autocatalytic processing are degraded by ERAD |
53 |
3.75e-05 |
2.96e-04 |
0.3580 |
NA |
-0.332000 |
-0.133000 |
2.88e-05 |
9.39e-02 |
| RET signaling |
33 |
1.85e-03 |
7.43e-03 |
0.3580 |
NA |
-0.328000 |
0.143000 |
1.12e-03 |
1.56e-01 |
| Physiological factors |
11 |
1.24e-01 |
1.95e-01 |
0.3570 |
NA |
-0.282000 |
0.218000 |
1.05e-01 |
2.11e-01 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism |
13 |
8.49e-02 |
1.44e-01 |
0.3570 |
NA |
0.180000 |
-0.308000 |
2.60e-01 |
5.49e-02 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors |
26 |
7.03e-03 |
2.12e-02 |
0.3560 |
NA |
-0.085000 |
-0.346000 |
4.53e-01 |
2.26e-03 |
| Negative regulation of FGFR3 signaling |
20 |
2.28e-02 |
5.22e-02 |
0.3560 |
NA |
-0.346000 |
0.081600 |
7.36e-03 |
5.27e-01 |
| O-linked glycosylation of mucins |
39 |
6.68e-04 |
3.19e-03 |
0.3540 |
NA |
-0.080300 |
0.345000 |
3.86e-01 |
1.93e-04 |
| Elevation of cytosolic Ca2+ levels |
10 |
1.55e-01 |
2.33e-01 |
0.3540 |
NA |
-0.217000 |
0.279000 |
2.35e-01 |
1.26e-01 |
| Role of phospholipids in phagocytosis |
15 |
6.11e-02 |
1.12e-01 |
0.3530 |
NA |
-0.139000 |
0.325000 |
3.52e-01 |
2.94e-02 |
| Incretin synthesis, secretion, and inactivation |
13 |
8.94e-02 |
1.50e-01 |
0.3520 |
NA |
-0.344000 |
0.076500 |
3.17e-02 |
6.33e-01 |
| Nef mediated downregulation of MHC class I complex cell surface expression |
10 |
1.56e-01 |
2.34e-01 |
0.3520 |
NA |
-0.002350 |
0.352000 |
9.90e-01 |
5.38e-02 |
| Peroxisomal protein import |
58 |
2.24e-05 |
1.93e-04 |
0.3520 |
NA |
0.202000 |
-0.289000 |
7.95e-03 |
1.43e-04 |
| The role of Nef in HIV-1 replication and disease pathogenesis |
23 |
1.43e-02 |
3.61e-02 |
0.3520 |
NA |
-0.159000 |
0.314000 |
1.88e-01 |
9.09e-03 |
| Retrograde neurotrophin signalling |
10 |
1.58e-01 |
2.36e-01 |
0.3520 |
NA |
-0.204000 |
0.287000 |
2.65e-01 |
1.16e-01 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters |
19 |
3.04e-02 |
6.53e-02 |
0.3510 |
NA |
-0.142000 |
0.321000 |
2.84e-01 |
1.54e-02 |
| Recycling pathway of L1 |
22 |
1.77e-02 |
4.26e-02 |
0.3510 |
NA |
-0.249000 |
0.247000 |
4.34e-02 |
4.46e-02 |
| Chondroitin sulfate biosynthesis |
19 |
3.05e-02 |
6.53e-02 |
0.3510 |
NA |
-0.090600 |
0.339000 |
4.94e-01 |
1.06e-02 |
| Hh mutants abrogate ligand secretion |
55 |
3.99e-05 |
3.07e-04 |
0.3500 |
NA |
-0.325000 |
-0.131000 |
3.08e-05 |
9.34e-02 |
| trans-Golgi Network Vesicle Budding |
69 |
3.85e-06 |
4.43e-05 |
0.3480 |
NA |
-0.330000 |
0.112000 |
2.17e-06 |
1.08e-01 |
| FOXO-mediated transcription of cell cycle genes |
15 |
6.68e-02 |
1.18e-01 |
0.3470 |
NA |
-0.334000 |
0.097300 |
2.53e-02 |
5.14e-01 |
| Mitophagy |
25 |
1.10e-02 |
2.99e-02 |
0.3460 |
NA |
-0.300000 |
-0.173000 |
9.43e-03 |
1.35e-01 |
| Transport of Mature mRNA Derived from an Intronless Transcript |
41 |
6.40e-04 |
3.09e-03 |
0.3460 |
NA |
-0.047300 |
-0.343000 |
6.01e-01 |
1.47e-04 |
| Regulation of PTEN stability and activity |
65 |
8.76e-06 |
9.01e-05 |
0.3450 |
NA |
-0.294000 |
-0.181000 |
4.14e-05 |
1.16e-02 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA |
17 |
4.72e-02 |
9.19e-02 |
0.3450 |
NA |
-0.218000 |
-0.268000 |
1.20e-01 |
5.56e-02 |
| Rev-mediated nuclear export of HIV RNA |
34 |
2.32e-03 |
9.06e-03 |
0.3450 |
NA |
-0.047400 |
-0.342000 |
6.33e-01 |
5.65e-04 |
| Signaling by FGFR3 |
31 |
4.08e-03 |
1.39e-02 |
0.3450 |
NA |
-0.326000 |
0.111000 |
1.66e-03 |
2.84e-01 |
| Defective CFTR causes cystic fibrosis |
56 |
4.79e-05 |
3.59e-04 |
0.3440 |
NA |
-0.319000 |
-0.129000 |
3.68e-05 |
9.51e-02 |
| Glutamate Neurotransmitter Release Cycle |
17 |
5.02e-02 |
9.67e-02 |
0.3430 |
NA |
-0.099400 |
0.329000 |
4.78e-01 |
1.90e-02 |
| Ras activation upon Ca2+ influx through NMDA receptor |
19 |
3.50e-02 |
7.28e-02 |
0.3430 |
NA |
0.065000 |
0.337000 |
6.24e-01 |
1.11e-02 |
| COPI-mediated anterograde transport |
77 |
1.42e-06 |
1.80e-05 |
0.3420 |
NA |
-0.341000 |
0.032600 |
2.37e-07 |
6.21e-01 |
| Degradation of AXIN |
52 |
1.06e-04 |
7.11e-04 |
0.3420 |
NA |
-0.279000 |
-0.197000 |
4.92e-04 |
1.38e-02 |
| Circadian Clock |
67 |
7.80e-06 |
8.29e-05 |
0.3420 |
NA |
-0.278000 |
-0.199000 |
8.38e-05 |
4.87e-03 |
| Serotonin Neurotransmitter Release Cycle |
12 |
1.22e-01 |
1.94e-01 |
0.3420 |
NA |
0.016900 |
0.341000 |
9.19e-01 |
4.07e-02 |
| Semaphorin interactions |
57 |
5.02e-05 |
3.71e-04 |
0.3420 |
NA |
-0.174000 |
0.294000 |
2.30e-02 |
1.25e-04 |
| FOXO-mediated transcription of cell death genes |
15 |
7.23e-02 |
1.25e-01 |
0.3410 |
NA |
-0.309000 |
-0.145000 |
3.85e-02 |
3.30e-01 |
| Opioid Signalling |
64 |
1.55e-05 |
1.40e-04 |
0.3410 |
NA |
-0.143000 |
0.310000 |
4.87e-02 |
1.84e-05 |
| HDR through Homologous Recombination (HRR) |
63 |
1.73e-05 |
1.54e-04 |
0.3410 |
NA |
0.330000 |
0.083800 |
5.82e-06 |
2.50e-01 |
| Extension of Telomeres |
30 |
5.35e-03 |
1.69e-02 |
0.3410 |
NA |
0.321000 |
0.115000 |
2.37e-03 |
2.75e-01 |
| SUMOylation of RNA binding proteins |
46 |
3.46e-04 |
1.93e-03 |
0.3400 |
NA |
-0.012000 |
-0.340000 |
8.88e-01 |
6.64e-05 |
| MyD88 cascade initiated on plasma membrane |
77 |
1.88e-06 |
2.24e-05 |
0.3390 |
NA |
-0.338000 |
0.028300 |
3.07e-07 |
6.68e-01 |
| Toll Like Receptor 10 (TLR10) Cascade |
77 |
1.88e-06 |
2.24e-05 |
0.3390 |
NA |
-0.338000 |
0.028300 |
3.07e-07 |
6.68e-01 |
| Toll Like Receptor 5 (TLR5) Cascade |
77 |
1.88e-06 |
2.24e-05 |
0.3390 |
NA |
-0.338000 |
0.028300 |
3.07e-07 |
6.68e-01 |
| mTORC1-mediated signalling |
23 |
1.90e-02 |
4.50e-02 |
0.3380 |
NA |
-0.296000 |
-0.164000 |
1.40e-02 |
1.74e-01 |
| CD28 co-stimulation |
27 |
1.01e-02 |
2.77e-02 |
0.3380 |
NA |
-0.331000 |
0.067400 |
2.93e-03 |
5.45e-01 |
| Downstream signaling of activated FGFR3 |
16 |
6.61e-02 |
1.18e-01 |
0.3380 |
NA |
-0.270000 |
0.202000 |
6.14e-02 |
1.61e-01 |
| Diseases associated with glycosaminoglycan metabolism |
34 |
2.97e-03 |
1.09e-02 |
0.3370 |
NA |
0.125000 |
0.313000 |
2.06e-01 |
1.57e-03 |
| Purine ribonucleoside monophosphate biosynthesis |
12 |
1.30e-01 |
2.03e-01 |
0.3370 |
NA |
0.124000 |
-0.313000 |
4.55e-01 |
6.02e-02 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase |
19 |
4.03e-02 |
8.12e-02 |
0.3370 |
NA |
0.240000 |
-0.236000 |
7.01e-02 |
7.46e-02 |
| Signaling by FGFR4 |
31 |
5.32e-03 |
1.69e-02 |
0.3360 |
NA |
-0.330000 |
0.063700 |
1.47e-03 |
5.40e-01 |
| NEP/NS2 Interacts with the Cellular Export Machinery |
31 |
5.25e-03 |
1.68e-02 |
0.3360 |
NA |
-0.058300 |
-0.331000 |
5.74e-01 |
1.43e-03 |
| MAP kinase activation |
61 |
3.44e-05 |
2.79e-04 |
0.3360 |
NA |
-0.334000 |
0.036000 |
6.47e-06 |
6.27e-01 |
| Gap junction trafficking |
15 |
7.96e-02 |
1.37e-01 |
0.3350 |
NA |
0.055500 |
0.331000 |
7.10e-01 |
2.66e-02 |
| Synthesis of very long-chain fatty acyl-CoAs |
18 |
4.78e-02 |
9.31e-02 |
0.3350 |
NA |
0.218000 |
0.254000 |
1.10e-01 |
6.17e-02 |
| EPHA-mediated growth cone collapse |
15 |
8.23e-02 |
1.40e-01 |
0.3340 |
NA |
-0.165000 |
0.291000 |
2.69e-01 |
5.14e-02 |
| EGFR downregulation |
25 |
1.54e-02 |
3.84e-02 |
0.3340 |
NA |
-0.330000 |
0.053500 |
4.32e-03 |
6.44e-01 |
| Hedgehog ligand biogenesis |
60 |
4.37e-05 |
3.31e-04 |
0.3340 |
NA |
-0.316000 |
-0.109000 |
2.34e-05 |
1.45e-01 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA |
17 |
5.83e-02 |
1.09e-01 |
0.3330 |
NA |
-0.240000 |
-0.231000 |
8.68e-02 |
9.91e-02 |
| FRS-mediated FGFR4 signaling |
12 |
1.37e-01 |
2.12e-01 |
0.3330 |
NA |
-0.284000 |
0.174000 |
8.83e-02 |
2.98e-01 |
| Transport of Ribonucleoproteins into the Host Nucleus |
31 |
5.80e-03 |
1.80e-02 |
0.3330 |
NA |
-0.080900 |
-0.323000 |
4.36e-01 |
1.88e-03 |
| Gamma carboxylation, hypusine formation and arylsulfatase activation |
34 |
3.62e-03 |
1.28e-02 |
0.3320 |
NA |
0.009360 |
-0.332000 |
9.25e-01 |
8.02e-04 |
| EPH-ephrin mediated repulsion of cells |
41 |
1.20e-03 |
5.19e-03 |
0.3320 |
NA |
-0.107000 |
0.314000 |
2.36e-01 |
5.09e-04 |
| Downstream signaling of activated FGFR4 |
17 |
6.16e-02 |
1.12e-01 |
0.3310 |
NA |
-0.300000 |
0.140000 |
3.20e-02 |
3.18e-01 |
| EPH-Ephrin signaling |
84 |
1.12e-06 |
1.45e-05 |
0.3310 |
NA |
-0.207000 |
0.259000 |
1.05e-03 |
4.13e-05 |
| Transport of inorganic cations/anions and amino acids/oligopeptides |
72 |
8.10e-06 |
8.40e-05 |
0.3310 |
NA |
-0.291000 |
0.158000 |
1.99e-05 |
2.07e-02 |
| Regulation of KIT signaling |
15 |
8.78e-02 |
1.48e-01 |
0.3300 |
NA |
-0.154000 |
0.291000 |
3.01e-01 |
5.08e-02 |
| Asparagine N-linked glycosylation |
259 |
8.27e-19 |
5.51e-17 |
0.3300 |
NA |
-0.330000 |
-0.001560 |
7.17e-20 |
9.66e-01 |
| ER to Golgi Anterograde Transport |
126 |
1.57e-09 |
3.14e-08 |
0.3290 |
NA |
-0.324000 |
0.054300 |
3.26e-10 |
2.93e-01 |
| Interleukin-12 signaling |
37 |
2.45e-03 |
9.41e-03 |
0.3290 |
NA |
-0.288000 |
-0.159000 |
2.45e-03 |
9.46e-02 |
| Nuclear Pore Complex (NPC) Disassembly |
35 |
3.60e-03 |
1.27e-02 |
0.3280 |
NA |
0.056300 |
-0.323000 |
5.65e-01 |
9.40e-04 |
| Initiation of Nuclear Envelope Reformation |
13 |
1.24e-01 |
1.95e-01 |
0.3260 |
NA |
-0.139000 |
-0.296000 |
3.87e-01 |
6.50e-02 |
| Nuclear Envelope Reassembly |
13 |
1.24e-01 |
1.95e-01 |
0.3260 |
NA |
-0.139000 |
-0.296000 |
3.87e-01 |
6.50e-02 |
| Transport of Mature mRNAs Derived from Intronless Transcripts |
42 |
1.23e-03 |
5.24e-03 |
0.3260 |
NA |
-0.066600 |
-0.319000 |
4.55e-01 |
3.43e-04 |
| Signaling by FGFR3 fusions in cancer |
10 |
2.04e-01 |
2.91e-01 |
0.3260 |
NA |
-0.325000 |
0.019200 |
7.49e-02 |
9.16e-01 |
| Platelet calcium homeostasis |
19 |
4.97e-02 |
9.60e-02 |
0.3250 |
NA |
-0.132000 |
0.298000 |
3.21e-01 |
2.48e-02 |
| TBC/RABGAPs |
43 |
1.21e-03 |
5.19e-03 |
0.3240 |
NA |
-0.293000 |
0.137000 |
8.79e-04 |
1.19e-01 |
| Trafficking of GluR2-containing AMPA receptors |
13 |
1.31e-01 |
2.04e-01 |
0.3240 |
NA |
-0.123000 |
0.299000 |
4.41e-01 |
6.16e-02 |
| Activation of NF-kappaB in B cells |
63 |
4.93e-05 |
3.67e-04 |
0.3240 |
NA |
-0.288000 |
-0.149000 |
7.93e-05 |
4.11e-02 |
| Misspliced GSK3beta mutants stabilize beta-catenin |
15 |
9.43e-02 |
1.55e-01 |
0.3240 |
NA |
-0.311000 |
-0.089700 |
3.71e-02 |
5.47e-01 |
| S33 mutants of beta-catenin aren’t phosphorylated |
15 |
9.43e-02 |
1.55e-01 |
0.3240 |
NA |
-0.311000 |
-0.089700 |
3.71e-02 |
5.47e-01 |
| S37 mutants of beta-catenin aren’t phosphorylated |
15 |
9.43e-02 |
1.55e-01 |
0.3240 |
NA |
-0.311000 |
-0.089700 |
3.71e-02 |
5.47e-01 |
| S45 mutants of beta-catenin aren’t phosphorylated |
15 |
9.43e-02 |
1.55e-01 |
0.3240 |
NA |
-0.311000 |
-0.089700 |
3.71e-02 |
5.47e-01 |
| T41 mutants of beta-catenin aren’t phosphorylated |
15 |
9.43e-02 |
1.55e-01 |
0.3240 |
NA |
-0.311000 |
-0.089700 |
3.71e-02 |
5.47e-01 |
| phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex |
15 |
9.43e-02 |
1.55e-01 |
0.3240 |
NA |
-0.311000 |
-0.089700 |
3.71e-02 |
5.47e-01 |
| Synthesis of IP3 and IP4 in the cytosol |
21 |
3.83e-02 |
7.79e-02 |
0.3230 |
NA |
-0.226000 |
0.231000 |
7.33e-02 |
6.72e-02 |
| Interleukin-17 signaling |
65 |
4.04e-05 |
3.09e-04 |
0.3230 |
NA |
-0.322000 |
0.024200 |
7.21e-06 |
7.36e-01 |
| Downstream signaling of activated FGFR2 |
17 |
7.14e-02 |
1.24e-01 |
0.3230 |
NA |
-0.182000 |
0.267000 |
1.94e-01 |
5.71e-02 |
| SUMOylation of ubiquitinylation proteins |
38 |
2.63e-03 |
1.00e-02 |
0.3230 |
NA |
-0.092900 |
-0.309000 |
3.22e-01 |
9.82e-04 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion |
28 |
1.29e-02 |
3.37e-02 |
0.3230 |
NA |
-0.114000 |
0.302000 |
2.97e-01 |
5.70e-03 |
| Degradation of DVL |
52 |
2.93e-04 |
1.68e-03 |
0.3230 |
NA |
-0.244000 |
-0.211000 |
2.33e-03 |
8.54e-03 |
| CS/DS degradation |
13 |
1.33e-01 |
2.06e-01 |
0.3220 |
NA |
-0.109000 |
0.303000 |
4.98e-01 |
5.82e-02 |
| mTOR signalling |
39 |
2.29e-03 |
8.98e-03 |
0.3220 |
NA |
-0.233000 |
-0.222000 |
1.18e-02 |
1.65e-02 |
| Adherens junctions interactions |
14 |
1.13e-01 |
1.80e-01 |
0.3220 |
NA |
0.252000 |
0.200000 |
1.02e-01 |
1.95e-01 |
| Interleukin receptor SHC signaling |
18 |
6.24e-02 |
1.13e-01 |
0.3210 |
NA |
-0.315000 |
0.060200 |
2.06e-02 |
6.58e-01 |
| Establishment of Sister Chromatid Cohesion |
10 |
2.15e-01 |
3.04e-01 |
0.3210 |
NA |
0.098800 |
-0.305000 |
5.88e-01 |
9.48e-02 |
| RIPK1-mediated regulated necrosis |
15 |
9.91e-02 |
1.61e-01 |
0.3210 |
NA |
0.002100 |
-0.321000 |
9.89e-01 |
3.15e-02 |
| Regulated Necrosis |
15 |
9.91e-02 |
1.61e-01 |
0.3210 |
NA |
0.002100 |
-0.321000 |
9.89e-01 |
3.15e-02 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation |
80 |
4.78e-06 |
5.35e-05 |
0.3200 |
NA |
-0.320000 |
0.014800 |
7.58e-07 |
8.19e-01 |
| Processing of Intronless Pre-mRNAs |
19 |
5.48e-02 |
1.04e-01 |
0.3190 |
NA |
-0.018600 |
-0.319000 |
8.89e-01 |
1.62e-02 |
| Golgi Associated Vesicle Biogenesis |
55 |
2.46e-04 |
1.43e-03 |
0.3180 |
NA |
-0.300000 |
0.106000 |
1.18e-04 |
1.75e-01 |
| SUMOylation of intracellular receptors |
27 |
1.64e-02 |
4.03e-02 |
0.3180 |
NA |
-0.262000 |
-0.181000 |
1.86e-02 |
1.04e-01 |
| APC-Cdc20 mediated degradation of Nek2A |
25 |
2.32e-02 |
5.29e-02 |
0.3180 |
NA |
0.219000 |
-0.231000 |
5.84e-02 |
4.59e-02 |
| CTLA4 inhibitory signaling |
18 |
6.64e-02 |
1.18e-01 |
0.3180 |
NA |
-0.289000 |
0.131000 |
3.36e-02 |
3.35e-01 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity |
24 |
2.64e-02 |
5.79e-02 |
0.3180 |
NA |
0.038700 |
0.315000 |
7.43e-01 |
7.50e-03 |
| Trafficking of AMPA receptors |
24 |
2.64e-02 |
5.79e-02 |
0.3180 |
NA |
0.038700 |
0.315000 |
7.43e-01 |
7.50e-03 |
| Peroxisomal lipid metabolism |
25 |
2.39e-02 |
5.37e-02 |
0.3170 |
NA |
0.254000 |
-0.189000 |
2.79e-02 |
1.02e-01 |
| Signaling by FGFR1 |
36 |
4.62e-03 |
1.53e-02 |
0.3170 |
NA |
-0.290000 |
0.128000 |
2.63e-03 |
1.86e-01 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) |
30 |
1.12e-02 |
3.02e-02 |
0.3160 |
NA |
0.009760 |
-0.316000 |
9.26e-01 |
2.74e-03 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein |
30 |
1.12e-02 |
3.02e-02 |
0.3160 |
NA |
0.009760 |
-0.316000 |
9.26e-01 |
2.74e-03 |
| Downstream signaling of activated FGFR1 |
19 |
5.90e-02 |
1.09e-01 |
0.3160 |
NA |
-0.210000 |
0.236000 |
1.13e-01 |
7.48e-02 |
| Glycogen storage diseases |
14 |
1.24e-01 |
1.95e-01 |
0.3160 |
NA |
0.135000 |
-0.286000 |
3.83e-01 |
6.41e-02 |
| Neurotransmitter receptors and postsynaptic signal transmission |
118 |
2.47e-08 |
3.95e-07 |
0.3150 |
NA |
0.028900 |
0.314000 |
5.88e-01 |
3.83e-09 |
| Transport to the Golgi and subsequent modification |
150 |
2.54e-10 |
5.54e-09 |
0.3150 |
NA |
-0.312000 |
0.040600 |
4.21e-11 |
3.91e-01 |
| Regulation of insulin secretion |
53 |
4.02e-04 |
2.13e-03 |
0.3140 |
NA |
-0.066800 |
0.307000 |
4.00e-01 |
1.10e-04 |
| Signaling by ROBO receptors |
195 |
3.41e-13 |
1.05e-11 |
0.3140 |
NA |
-0.277000 |
-0.149000 |
2.73e-11 |
3.54e-04 |
| O-linked glycosylation |
68 |
4.54e-05 |
3.42e-04 |
0.3140 |
NA |
-0.008960 |
0.314000 |
8.98e-01 |
7.78e-06 |
| APC/C:Cdc20 mediated degradation of Cyclin B |
23 |
3.43e-02 |
7.14e-02 |
0.3140 |
NA |
0.162000 |
-0.268000 |
1.78e-01 |
2.58e-02 |
| Reversible hydration of carbon dioxide |
10 |
2.28e-01 |
3.20e-01 |
0.3140 |
NA |
0.083700 |
0.302000 |
6.47e-01 |
9.80e-02 |
| Mitochondrial protein import |
58 |
1.93e-04 |
1.16e-03 |
0.3140 |
NA |
-0.096300 |
-0.298000 |
2.05e-01 |
8.52e-05 |
| Transport of the SLBP independent Mature mRNA |
34 |
6.66e-03 |
2.03e-02 |
0.3140 |
NA |
-0.049400 |
-0.310000 |
6.18e-01 |
1.79e-03 |
| PI-3K cascade:FGFR2 |
10 |
2.31e-01 |
3.24e-01 |
0.3130 |
NA |
-0.153000 |
0.273000 |
4.01e-01 |
1.35e-01 |
| CD209 (DC-SIGN) signaling |
19 |
6.27e-02 |
1.13e-01 |
0.3130 |
NA |
-0.260000 |
0.174000 |
4.99e-02 |
1.89e-01 |
| Autodegradation of the E3 ubiquitin ligase COP1 |
49 |
7.48e-04 |
3.51e-03 |
0.3130 |
NA |
-0.242000 |
-0.197000 |
3.33e-03 |
1.70e-02 |
| The canonical retinoid cycle in rods (twilight vision) |
15 |
1.10e-01 |
1.77e-01 |
0.3120 |
NA |
0.194000 |
0.245000 |
1.93e-01 |
1.01e-01 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation |
47 |
1.02e-03 |
4.50e-03 |
0.3120 |
NA |
-0.256000 |
-0.178000 |
2.36e-03 |
3.49e-02 |
| Macroautophagy |
84 |
4.82e-06 |
5.35e-05 |
0.3120 |
NA |
-0.305000 |
-0.066800 |
1.38e-06 |
2.90e-01 |
| Assembly of collagen fibrils and other multimeric structures |
36 |
5.17e-03 |
1.66e-02 |
0.3120 |
NA |
0.221000 |
0.220000 |
2.19e-02 |
2.24e-02 |
| Acyl chain remodelling of PC |
18 |
7.19e-02 |
1.25e-01 |
0.3120 |
NA |
0.231000 |
0.209000 |
8.96e-02 |
1.25e-01 |
| Toll Like Receptor 9 (TLR9) Cascade |
84 |
5.29e-06 |
5.77e-05 |
0.3110 |
NA |
-0.311000 |
0.018100 |
8.54e-07 |
7.75e-01 |
| Endosomal/Vacuolar pathway |
12 |
1.74e-01 |
2.55e-01 |
0.3110 |
NA |
0.162000 |
0.266000 |
3.31e-01 |
1.11e-01 |
| Iron uptake and transport |
55 |
3.74e-04 |
2.04e-03 |
0.3100 |
NA |
-0.295000 |
0.095500 |
1.53e-04 |
2.21e-01 |
| G alpha (q) signalling events |
98 |
8.22e-07 |
1.09e-05 |
0.3100 |
NA |
-0.123000 |
0.285000 |
3.60e-02 |
1.11e-06 |
| Signaling by EGFR |
42 |
2.41e-03 |
9.33e-03 |
0.3100 |
NA |
-0.301000 |
0.073200 |
7.31e-04 |
4.12e-01 |
| Transcriptional regulation of pluripotent stem cells |
23 |
3.66e-02 |
7.52e-02 |
0.3100 |
NA |
-0.024800 |
0.309000 |
8.37e-01 |
1.03e-02 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) |
10 |
2.39e-01 |
3.31e-01 |
0.3090 |
NA |
-0.297000 |
0.088300 |
1.04e-01 |
6.29e-01 |
| MyD88 dependent cascade initiated on endosome |
81 |
9.47e-06 |
9.43e-05 |
0.3090 |
NA |
-0.309000 |
0.018800 |
1.57e-06 |
7.70e-01 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade |
81 |
9.47e-06 |
9.43e-05 |
0.3090 |
NA |
-0.309000 |
0.018800 |
1.57e-06 |
7.70e-01 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA |
52 |
5.94e-04 |
2.96e-03 |
0.3080 |
NA |
-0.245000 |
-0.187000 |
2.27e-03 |
1.95e-02 |
| Deadenylation-dependent mRNA decay |
56 |
3.42e-04 |
1.92e-03 |
0.3080 |
NA |
-0.092800 |
-0.294000 |
2.30e-01 |
1.43e-04 |
| RMTs methylate histone arginines |
36 |
6.00e-03 |
1.85e-02 |
0.3080 |
NA |
-0.000170 |
-0.308000 |
9.99e-01 |
1.38e-03 |
| Signaling by FGFR3 in disease |
13 |
1.59e-01 |
2.37e-01 |
0.3080 |
NA |
-0.263000 |
0.159000 |
1.00e-01 |
3.20e-01 |
| Signaling by FGFR3 point mutants in cancer |
13 |
1.59e-01 |
2.37e-01 |
0.3080 |
NA |
-0.263000 |
0.159000 |
1.00e-01 |
3.20e-01 |
| Vpr-mediated nuclear import of PICs |
33 |
9.22e-03 |
2.57e-02 |
0.3080 |
NA |
-0.035300 |
-0.306000 |
7.26e-01 |
2.37e-03 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis |
51 |
7.35e-04 |
3.46e-03 |
0.3070 |
NA |
-0.246000 |
-0.183000 |
2.39e-03 |
2.35e-02 |
| Muscle contraction |
120 |
5.05e-08 |
7.61e-07 |
0.3070 |
NA |
-0.021800 |
0.306000 |
6.80e-01 |
7.29e-09 |
| Insulin receptor signalling cascade |
34 |
8.41e-03 |
2.45e-02 |
0.3060 |
NA |
-0.301000 |
-0.057400 |
2.42e-03 |
5.63e-01 |
| Toll Like Receptor 3 (TLR3) Cascade |
87 |
5.62e-06 |
6.08e-05 |
0.3050 |
NA |
-0.303000 |
0.035800 |
1.03e-06 |
5.64e-01 |
| GPVI-mediated activation cascade |
21 |
5.42e-02 |
1.03e-01 |
0.3050 |
NA |
-0.280000 |
0.122000 |
2.66e-02 |
3.33e-01 |
| Negative regulation of FGFR2 signaling |
21 |
5.44e-02 |
1.03e-01 |
0.3050 |
NA |
-0.271000 |
0.139000 |
3.15e-02 |
2.69e-01 |
| Blood group systems biosynthesis |
12 |
1.88e-01 |
2.72e-01 |
0.3050 |
NA |
0.028400 |
-0.303000 |
8.65e-01 |
6.88e-02 |
| Gastrin-CREB signalling pathway via PKC and MAPK |
16 |
1.09e-01 |
1.75e-01 |
0.3050 |
NA |
-0.289000 |
0.097300 |
4.56e-02 |
5.01e-01 |
| Ubiquitin-dependent degradation of Cyclin D |
49 |
1.08e-03 |
4.73e-03 |
0.3050 |
NA |
-0.264000 |
-0.152000 |
1.39e-03 |
6.64e-02 |
| Netrin-1 signaling |
38 |
5.26e-03 |
1.68e-02 |
0.3040 |
NA |
-0.124000 |
0.278000 |
1.86e-01 |
3.03e-03 |
| SUMOylation of SUMOylation proteins |
34 |
9.07e-03 |
2.56e-02 |
0.3040 |
NA |
-0.040800 |
-0.301000 |
6.80e-01 |
2.39e-03 |
| Export of Viral Ribonucleoproteins from Nucleus |
32 |
1.21e-02 |
3.20e-02 |
0.3030 |
NA |
-0.030500 |
-0.302000 |
7.66e-01 |
3.13e-03 |
| ABC transporter disorders |
68 |
8.33e-05 |
5.78e-04 |
0.3030 |
NA |
-0.243000 |
-0.181000 |
5.31e-04 |
9.75e-03 |
| Glyoxylate metabolism and glycine degradation |
27 |
2.45e-02 |
5.47e-02 |
0.3030 |
NA |
0.293000 |
-0.077700 |
8.39e-03 |
4.85e-01 |
| ATF4 activates genes in response to endoplasmic reticulum stress |
24 |
3.61e-02 |
7.46e-02 |
0.3030 |
NA |
-0.183000 |
-0.241000 |
1.20e-01 |
4.07e-02 |
| Regulation of gene expression in beta cells |
14 |
1.47e-01 |
2.23e-01 |
0.3030 |
NA |
0.199000 |
-0.228000 |
1.97e-01 |
1.39e-01 |
| Rap1 signalling |
14 |
1.49e-01 |
2.25e-01 |
0.3020 |
NA |
-0.127000 |
0.274000 |
4.10e-01 |
7.59e-02 |
| IRAK1 recruits IKK complex |
10 |
2.57e-01 |
3.51e-01 |
0.3020 |
NA |
-0.235000 |
0.189000 |
1.97e-01 |
3.00e-01 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation |
10 |
2.57e-01 |
3.51e-01 |
0.3020 |
NA |
-0.235000 |
0.189000 |
1.97e-01 |
3.00e-01 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) |
12 |
1.95e-01 |
2.80e-01 |
0.3020 |
NA |
-0.297000 |
0.052000 |
7.47e-02 |
7.55e-01 |
| Activation of BAD and translocation to mitochondria |
15 |
1.30e-01 |
2.03e-01 |
0.3010 |
NA |
-0.298000 |
0.043000 |
4.54e-02 |
7.73e-01 |
| RAB geranylgeranylation |
54 |
6.83e-04 |
3.25e-03 |
0.3010 |
NA |
-0.187000 |
0.236000 |
1.75e-02 |
2.70e-03 |
| G alpha (s) signalling events |
68 |
1.03e-04 |
6.96e-04 |
0.3010 |
NA |
-0.074400 |
0.292000 |
2.89e-01 |
3.23e-05 |
| Inactivation, recovery and regulation of the phototransduction cascade |
20 |
6.84e-02 |
1.20e-01 |
0.3000 |
NA |
-0.110000 |
0.279000 |
3.94e-01 |
3.09e-02 |
| UCH proteinases |
85 |
1.07e-05 |
1.05e-04 |
0.3000 |
NA |
-0.252000 |
-0.162000 |
5.82e-05 |
1.01e-02 |
| Sema4D in semaphorin signaling |
24 |
4.07e-02 |
8.21e-02 |
0.2990 |
NA |
-0.196000 |
0.226000 |
9.59e-02 |
5.57e-02 |
| Regulation of RUNX3 expression and activity |
54 |
7.06e-04 |
3.34e-03 |
0.2990 |
NA |
-0.263000 |
-0.143000 |
8.49e-04 |
6.87e-02 |
| Phase II - Conjugation of compounds |
74 |
5.83e-05 |
4.24e-04 |
0.2980 |
NA |
0.258000 |
-0.149000 |
1.27e-04 |
2.68e-02 |
| Formation of the cornified envelope |
20 |
6.98e-02 |
1.22e-01 |
0.2980 |
NA |
-0.113000 |
-0.275000 |
3.82e-01 |
3.31e-02 |
| PTEN Regulation |
136 |
1.58e-08 |
2.62e-07 |
0.2970 |
NA |
-0.239000 |
-0.176000 |
1.49e-06 |
3.91e-04 |
| Cyclin A/B1/B2 associated events during G2/M transition |
24 |
4.25e-02 |
8.45e-02 |
0.2970 |
NA |
0.274000 |
-0.114000 |
2.00e-02 |
3.34e-01 |
| Constitutive Signaling by AKT1 E17K in Cancer |
26 |
3.26e-02 |
6.92e-02 |
0.2960 |
NA |
-0.291000 |
-0.055700 |
1.02e-02 |
6.23e-01 |
| p75NTR recruits signalling complexes |
12 |
2.06e-01 |
2.95e-01 |
0.2960 |
NA |
-0.296000 |
-0.011500 |
7.60e-02 |
9.45e-01 |
| RNA Polymerase III Transcription Termination |
23 |
4.83e-02 |
9.38e-02 |
0.2960 |
NA |
-0.252000 |
-0.155000 |
3.66e-02 |
1.97e-01 |
| RHO GTPases activate KTN1 |
11 |
2.38e-01 |
3.30e-01 |
0.2960 |
NA |
-0.273000 |
0.113000 |
1.17e-01 |
5.16e-01 |
| Downstream TCR signaling |
77 |
4.10e-05 |
3.12e-04 |
0.2960 |
NA |
-0.269000 |
-0.122000 |
4.44e-05 |
6.34e-02 |
| DARPP-32 events |
22 |
5.69e-02 |
1.07e-01 |
0.2960 |
NA |
-0.236000 |
0.178000 |
5.52e-02 |
1.49e-01 |
| Regulation of mRNA stability by proteins that bind AU-rich elements |
86 |
1.29e-05 |
1.22e-04 |
0.2950 |
NA |
-0.223000 |
-0.194000 |
3.61e-04 |
1.88e-03 |
| PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases |
13 |
1.83e-01 |
2.65e-01 |
0.2950 |
NA |
-0.295000 |
0.017100 |
6.58e-02 |
9.15e-01 |
| Signaling by FGFR4 in disease |
11 |
2.39e-01 |
3.31e-01 |
0.2950 |
NA |
-0.295000 |
-0.006960 |
9.06e-02 |
9.68e-01 |
| Dectin-1 mediated noncanonical NF-kB signaling |
57 |
5.94e-04 |
2.96e-03 |
0.2950 |
NA |
-0.262000 |
-0.135000 |
6.32e-04 |
7.78e-02 |
| Elastic fibre formation |
29 |
2.27e-02 |
5.22e-02 |
0.2940 |
NA |
0.147000 |
0.255000 |
1.71e-01 |
1.74e-02 |
| Ion transport by P-type ATPases |
37 |
8.38e-03 |
2.45e-02 |
0.2940 |
NA |
-0.079600 |
0.283000 |
4.02e-01 |
2.87e-03 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding |
31 |
1.84e-02 |
4.39e-02 |
0.2940 |
NA |
-0.276000 |
0.101000 |
7.78e-03 |
3.32e-01 |
| Biosynthesis of specialized proresolving mediators (SPMs) |
11 |
2.40e-01 |
3.33e-01 |
0.2940 |
NA |
0.076600 |
0.284000 |
6.60e-01 |
1.03e-01 |
| Signaling by TGF-beta Receptor Complex |
72 |
9.42e-05 |
6.44e-04 |
0.2930 |
NA |
-0.281000 |
-0.083100 |
3.74e-05 |
2.23e-01 |
| Chondroitin sulfate/dermatan sulfate metabolism |
47 |
2.43e-03 |
9.39e-03 |
0.2930 |
NA |
-0.016000 |
0.292000 |
8.49e-01 |
5.30e-04 |
| Transport of the SLBP Dependant Mature mRNA |
35 |
1.14e-02 |
3.06e-02 |
0.2920 |
NA |
-0.072600 |
-0.283000 |
4.58e-01 |
3.82e-03 |
| Sema3A PAK dependent Axon repulsion |
16 |
1.32e-01 |
2.05e-01 |
0.2910 |
NA |
-0.121000 |
0.265000 |
4.01e-01 |
6.68e-02 |
| Beta-catenin phosphorylation cascade |
17 |
1.15e-01 |
1.84e-01 |
0.2910 |
NA |
-0.278000 |
-0.084800 |
4.70e-02 |
5.45e-01 |
| Pink/Parkin Mediated Mitophagy |
18 |
1.02e-01 |
1.66e-01 |
0.2910 |
NA |
-0.287000 |
-0.044900 |
3.48e-02 |
7.42e-01 |
| NIK–>noncanonical NF-kB signaling |
56 |
8.20e-04 |
3.77e-03 |
0.2910 |
NA |
-0.259000 |
-0.131000 |
7.86e-04 |
9.00e-02 |
| p38MAPK events |
13 |
1.94e-01 |
2.79e-01 |
0.2910 |
NA |
-0.264000 |
0.122000 |
9.95e-02 |
4.47e-01 |
| Signaling by Leptin |
10 |
2.87e-01 |
3.81e-01 |
0.2890 |
NA |
0.152000 |
-0.246000 |
4.04e-01 |
1.78e-01 |
| PI3K Cascade |
25 |
4.31e-02 |
8.52e-02 |
0.2890 |
NA |
-0.274000 |
-0.093100 |
1.78e-02 |
4.21e-01 |
| Membrane binding and targetting of GAG proteins |
14 |
1.71e-01 |
2.53e-01 |
0.2890 |
NA |
-0.232000 |
-0.172000 |
1.32e-01 |
2.65e-01 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins |
14 |
1.71e-01 |
2.53e-01 |
0.2890 |
NA |
-0.232000 |
-0.172000 |
1.32e-01 |
2.65e-01 |
| L1CAM interactions |
78 |
6.43e-05 |
4.62e-04 |
0.2890 |
NA |
-0.140000 |
0.252000 |
3.25e-02 |
1.18e-04 |
| MyD88-independent TLR4 cascade |
90 |
1.42e-05 |
1.30e-04 |
0.2880 |
NA |
-0.287000 |
0.028700 |
2.56e-06 |
6.38e-01 |
| TRIF(TICAM1)-mediated TLR4 signaling |
90 |
1.42e-05 |
1.30e-04 |
0.2880 |
NA |
-0.287000 |
0.028700 |
2.56e-06 |
6.38e-01 |
| Non-genomic estrogen signaling |
57 |
8.73e-04 |
3.98e-03 |
0.2880 |
NA |
-0.273000 |
0.092800 |
3.73e-04 |
2.26e-01 |
| Metabolism of non-coding RNA |
52 |
1.59e-03 |
6.53e-03 |
0.2880 |
NA |
0.026900 |
-0.287000 |
7.37e-01 |
3.49e-04 |
| snRNP Assembly |
52 |
1.59e-03 |
6.53e-03 |
0.2880 |
NA |
0.026900 |
-0.287000 |
7.37e-01 |
3.49e-04 |
| Downstream signaling events of B Cell Receptor (BCR) |
77 |
7.37e-05 |
5.21e-04 |
0.2870 |
NA |
-0.281000 |
-0.061400 |
2.07e-05 |
3.52e-01 |
| Protein methylation |
15 |
1.57e-01 |
2.35e-01 |
0.2870 |
NA |
-0.003430 |
-0.287000 |
9.82e-01 |
5.43e-02 |
| SCF-beta-TrCP mediated degradation of Emi1 |
52 |
1.60e-03 |
6.53e-03 |
0.2870 |
NA |
-0.225000 |
-0.179000 |
5.08e-03 |
2.60e-02 |
| ADP signalling through P2Y purinoceptor 12 |
12 |
2.29e-01 |
3.21e-01 |
0.2870 |
NA |
-0.165000 |
0.235000 |
3.22e-01 |
1.59e-01 |
| Biosynthesis of DHA-derived SPMs |
10 |
2.90e-01 |
3.84e-01 |
0.2870 |
NA |
0.166000 |
0.234000 |
3.64e-01 |
2.00e-01 |
| Attenuation phase |
23 |
5.87e-02 |
1.09e-01 |
0.2860 |
NA |
-0.269000 |
-0.098200 |
2.56e-02 |
4.15e-01 |
| Signaling by NTRKs |
84 |
3.66e-05 |
2.91e-04 |
0.2860 |
NA |
-0.276000 |
0.075100 |
1.26e-05 |
2.35e-01 |
| E2F mediated regulation of DNA replication |
22 |
6.71e-02 |
1.19e-01 |
0.2860 |
NA |
0.267000 |
0.103000 |
3.05e-02 |
4.03e-01 |
| KSRP (KHSRP) binds and destabilizes mRNA |
17 |
1.24e-01 |
1.95e-01 |
0.2860 |
NA |
-0.127000 |
-0.256000 |
3.66e-01 |
6.75e-02 |
| Glutathione synthesis and recycling |
12 |
2.33e-01 |
3.25e-01 |
0.2850 |
NA |
0.277000 |
-0.068400 |
9.72e-02 |
6.82e-01 |
| Regulation of actin dynamics for phagocytic cup formation |
50 |
2.39e-03 |
9.26e-03 |
0.2850 |
NA |
-0.275000 |
0.073600 |
7.76e-04 |
3.68e-01 |
| TAK1 activates NFkB by phosphorylation and activation of IKKs complex |
25 |
4.85e-02 |
9.39e-02 |
0.2840 |
NA |
-0.268000 |
-0.094100 |
2.05e-02 |
4.15e-01 |
| Myogenesis |
21 |
8.08e-02 |
1.38e-01 |
0.2840 |
NA |
-0.203000 |
0.198000 |
1.07e-01 |
1.16e-01 |
| Resolution of Abasic Sites (AP sites) |
38 |
1.04e-02 |
2.85e-02 |
0.2830 |
NA |
0.280000 |
-0.040900 |
2.78e-03 |
6.63e-01 |
| RNA Polymerase III Abortive And Retractive Initiation |
41 |
7.07e-03 |
2.12e-02 |
0.2830 |
NA |
-0.202000 |
-0.199000 |
2.54e-02 |
2.76e-02 |
| RNA Polymerase III Transcription |
41 |
7.07e-03 |
2.12e-02 |
0.2830 |
NA |
-0.202000 |
-0.199000 |
2.54e-02 |
2.76e-02 |
| Mitochondrial calcium ion transport |
22 |
7.02e-02 |
1.23e-01 |
0.2830 |
NA |
-0.114000 |
-0.259000 |
3.53e-01 |
3.54e-02 |
| Vif-mediated degradation of APOBEC3G |
49 |
2.73e-03 |
1.04e-02 |
0.2830 |
NA |
-0.221000 |
-0.176000 |
7.35e-03 |
3.28e-02 |
| Inwardly rectifying K+ channels |
13 |
2.10e-01 |
2.99e-01 |
0.2830 |
NA |
-0.005150 |
0.283000 |
9.74e-01 |
7.73e-02 |
| Degradation of GLI2 by the proteasome |
55 |
1.43e-03 |
5.95e-03 |
0.2820 |
NA |
-0.248000 |
-0.134000 |
1.49e-03 |
8.65e-02 |
| GLI3 is processed to GLI3R by the proteasome |
55 |
1.43e-03 |
5.95e-03 |
0.2820 |
NA |
-0.248000 |
-0.134000 |
1.49e-03 |
8.65e-02 |
| Degradation of GLI1 by the proteasome |
56 |
1.29e-03 |
5.45e-03 |
0.2810 |
NA |
-0.254000 |
-0.120000 |
9.91e-04 |
1.21e-01 |
| Intra-Golgi traffic |
40 |
9.01e-03 |
2.56e-02 |
0.2810 |
NA |
-0.268000 |
0.083200 |
3.33e-03 |
3.63e-01 |
| Basigin interactions |
23 |
6.84e-02 |
1.20e-01 |
0.2800 |
NA |
-0.203000 |
0.192000 |
9.17e-02 |
1.10e-01 |
| TICAM1-dependent activation of IRF3/IRF7 |
11 |
2.76e-01 |
3.72e-01 |
0.2800 |
NA |
-0.267000 |
0.082800 |
1.25e-01 |
6.34e-01 |
| IRS-mediated signalling |
29 |
3.33e-02 |
7.01e-02 |
0.2800 |
NA |
-0.272000 |
-0.063300 |
1.12e-02 |
5.55e-01 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC |
25 |
5.47e-02 |
1.03e-01 |
0.2780 |
NA |
-0.273000 |
-0.053800 |
1.81e-02 |
6.42e-01 |
| Interactions of Vpr with host cellular proteins |
36 |
1.52e-02 |
3.80e-02 |
0.2780 |
NA |
-0.075300 |
-0.268000 |
4.34e-01 |
5.42e-03 |
| Degradation of beta-catenin by the destruction complex |
81 |
8.36e-05 |
5.78e-04 |
0.2780 |
NA |
-0.250000 |
-0.122000 |
1.01e-04 |
5.84e-02 |
| Interleukin-12 family signaling |
45 |
5.39e-03 |
1.70e-02 |
0.2780 |
NA |
-0.239000 |
-0.143000 |
5.64e-03 |
9.81e-02 |
| N-glycan antennae elongation in the medial/trans-Golgi |
19 |
1.10e-01 |
1.77e-01 |
0.2780 |
NA |
-0.247000 |
-0.127000 |
6.23e-02 |
3.38e-01 |
| TCR signaling |
92 |
2.47e-05 |
2.10e-04 |
0.2780 |
NA |
-0.275000 |
-0.036200 |
5.03e-06 |
5.49e-01 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus |
24 |
6.35e-02 |
1.14e-01 |
0.2780 |
NA |
-0.195000 |
0.198000 |
9.90e-02 |
9.30e-02 |
| The role of GTSE1 in G2/M progression after G2 checkpoint |
57 |
1.36e-03 |
5.71e-03 |
0.2780 |
NA |
-0.201000 |
-0.191000 |
8.60e-03 |
1.26e-02 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling |
31 |
2.89e-02 |
6.24e-02 |
0.2770 |
NA |
-0.240000 |
0.139000 |
2.10e-02 |
1.81e-01 |
| Association of TriC/CCT with target proteins during biosynthesis |
38 |
1.25e-02 |
3.29e-02 |
0.2770 |
NA |
-0.133000 |
-0.243000 |
1.56e-01 |
9.57e-03 |
| PI Metabolism |
71 |
3.13e-04 |
1.77e-03 |
0.2760 |
NA |
-0.272000 |
0.049400 |
7.61e-05 |
4.72e-01 |
| Glucagon-type ligand receptors |
15 |
1.81e-01 |
2.63e-01 |
0.2750 |
NA |
0.103000 |
0.255000 |
4.90e-01 |
8.68e-02 |
| Sema4D induced cell migration and growth-cone collapse |
20 |
1.05e-01 |
1.71e-01 |
0.2750 |
NA |
-0.127000 |
0.244000 |
3.27e-01 |
5.92e-02 |
| Metabolism of water-soluble vitamins and cofactors |
98 |
1.77e-05 |
1.56e-04 |
0.2740 |
NA |
0.075400 |
-0.263000 |
1.97e-01 |
6.67e-06 |
| mRNA decay by 3’ to 5’ exoribonuclease |
16 |
1.67e-01 |
2.48e-01 |
0.2740 |
NA |
0.069300 |
-0.265000 |
6.31e-01 |
6.67e-02 |
| Signaling by the B Cell Receptor (BCR) |
100 |
1.41e-05 |
1.30e-04 |
0.2740 |
NA |
-0.273000 |
0.014000 |
2.34e-06 |
8.08e-01 |
| Energy dependent regulation of mTOR by LKB1-AMPK |
28 |
4.33e-02 |
8.55e-02 |
0.2730 |
NA |
-0.247000 |
-0.117000 |
2.38e-02 |
2.86e-01 |
| Host Interactions with Influenza Factors |
42 |
9.03e-03 |
2.56e-02 |
0.2730 |
NA |
-0.166000 |
-0.217000 |
6.27e-02 |
1.51e-02 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism |
13 |
2.33e-01 |
3.25e-01 |
0.2730 |
NA |
0.254000 |
0.098500 |
1.12e-01 |
5.39e-01 |
| alpha-linolenic acid (ALA) metabolism |
13 |
2.33e-01 |
3.25e-01 |
0.2730 |
NA |
0.254000 |
0.098500 |
1.12e-01 |
5.39e-01 |
| Regulation of Apoptosis |
50 |
3.73e-03 |
1.30e-02 |
0.2730 |
NA |
-0.223000 |
-0.158000 |
6.48e-03 |
5.41e-02 |
| Regulation of ornithine decarboxylase (ODC) |
48 |
4.67e-03 |
1.54e-02 |
0.2730 |
NA |
-0.230000 |
-0.147000 |
5.88e-03 |
7.86e-02 |
| SUMOylation of DNA replication proteins |
45 |
6.95e-03 |
2.11e-02 |
0.2720 |
NA |
0.070300 |
-0.263000 |
4.15e-01 |
2.29e-03 |
| SHC1 events in ERBB2 signaling |
18 |
1.38e-01 |
2.13e-01 |
0.2720 |
NA |
-0.212000 |
0.170000 |
1.20e-01 |
2.11e-01 |
| DNA Damage Recognition in GG-NER |
38 |
1.49e-02 |
3.75e-02 |
0.2710 |
NA |
-0.090500 |
-0.256000 |
3.34e-01 |
6.34e-03 |
| Negative regulation of NOTCH4 signaling |
53 |
2.83e-03 |
1.05e-02 |
0.2710 |
NA |
-0.213000 |
-0.169000 |
7.47e-03 |
3.36e-02 |
| Fcgamma receptor (FCGR) dependent phagocytosis |
69 |
5.25e-04 |
2.67e-03 |
0.2710 |
NA |
-0.230000 |
0.144000 |
9.50e-04 |
3.92e-02 |
| Purine catabolism |
15 |
1.93e-01 |
2.78e-01 |
0.2710 |
NA |
0.078600 |
-0.259000 |
5.98e-01 |
8.23e-02 |
| Pausing and recovery of Tat-mediated HIV elongation |
27 |
5.15e-02 |
9.86e-02 |
0.2710 |
NA |
-0.265000 |
-0.055200 |
1.72e-02 |
6.20e-01 |
| Tat-mediated HIV elongation arrest and recovery |
27 |
5.15e-02 |
9.86e-02 |
0.2710 |
NA |
-0.265000 |
-0.055200 |
1.72e-02 |
6.20e-01 |
| EPHB-mediated forward signaling |
34 |
2.46e-02 |
5.47e-02 |
0.2700 |
NA |
-0.226000 |
0.148000 |
2.25e-02 |
1.35e-01 |
| NS1 Mediated Effects on Host Pathways |
40 |
1.26e-02 |
3.30e-02 |
0.2700 |
NA |
-0.136000 |
-0.233000 |
1.36e-01 |
1.09e-02 |
| Signaling by Erythropoietin |
22 |
9.19e-02 |
1.53e-01 |
0.2700 |
NA |
-0.249000 |
0.104000 |
4.35e-02 |
3.98e-01 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 |
13 |
2.42e-01 |
3.35e-01 |
0.2690 |
NA |
0.247000 |
0.107000 |
1.23e-01 |
5.04e-01 |
| FCERI mediated NF-kB activation |
73 |
3.57e-04 |
1.97e-03 |
0.2690 |
NA |
-0.229000 |
-0.141000 |
7.18e-04 |
3.69e-02 |
| Acyl chain remodelling of PG |
11 |
3.02e-01 |
3.96e-01 |
0.2690 |
NA |
0.253000 |
0.091000 |
1.46e-01 |
6.01e-01 |
| RUNX2 regulates osteoblast differentiation |
18 |
1.41e-01 |
2.17e-01 |
0.2690 |
NA |
0.074800 |
0.258000 |
5.83e-01 |
5.77e-02 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus |
21 |
1.04e-01 |
1.69e-01 |
0.2690 |
NA |
-0.103000 |
0.248000 |
4.16e-01 |
4.89e-02 |
| Retrograde transport at the Trans-Golgi-Network |
48 |
5.77e-03 |
1.79e-02 |
0.2680 |
NA |
-0.267000 |
-0.014400 |
1.35e-03 |
8.63e-01 |
| Glucagon signaling in metabolic regulation |
23 |
8.50e-02 |
1.44e-01 |
0.2670 |
NA |
0.038900 |
0.264000 |
7.47e-01 |
2.82e-02 |
| Transmission across Chemical Synapses |
161 |
3.82e-08 |
5.90e-07 |
0.2670 |
NA |
-0.007450 |
0.267000 |
8.71e-01 |
5.12e-09 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha |
61 |
1.45e-03 |
5.99e-03 |
0.2670 |
NA |
-0.215000 |
-0.158000 |
3.70e-03 |
3.24e-02 |
| Stabilization of p53 |
54 |
3.12e-03 |
1.13e-02 |
0.2670 |
NA |
-0.197000 |
-0.180000 |
1.23e-02 |
2.24e-02 |
| Hyaluronan uptake and degradation |
11 |
3.11e-01 |
4.07e-01 |
0.2660 |
NA |
-0.078600 |
0.255000 |
6.52e-01 |
1.44e-01 |
| Nuclear Envelope Breakdown |
52 |
4.09e-03 |
1.39e-02 |
0.2660 |
NA |
0.024600 |
-0.265000 |
7.59e-01 |
9.54e-04 |
| IGF1R signaling cascade |
32 |
3.34e-02 |
7.01e-02 |
0.2660 |
NA |
-0.258000 |
-0.064300 |
1.15e-02 |
5.29e-01 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) |
32 |
3.34e-02 |
7.01e-02 |
0.2660 |
NA |
-0.258000 |
-0.064300 |
1.15e-02 |
5.29e-01 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling |
20 |
1.20e-01 |
1.90e-01 |
0.2660 |
NA |
-0.260000 |
-0.057200 |
4.44e-02 |
6.58e-01 |
| Cellular response to hypoxia |
70 |
6.04e-04 |
2.97e-03 |
0.2660 |
NA |
-0.210000 |
-0.163000 |
2.41e-03 |
1.86e-02 |
| Import of palmitoyl-CoA into the mitochondrial matrix |
11 |
3.15e-01 |
4.10e-01 |
0.2650 |
NA |
0.188000 |
-0.188000 |
2.81e-01 |
2.81e-01 |
| Neuronal System |
223 |
8.12e-11 |
1.90e-09 |
0.2650 |
NA |
0.002920 |
0.265000 |
9.40e-01 |
9.37e-12 |
| Cargo recognition for clathrin-mediated endocytosis |
82 |
1.96e-04 |
1.17e-03 |
0.2650 |
NA |
-0.186000 |
0.188000 |
3.53e-03 |
3.26e-03 |
| Kinesins |
38 |
1.84e-02 |
4.40e-02 |
0.2640 |
NA |
0.165000 |
0.207000 |
7.92e-02 |
2.74e-02 |
| TP53 Regulates Transcription of Death Receptors and Ligands |
11 |
3.15e-01 |
4.10e-01 |
0.2640 |
NA |
-0.139000 |
-0.224000 |
4.23e-01 |
1.98e-01 |
| Synthesis of bile acids and bile salts |
28 |
5.33e-02 |
1.02e-01 |
0.2640 |
NA |
-0.164000 |
-0.207000 |
1.33e-01 |
5.86e-02 |
| RHO GTPases activate CIT |
19 |
1.38e-01 |
2.13e-01 |
0.2640 |
NA |
-0.027000 |
0.262000 |
8.39e-01 |
4.78e-02 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter |
28 |
5.35e-02 |
1.02e-01 |
0.2640 |
NA |
-0.208000 |
-0.162000 |
5.69e-02 |
1.38e-01 |
| Activation of G protein gated Potassium channels |
11 |
3.18e-01 |
4.12e-01 |
0.2640 |
NA |
0.005520 |
0.263000 |
9.75e-01 |
1.30e-01 |
| G protein gated Potassium channels |
11 |
3.18e-01 |
4.12e-01 |
0.2640 |
NA |
0.005520 |
0.263000 |
9.75e-01 |
1.30e-01 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits |
11 |
3.18e-01 |
4.12e-01 |
0.2640 |
NA |
0.005520 |
0.263000 |
9.75e-01 |
1.30e-01 |
| Vpu mediated degradation of CD4 |
49 |
6.07e-03 |
1.86e-02 |
0.2630 |
NA |
-0.212000 |
-0.157000 |
1.04e-02 |
5.80e-02 |
| Signal transduction by L1 |
20 |
1.26e-01 |
1.98e-01 |
0.2630 |
NA |
-0.245000 |
0.095300 |
5.76e-02 |
4.61e-01 |
| Processing and activation of SUMO |
10 |
3.55e-01 |
4.51e-01 |
0.2630 |
NA |
-0.013600 |
-0.262000 |
9.41e-01 |
1.51e-01 |
| Termination of O-glycan biosynthesis |
14 |
2.40e-01 |
3.33e-01 |
0.2610 |
NA |
-0.237000 |
0.111000 |
1.25e-01 |
4.73e-01 |
| Dopamine Neurotransmitter Release Cycle |
17 |
1.76e-01 |
2.57e-01 |
0.2610 |
NA |
0.027600 |
0.260000 |
8.44e-01 |
6.38e-02 |
| PIP3 activates AKT signaling |
225 |
1.45e-10 |
3.33e-09 |
0.2600 |
NA |
-0.244000 |
-0.090600 |
3.00e-10 |
1.94e-02 |
| RAF activation |
30 |
4.84e-02 |
9.38e-02 |
0.2600 |
NA |
-0.258000 |
0.026300 |
1.43e-02 |
8.03e-01 |
| Lysine catabolism |
12 |
2.98e-01 |
3.92e-01 |
0.2590 |
NA |
0.258000 |
0.021500 |
1.21e-01 |
8.97e-01 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 |
11 |
3.29e-01 |
4.24e-01 |
0.2590 |
NA |
-0.239000 |
-0.099600 |
1.70e-01 |
5.67e-01 |
| Cilium Assembly |
177 |
2.06e-08 |
3.36e-07 |
0.2590 |
NA |
0.166000 |
0.199000 |
1.45e-04 |
5.20e-06 |
| Activation of kainate receptors upon glutamate binding |
17 |
1.83e-01 |
2.65e-01 |
0.2580 |
NA |
0.022500 |
0.257000 |
8.73e-01 |
6.63e-02 |
| Interleukin-1 signaling |
93 |
9.24e-05 |
6.35e-04 |
0.2580 |
NA |
-0.238000 |
-0.101000 |
7.59e-05 |
9.16e-02 |
| Signaling by MET |
62 |
2.13e-03 |
8.46e-03 |
0.2580 |
NA |
-0.244000 |
0.082900 |
8.79e-04 |
2.59e-01 |
| HDL remodeling |
10 |
3.72e-01 |
4.68e-01 |
0.2570 |
NA |
0.249000 |
-0.064200 |
1.73e-01 |
7.25e-01 |
| Signaling by VEGF |
90 |
1.41e-04 |
8.99e-04 |
0.2570 |
NA |
-0.253000 |
0.043200 |
3.26e-05 |
4.79e-01 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway |
25 |
8.47e-02 |
1.44e-01 |
0.2560 |
NA |
0.242000 |
0.083900 |
3.61e-02 |
4.68e-01 |
| Early Phase of HIV Life Cycle |
13 |
2.80e-01 |
3.75e-01 |
0.2560 |
NA |
0.114000 |
-0.229000 |
4.75e-01 |
1.52e-01 |
| Hyaluronan metabolism |
13 |
2.80e-01 |
3.75e-01 |
0.2560 |
NA |
-0.084700 |
0.242000 |
5.97e-01 |
1.31e-01 |
| PKMTs methylate histone lysines |
37 |
2.64e-02 |
5.79e-02 |
0.2550 |
NA |
-0.182000 |
-0.179000 |
5.55e-02 |
5.92e-02 |
| HDACs deacetylate histones |
43 |
1.49e-02 |
3.75e-02 |
0.2550 |
NA |
-0.243000 |
-0.079100 |
5.91e-03 |
3.70e-01 |
| Infectious disease |
351 |
2.26e-15 |
7.94e-14 |
0.2550 |
NA |
-0.225000 |
-0.121000 |
5.26e-13 |
1.08e-04 |
| PI3K/AKT Signaling in Cancer |
69 |
1.25e-03 |
5.31e-03 |
0.2550 |
NA |
-0.249000 |
0.056700 |
3.58e-04 |
4.16e-01 |
| Fc epsilon receptor (FCERI) signaling |
115 |
1.51e-05 |
1.37e-04 |
0.2540 |
NA |
-0.254000 |
-0.006850 |
2.48e-06 |
8.99e-01 |
| Keratinization |
28 |
6.55e-02 |
1.17e-01 |
0.2540 |
NA |
-0.199000 |
-0.158000 |
6.79e-02 |
1.48e-01 |
| IRAK2 mediated activation of TAK1 complex |
10 |
3.78e-01 |
4.74e-01 |
0.2540 |
NA |
-0.138000 |
-0.214000 |
4.51e-01 |
2.42e-01 |
| SUMOylation of chromatin organization proteins |
56 |
4.53e-03 |
1.52e-02 |
0.2540 |
NA |
-0.009080 |
-0.254000 |
9.07e-01 |
1.03e-03 |
| Biological oxidations |
153 |
5.36e-07 |
7.45e-06 |
0.2530 |
NA |
0.216000 |
-0.130000 |
3.96e-06 |
5.46e-03 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation |
13 |
2.88e-01 |
3.82e-01 |
0.2520 |
NA |
-0.075600 |
-0.241000 |
6.37e-01 |
1.33e-01 |
| Synthesis of PIPs at the plasma membrane |
44 |
1.52e-02 |
3.79e-02 |
0.2520 |
NA |
-0.251000 |
-0.024300 |
3.98e-03 |
7.80e-01 |
| Vasopressin regulates renal water homeostasis via Aquaporins |
27 |
7.75e-02 |
1.33e-01 |
0.2520 |
NA |
-0.023400 |
0.251000 |
8.33e-01 |
2.43e-02 |
| IRS-related events triggered by IGF1R |
31 |
5.27e-02 |
1.01e-01 |
0.2510 |
NA |
-0.235000 |
-0.089000 |
2.35e-02 |
3.91e-01 |
| mRNA decay by 5’ to 3’ exoribonuclease |
15 |
2.41e-01 |
3.33e-01 |
0.2510 |
NA |
-0.099900 |
-0.231000 |
5.03e-01 |
1.22e-01 |
| Synthesis of PA |
25 |
9.46e-02 |
1.56e-01 |
0.2510 |
NA |
0.247000 |
0.040600 |
3.23e-02 |
7.25e-01 |
| Complex I biogenesis |
55 |
5.69e-03 |
1.77e-02 |
0.2510 |
NA |
-0.029900 |
-0.249000 |
7.01e-01 |
1.42e-03 |
| TICAM1,TRAF6-dependent induction of TAK1 complex |
10 |
3.90e-01 |
4.86e-01 |
0.2500 |
NA |
-0.073500 |
-0.239000 |
6.87e-01 |
1.90e-01 |
| Transcriptional activation of mitochondrial biogenesis |
50 |
9.09e-03 |
2.56e-02 |
0.2500 |
NA |
-0.113000 |
-0.223000 |
1.69e-01 |
6.29e-03 |
| Endogenous sterols |
19 |
1.71e-01 |
2.53e-01 |
0.2500 |
NA |
0.158000 |
-0.194000 |
2.34e-01 |
1.44e-01 |
| Signal amplification |
18 |
1.88e-01 |
2.71e-01 |
0.2500 |
NA |
-0.182000 |
0.171000 |
1.81e-01 |
2.10e-01 |
| Ion channel transport |
116 |
2.26e-05 |
1.93e-04 |
0.2490 |
NA |
-0.168000 |
0.184000 |
1.78e-03 |
6.10e-04 |
| mRNA Splicing - Minor Pathway |
51 |
8.53e-03 |
2.48e-02 |
0.2490 |
NA |
-0.129000 |
-0.213000 |
1.10e-01 |
8.48e-03 |
| HIV elongation arrest and recovery |
29 |
6.68e-02 |
1.18e-01 |
0.2490 |
NA |
-0.239000 |
-0.071200 |
2.60e-02 |
5.07e-01 |
| Pausing and recovery of HIV elongation |
29 |
6.68e-02 |
1.18e-01 |
0.2490 |
NA |
-0.239000 |
-0.071200 |
2.60e-02 |
5.07e-01 |
| Repression of WNT target genes |
14 |
2.73e-01 |
3.70e-01 |
0.2490 |
NA |
-0.235000 |
0.082400 |
1.28e-01 |
5.94e-01 |
| Ovarian tumor domain proteases |
35 |
3.90e-02 |
7.91e-02 |
0.2490 |
NA |
-0.245000 |
-0.043700 |
1.22e-02 |
6.54e-01 |
| Mitochondrial biogenesis |
71 |
1.41e-03 |
5.89e-03 |
0.2480 |
NA |
-0.134000 |
-0.209000 |
5.14e-02 |
2.33e-03 |
| Regulation of RAS by GAPs |
63 |
2.98e-03 |
1.09e-02 |
0.2480 |
NA |
-0.225000 |
-0.104000 |
2.02e-03 |
1.52e-01 |
| Transcriptional regulation by RUNX3 |
94 |
1.73e-04 |
1.07e-03 |
0.2480 |
NA |
-0.190000 |
-0.160000 |
1.50e-03 |
7.49e-03 |
| Chromosome Maintenance |
76 |
9.38e-04 |
4.19e-03 |
0.2480 |
NA |
0.241000 |
0.056300 |
2.81e-04 |
3.97e-01 |
| Lewis blood group biosynthesis |
11 |
3.64e-01 |
4.59e-01 |
0.2470 |
NA |
-0.047400 |
-0.243000 |
7.86e-01 |
1.63e-01 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane |
86 |
3.94e-04 |
2.09e-03 |
0.2470 |
NA |
-0.245000 |
0.032900 |
8.59e-05 |
5.99e-01 |
| Toll Like Receptor 2 (TLR2) Cascade |
86 |
3.94e-04 |
2.09e-03 |
0.2470 |
NA |
-0.245000 |
0.032900 |
8.59e-05 |
5.99e-01 |
| Toll Like Receptor TLR1:TLR2 Cascade |
86 |
3.94e-04 |
2.09e-03 |
0.2470 |
NA |
-0.245000 |
0.032900 |
8.59e-05 |
5.99e-01 |
| Toll Like Receptor TLR6:TLR2 Cascade |
86 |
3.94e-04 |
2.09e-03 |
0.2470 |
NA |
-0.245000 |
0.032900 |
8.59e-05 |
5.99e-01 |
| Aquaporin-mediated transport |
31 |
5.90e-02 |
1.09e-01 |
0.2470 |
NA |
-0.028000 |
0.246000 |
7.88e-01 |
1.80e-02 |
| Constitutive Signaling by Aberrant PI3K in Cancer |
42 |
2.21e-02 |
5.11e-02 |
0.2470 |
NA |
-0.211000 |
0.128000 |
1.79e-02 |
1.51e-01 |
| SUMOylation of DNA damage response and repair proteins |
75 |
1.11e-03 |
4.83e-03 |
0.2460 |
NA |
0.005230 |
-0.246000 |
9.38e-01 |
2.26e-04 |
| Integrin cell surface interactions |
42 |
2.20e-02 |
5.10e-02 |
0.2460 |
NA |
0.220000 |
0.110000 |
1.38e-02 |
2.16e-01 |
| Organic cation/anion/zwitterion transport |
10 |
4.04e-01 |
4.95e-01 |
0.2460 |
NA |
-0.241000 |
-0.049000 |
1.87e-01 |
7.88e-01 |
| Formation of TC-NER Pre-Incision Complex |
53 |
8.25e-03 |
2.41e-02 |
0.2450 |
NA |
-0.182000 |
-0.165000 |
2.20e-02 |
3.82e-02 |
| Regulation of PTEN gene transcription |
59 |
5.07e-03 |
1.64e-02 |
0.2440 |
NA |
-0.222000 |
-0.103000 |
3.23e-03 |
1.73e-01 |
| Cross-presentation of soluble exogenous antigens (endosomes) |
44 |
1.93e-02 |
4.55e-02 |
0.2440 |
NA |
-0.203000 |
-0.136000 |
2.00e-02 |
1.18e-01 |
| Costimulation by the CD28 family |
45 |
1.87e-02 |
4.44e-02 |
0.2440 |
NA |
-0.219000 |
0.106000 |
1.09e-02 |
2.19e-01 |
| MicroRNA (miRNA) biogenesis |
24 |
1.17e-01 |
1.87e-01 |
0.2430 |
NA |
-0.174000 |
-0.171000 |
1.41e-01 |
1.48e-01 |
| Bile acid and bile salt metabolism |
31 |
6.34e-02 |
1.14e-01 |
0.2430 |
NA |
-0.125000 |
-0.209000 |
2.28e-01 |
4.45e-02 |
| TP53 Regulates Transcription of Caspase Activators and Caspases |
10 |
4.14e-01 |
5.05e-01 |
0.2430 |
NA |
0.241000 |
-0.030200 |
1.87e-01 |
8.69e-01 |
| MET activates PTK2 signaling |
15 |
2.67e-01 |
3.64e-01 |
0.2430 |
NA |
-0.236000 |
0.055200 |
1.13e-01 |
7.12e-01 |
| Integration of energy metabolism |
81 |
8.33e-04 |
3.82e-03 |
0.2420 |
NA |
-0.037700 |
0.239000 |
5.57e-01 |
1.97e-04 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest |
13 |
3.17e-01 |
4.12e-01 |
0.2420 |
NA |
0.139000 |
0.199000 |
3.86e-01 |
2.15e-01 |
| Clathrin-mediated endocytosis |
117 |
3.82e-05 |
2.98e-04 |
0.2420 |
NA |
-0.187000 |
0.154000 |
4.83e-04 |
4.03e-03 |
| Neurexins and neuroligins |
39 |
3.23e-02 |
6.87e-02 |
0.2420 |
NA |
0.073200 |
0.231000 |
4.29e-01 |
1.26e-02 |
| MET promotes cell motility |
26 |
1.03e-01 |
1.67e-01 |
0.2420 |
NA |
-0.238000 |
0.044800 |
3.59e-02 |
6.92e-01 |
| Fatty acyl-CoA biosynthesis |
30 |
7.17e-02 |
1.25e-01 |
0.2420 |
NA |
0.205000 |
0.127000 |
5.15e-02 |
2.28e-01 |
| Insulin processing |
20 |
1.76e-01 |
2.57e-01 |
0.2410 |
NA |
-0.174000 |
0.167000 |
1.77e-01 |
1.96e-01 |
| Fanconi Anemia Pathway |
34 |
5.11e-02 |
9.83e-02 |
0.2410 |
NA |
0.214000 |
0.112000 |
3.11e-02 |
2.59e-01 |
| Anchoring of the basal body to the plasma membrane |
94 |
2.77e-04 |
1.60e-03 |
0.2410 |
NA |
0.185000 |
0.155000 |
1.97e-03 |
9.59e-03 |
| GPCR ligand binding |
136 |
7.93e-06 |
8.36e-05 |
0.2410 |
NA |
0.027900 |
0.239000 |
5.75e-01 |
1.50e-06 |
| Heparan sulfate/heparin (HS-GAG) metabolism |
43 |
2.37e-02 |
5.36e-02 |
0.2410 |
NA |
0.105000 |
0.216000 |
2.32e-01 |
1.41e-02 |
| tRNA processing |
135 |
8.88e-06 |
9.05e-05 |
0.2410 |
NA |
0.005900 |
-0.241000 |
9.06e-01 |
1.42e-06 |
| VEGFA-VEGFR2 Pathway |
86 |
6.46e-04 |
3.10e-03 |
0.2390 |
NA |
-0.236000 |
0.040800 |
1.57e-04 |
5.14e-01 |
| Regulation of FZD by ubiquitination |
15 |
2.74e-01 |
3.71e-01 |
0.2390 |
NA |
-0.106000 |
-0.215000 |
4.77e-01 |
1.50e-01 |
| Negative regulation of the PI3K/AKT network |
74 |
1.82e-03 |
7.32e-03 |
0.2390 |
NA |
-0.234000 |
0.050300 |
5.07e-04 |
4.54e-01 |
| The phototransduction cascade |
21 |
1.67e-01 |
2.48e-01 |
0.2390 |
NA |
-0.074600 |
0.227000 |
5.54e-01 |
7.19e-02 |
| G1/S-Specific Transcription |
28 |
9.07e-02 |
1.51e-01 |
0.2390 |
NA |
0.195000 |
0.138000 |
7.41e-02 |
2.08e-01 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) |
54 |
1.04e-02 |
2.85e-02 |
0.2380 |
NA |
0.089400 |
-0.221000 |
2.56e-01 |
5.03e-03 |
| Regulation of RUNX2 expression and activity |
66 |
3.70e-03 |
1.29e-02 |
0.2380 |
NA |
-0.232000 |
-0.051100 |
1.10e-03 |
4.73e-01 |
| CLEC7A (Dectin-1) signaling |
91 |
4.47e-04 |
2.34e-03 |
0.2380 |
NA |
-0.223000 |
-0.082700 |
2.37e-04 |
1.73e-01 |
| Chylomicron assembly |
10 |
4.30e-01 |
5.20e-01 |
0.2370 |
NA |
0.030500 |
-0.235000 |
8.67e-01 |
1.97e-01 |
| SUMOylation of DNA methylation proteins |
16 |
2.61e-01 |
3.57e-01 |
0.2370 |
NA |
0.077400 |
-0.224000 |
5.92e-01 |
1.21e-01 |
| RA biosynthesis pathway |
15 |
2.85e-01 |
3.80e-01 |
0.2370 |
NA |
0.151000 |
-0.182000 |
3.10e-01 |
2.21e-01 |
| Cell-Cell communication |
84 |
9.14e-04 |
4.10e-03 |
0.2370 |
NA |
-0.093900 |
0.217000 |
1.37e-01 |
5.81e-04 |
| Synthesis of PIPs at the late endosome membrane |
11 |
4.01e-01 |
4.94e-01 |
0.2360 |
NA |
-0.218000 |
0.090200 |
2.11e-01 |
6.05e-01 |
| Ubiquitin Mediated Degradation of Phosphorylated Cdc25A |
49 |
1.68e-02 |
4.09e-02 |
0.2360 |
NA |
-0.183000 |
-0.148000 |
2.64e-02 |
7.35e-02 |
| p53-Independent DNA Damage Response |
49 |
1.68e-02 |
4.09e-02 |
0.2360 |
NA |
-0.183000 |
-0.148000 |
2.64e-02 |
7.35e-02 |
| p53-Independent G1/S DNA damage checkpoint |
49 |
1.68e-02 |
4.09e-02 |
0.2360 |
NA |
-0.183000 |
-0.148000 |
2.64e-02 |
7.35e-02 |
| SUMOylation |
164 |
1.35e-06 |
1.73e-05 |
0.2350 |
NA |
-0.095600 |
-0.215000 |
3.48e-02 |
2.15e-06 |
| Ub-specific processing proteases |
162 |
1.60e-06 |
1.98e-05 |
0.2350 |
NA |
-0.169000 |
-0.163000 |
2.03e-04 |
3.59e-04 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling |
67 |
4.09e-03 |
1.39e-02 |
0.2350 |
NA |
-0.218000 |
0.087300 |
2.04e-03 |
2.17e-01 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter |
27 |
1.06e-01 |
1.72e-01 |
0.2350 |
NA |
-0.186000 |
-0.144000 |
9.50e-02 |
1.96e-01 |
| Homology Directed Repair |
107 |
1.51e-04 |
9.47e-04 |
0.2350 |
NA |
0.233000 |
0.026000 |
3.08e-05 |
6.42e-01 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer |
43 |
2.85e-02 |
6.18e-02 |
0.2350 |
NA |
-0.194000 |
-0.132000 |
2.81e-02 |
1.33e-01 |
| Autodegradation of Cdh1 by Cdh1:APC/C |
62 |
6.03e-03 |
1.85e-02 |
0.2340 |
NA |
-0.108000 |
-0.208000 |
1.42e-01 |
4.62e-03 |
| Inositol phosphate metabolism |
40 |
3.81e-02 |
7.78e-02 |
0.2340 |
NA |
-0.169000 |
0.163000 |
6.52e-02 |
7.50e-02 |
| SUMO E3 ligases SUMOylate target proteins |
158 |
2.44e-06 |
2.89e-05 |
0.2340 |
NA |
-0.092300 |
-0.215000 |
4.56e-02 |
3.11e-06 |
| MET activates RAP1 and RAC1 |
10 |
4.40e-01 |
5.29e-01 |
0.2340 |
NA |
-0.232000 |
0.030700 |
2.04e-01 |
8.66e-01 |
| Cell-cell junction organization |
35 |
5.59e-02 |
1.05e-01 |
0.2340 |
NA |
0.111000 |
0.206000 |
2.58e-01 |
3.47e-02 |
| PIWI-interacting RNA (piRNA) biogenesis |
21 |
1.83e-01 |
2.65e-01 |
0.2330 |
NA |
-0.114000 |
0.203000 |
3.65e-01 |
1.07e-01 |
| HS-GAG biosynthesis |
23 |
1.54e-01 |
2.33e-01 |
0.2320 |
NA |
0.153000 |
0.175000 |
2.04e-01 |
1.47e-01 |
| Axon guidance |
443 |
8.09e-16 |
3.20e-14 |
0.2320 |
NA |
-0.218000 |
0.080300 |
4.70e-15 |
3.90e-03 |
| Gap junction trafficking and regulation |
17 |
2.54e-01 |
3.49e-01 |
0.2320 |
NA |
0.038600 |
0.229000 |
7.83e-01 |
1.03e-01 |
| Regulation of gene expression by Hypoxia-inducible Factor |
11 |
4.13e-01 |
5.04e-01 |
0.2310 |
NA |
-0.226000 |
-0.047500 |
1.93e-01 |
7.85e-01 |
| Interleukin-1 family signaling |
111 |
1.40e-04 |
8.99e-04 |
0.2310 |
NA |
-0.204000 |
-0.109000 |
2.11e-04 |
4.75e-02 |
| Cellular response to heat stress |
94 |
5.39e-04 |
2.73e-03 |
0.2310 |
NA |
-0.168000 |
-0.159000 |
4.95e-03 |
7.83e-03 |
| Synthesis of PIPs at the Golgi membrane |
15 |
3.04e-01 |
3.98e-01 |
0.2310 |
NA |
-0.176000 |
0.149000 |
2.38e-01 |
3.18e-01 |
| Metabolism of cofactors |
18 |
2.43e-01 |
3.35e-01 |
0.2300 |
NA |
0.064800 |
-0.220000 |
6.34e-01 |
1.06e-01 |
| Purine salvage |
12 |
3.87e-01 |
4.82e-01 |
0.2300 |
NA |
0.072100 |
0.218000 |
6.66e-01 |
1.91e-01 |
| Other interleukin signaling |
18 |
2.45e-01 |
3.38e-01 |
0.2290 |
NA |
-0.027800 |
0.227000 |
8.38e-01 |
9.58e-02 |
| Cytosolic sensors of pathogen-associated DNA |
57 |
1.16e-02 |
3.08e-02 |
0.2280 |
NA |
-0.198000 |
-0.114000 |
9.87e-03 |
1.36e-01 |
| Signaling by NOTCH3 |
44 |
3.35e-02 |
7.02e-02 |
0.2280 |
NA |
-0.126000 |
0.190000 |
1.49e-01 |
2.95e-02 |
| Signaling by TGF-beta family members |
89 |
1.01e-03 |
4.46e-03 |
0.2280 |
NA |
-0.224000 |
-0.041900 |
2.66e-04 |
4.94e-01 |
| ABC-family proteins mediated transport |
92 |
8.04e-04 |
3.74e-03 |
0.2280 |
NA |
-0.224000 |
-0.041600 |
2.09e-04 |
4.91e-01 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling |
26 |
1.33e-01 |
2.06e-01 |
0.2270 |
NA |
0.013800 |
0.227000 |
9.03e-01 |
4.51e-02 |
| Regulated proteolysis of p75NTR |
11 |
4.26e-01 |
5.17e-01 |
0.2270 |
NA |
-0.198000 |
-0.110000 |
2.55e-01 |
5.28e-01 |
| Processing of Capped Intronless Pre-mRNA |
28 |
1.16e-01 |
1.84e-01 |
0.2270 |
NA |
-0.035000 |
-0.224000 |
7.49e-01 |
4.03e-02 |
| Cellular hexose transport |
16 |
2.93e-01 |
3.87e-01 |
0.2270 |
NA |
-0.067800 |
0.216000 |
6.39e-01 |
1.34e-01 |
| Signaling by GPCR |
384 |
2.94e-13 |
9.30e-12 |
0.2270 |
NA |
-0.051800 |
0.221000 |
8.25e-02 |
1.32e-13 |
| Mucopolysaccharidoses |
11 |
4.28e-01 |
5.18e-01 |
0.2260 |
NA |
-0.197000 |
-0.111000 |
2.57e-01 |
5.25e-01 |
| tRNA processing in the nucleus |
57 |
1.29e-02 |
3.37e-02 |
0.2260 |
NA |
-0.073100 |
-0.213000 |
3.40e-01 |
5.33e-03 |
| PCNA-Dependent Long Patch Base Excision Repair |
21 |
2.01e-01 |
2.87e-01 |
0.2250 |
NA |
0.198000 |
0.108000 |
1.16e-01 |
3.93e-01 |
| Nonhomologous End-Joining (NHEJ) |
42 |
4.16e-02 |
8.31e-02 |
0.2250 |
NA |
0.046300 |
-0.220000 |
6.04e-01 |
1.35e-02 |
| Keratan sulfate/keratin metabolism |
23 |
1.77e-01 |
2.59e-01 |
0.2250 |
NA |
-0.172000 |
0.145000 |
1.54e-01 |
2.28e-01 |
| Interleukin-10 signaling |
18 |
2.56e-01 |
3.51e-01 |
0.2240 |
NA |
0.139000 |
0.176000 |
3.08e-01 |
1.95e-01 |
| Signaling by ERBB4 |
36 |
6.73e-02 |
1.19e-01 |
0.2240 |
NA |
-0.218000 |
-0.047500 |
2.33e-02 |
6.22e-01 |
| Intracellular signaling by second messengers |
255 |
6.67e-09 |
1.16e-07 |
0.2230 |
NA |
-0.221000 |
-0.029500 |
1.22e-09 |
4.18e-01 |
| Sulfur amino acid metabolism |
25 |
1.56e-01 |
2.35e-01 |
0.2230 |
NA |
0.219000 |
-0.040900 |
5.79e-02 |
7.23e-01 |
| AURKA Activation by TPX2 |
71 |
5.06e-03 |
1.64e-02 |
0.2230 |
NA |
0.211000 |
0.070700 |
2.08e-03 |
3.03e-01 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain |
13 |
3.79e-01 |
4.75e-01 |
0.2230 |
NA |
-0.115000 |
-0.190000 |
4.71e-01 |
2.35e-01 |
| RHO GTPases Activate WASPs and WAVEs |
33 |
8.75e-02 |
1.48e-01 |
0.2220 |
NA |
-0.206000 |
0.084200 |
4.07e-02 |
4.03e-01 |
| Deubiquitination |
234 |
3.70e-08 |
5.78e-07 |
0.2220 |
NA |
-0.164000 |
-0.149000 |
1.53e-05 |
9.06e-05 |
| Hedgehog ‘on’ state |
75 |
4.03e-03 |
1.39e-02 |
0.2220 |
NA |
-0.217000 |
-0.042900 |
1.13e-03 |
5.21e-01 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) |
101 |
6.07e-04 |
2.97e-03 |
0.2220 |
NA |
0.221000 |
0.020800 |
1.28e-04 |
7.19e-01 |
| APC/C:Cdc20 mediated degradation of Securin |
64 |
8.99e-03 |
2.56e-02 |
0.2210 |
NA |
-0.094400 |
-0.200000 |
1.92e-01 |
5.58e-03 |
| Diseases of metabolism |
77 |
3.67e-03 |
1.29e-02 |
0.2210 |
NA |
0.029800 |
-0.219000 |
6.51e-01 |
8.97e-04 |
| TICAM1, RIP1-mediated IKK complex recruitment |
18 |
2.68e-01 |
3.65e-01 |
0.2210 |
NA |
-0.217000 |
-0.039300 |
1.11e-01 |
7.73e-01 |
| Pre-NOTCH Processing in Golgi |
18 |
2.71e-01 |
3.67e-01 |
0.2210 |
NA |
-0.096100 |
0.199000 |
4.80e-01 |
1.45e-01 |
| Protein localization |
150 |
1.92e-05 |
1.66e-04 |
0.2210 |
NA |
-0.028400 |
-0.219000 |
5.49e-01 |
3.86e-06 |
| TNFR1-induced NFkappaB signaling pathway |
24 |
1.75e-01 |
2.56e-01 |
0.2200 |
NA |
-0.040600 |
-0.216000 |
7.31e-01 |
6.67e-02 |
| Signaling by SCF-KIT |
37 |
7.11e-02 |
1.24e-01 |
0.2190 |
NA |
-0.104000 |
0.193000 |
2.73e-01 |
4.27e-02 |
| NOTCH3 Intracellular Domain Regulates Transcription |
21 |
2.24e-01 |
3.15e-01 |
0.2180 |
NA |
-0.006090 |
0.218000 |
9.61e-01 |
8.35e-02 |
| HSF1-dependent transactivation |
33 |
9.54e-02 |
1.56e-01 |
0.2180 |
NA |
-0.203000 |
-0.077600 |
4.32e-02 |
4.41e-01 |
| Regulation of HSF1-mediated heat shock response |
76 |
4.58e-03 |
1.53e-02 |
0.2170 |
NA |
-0.164000 |
-0.143000 |
1.37e-02 |
3.12e-02 |
| Loss of Nlp from mitotic centrosomes |
68 |
8.14e-03 |
2.39e-02 |
0.2170 |
NA |
0.198000 |
0.088300 |
4.68e-03 |
2.08e-01 |
| Loss of proteins required for interphase microtubule organization from the centrosome |
68 |
8.14e-03 |
2.39e-02 |
0.2170 |
NA |
0.198000 |
0.088300 |
4.68e-03 |
2.08e-01 |
| RNA Polymerase I Transcription Initiation |
47 |
3.62e-02 |
7.46e-02 |
0.2170 |
NA |
-0.022500 |
-0.216000 |
7.90e-01 |
1.04e-02 |
| Regulation of TP53 Degradation |
35 |
8.35e-02 |
1.42e-01 |
0.2170 |
NA |
-0.143000 |
-0.163000 |
1.43e-01 |
9.49e-02 |
| Regulation of TP53 Expression and Degradation |
35 |
8.35e-02 |
1.42e-01 |
0.2170 |
NA |
-0.143000 |
-0.163000 |
1.43e-01 |
9.49e-02 |
| Regulation of IFNA signaling |
12 |
4.29e-01 |
5.19e-01 |
0.2170 |
NA |
0.211000 |
0.049400 |
2.06e-01 |
7.67e-01 |
| SCF(Skp2)-mediated degradation of p27/p21 |
57 |
1.82e-02 |
4.36e-02 |
0.2160 |
NA |
-0.183000 |
-0.115000 |
1.68e-02 |
1.33e-01 |
| TP53 Regulates Transcription of Cell Death Genes |
40 |
6.00e-02 |
1.11e-01 |
0.2160 |
NA |
-0.132000 |
-0.172000 |
1.50e-01 |
6.06e-02 |
| GPCR downstream signalling |
353 |
3.69e-11 |
9.33e-10 |
0.2150 |
NA |
-0.056300 |
0.208000 |
6.98e-02 |
2.09e-11 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane |
28 |
1.42e-01 |
2.18e-01 |
0.2150 |
NA |
-0.212000 |
-0.038600 |
5.23e-02 |
7.24e-01 |
| RAF/MAP kinase cascade |
194 |
1.70e-06 |
2.09e-05 |
0.2150 |
NA |
-0.185000 |
0.110000 |
9.04e-06 |
8.25e-03 |
| Budding and maturation of HIV virion |
28 |
1.42e-01 |
2.18e-01 |
0.2150 |
NA |
-0.142000 |
-0.162000 |
1.94e-01 |
1.38e-01 |
| Signaling by Activin |
11 |
4.66e-01 |
5.56e-01 |
0.2150 |
NA |
-0.215000 |
0.006250 |
2.17e-01 |
9.71e-01 |
| G beta:gamma signalling through PLC beta |
11 |
4.69e-01 |
5.57e-01 |
0.2150 |
NA |
-0.144000 |
0.159000 |
4.07e-01 |
3.61e-01 |
| Presynaptic function of Kainate receptors |
11 |
4.69e-01 |
5.57e-01 |
0.2150 |
NA |
-0.144000 |
0.159000 |
4.07e-01 |
3.61e-01 |
| Regulation of APC/C activators between G1/S and early anaphase |
76 |
5.27e-03 |
1.68e-02 |
0.2150 |
NA |
-0.041700 |
-0.211000 |
5.30e-01 |
1.50e-03 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A |
68 |
9.22e-03 |
2.57e-02 |
0.2150 |
NA |
-0.045600 |
-0.210000 |
5.16e-01 |
2.81e-03 |
| Assembly of active LPL and LIPC lipase complexes |
15 |
3.57e-01 |
4.53e-01 |
0.2140 |
NA |
0.193000 |
-0.094000 |
1.96e-01 |
5.28e-01 |
| Phase I - Functionalization of compounds |
72 |
7.49e-03 |
2.23e-02 |
0.2140 |
NA |
0.172000 |
-0.127000 |
1.18e-02 |
6.16e-02 |
| C-type lectin receptors (CLRs) |
117 |
3.50e-04 |
1.94e-03 |
0.2140 |
NA |
-0.214000 |
-0.005260 |
6.68e-05 |
9.22e-01 |
| TP53 Regulates Metabolic Genes |
84 |
3.20e-03 |
1.15e-02 |
0.2140 |
NA |
-0.188000 |
-0.101000 |
2.90e-03 |
1.09e-01 |
| Cell junction organization |
55 |
2.40e-02 |
5.39e-02 |
0.2130 |
NA |
-0.084600 |
0.196000 |
2.78e-01 |
1.20e-02 |
| Signaling by Receptor Tyrosine Kinases |
357 |
4.97e-11 |
1.21e-09 |
0.2130 |
NA |
-0.201000 |
0.069200 |
6.77e-11 |
2.52e-02 |
| Interferon gamma signaling |
65 |
1.19e-02 |
3.16e-02 |
0.2130 |
NA |
0.124000 |
0.173000 |
8.46e-02 |
1.57e-02 |
| Host Interactions of HIV factors |
120 |
2.93e-04 |
1.68e-03 |
0.2130 |
NA |
-0.168000 |
-0.131000 |
1.51e-03 |
1.34e-02 |
| Abortive elongation of HIV-1 transcript in the absence of Tat |
23 |
2.14e-01 |
3.03e-01 |
0.2120 |
NA |
-0.211000 |
0.019000 |
8.02e-02 |
8.75e-01 |
| Signaling by FGFR |
68 |
1.07e-02 |
2.91e-02 |
0.2120 |
NA |
-0.210000 |
0.022200 |
2.72e-03 |
7.52e-01 |
| Metabolism of porphyrins |
14 |
3.92e-01 |
4.87e-01 |
0.2110 |
NA |
0.005700 |
0.211000 |
9.71e-01 |
1.71e-01 |
| Glycogen synthesis |
14 |
3.92e-01 |
4.87e-01 |
0.2110 |
NA |
-0.101000 |
-0.185000 |
5.15e-01 |
2.30e-01 |
| Disorders of transmembrane transporters |
136 |
1.18e-04 |
7.70e-04 |
0.2110 |
NA |
-0.154000 |
-0.144000 |
1.97e-03 |
3.73e-03 |
| Collagen biosynthesis and modifying enzymes |
34 |
1.04e-01 |
1.69e-01 |
0.2110 |
NA |
0.207000 |
0.039500 |
3.69e-02 |
6.91e-01 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex |
14 |
3.94e-01 |
4.89e-01 |
0.2100 |
NA |
-0.089700 |
-0.190000 |
5.61e-01 |
2.18e-01 |
| Activation of NMDA receptors and postsynaptic events |
61 |
1.80e-02 |
4.32e-02 |
0.2100 |
NA |
0.034700 |
0.207000 |
6.39e-01 |
5.21e-03 |
| Mitochondrial iron-sulfur cluster biogenesis |
12 |
4.54e-01 |
5.44e-01 |
0.2090 |
NA |
0.206000 |
0.035100 |
2.16e-01 |
8.33e-01 |
| MAPK6/MAPK4 signaling |
84 |
4.08e-03 |
1.39e-02 |
0.2090 |
NA |
-0.206000 |
-0.036800 |
1.11e-03 |
5.60e-01 |
| p53-Dependent G1 DNA Damage Response |
62 |
1.70e-02 |
4.11e-02 |
0.2090 |
NA |
-0.175000 |
-0.115000 |
1.74e-02 |
1.17e-01 |
| p53-Dependent G1/S DNA damage checkpoint |
62 |
1.70e-02 |
4.11e-02 |
0.2090 |
NA |
-0.175000 |
-0.115000 |
1.74e-02 |
1.17e-01 |
| Toll Like Receptor 4 (TLR4) Cascade |
110 |
8.13e-04 |
3.75e-03 |
0.2090 |
NA |
-0.202000 |
0.051100 |
2.50e-04 |
3.55e-01 |
| FGFR2 mutant receptor activation |
20 |
2.72e-01 |
3.69e-01 |
0.2090 |
NA |
-0.029100 |
0.207000 |
8.22e-01 |
1.10e-01 |
| Deposition of new CENPA-containing nucleosomes at the centromere |
41 |
6.93e-02 |
1.22e-01 |
0.2080 |
NA |
0.205000 |
0.038500 |
2.33e-02 |
6.69e-01 |
| Nucleosome assembly |
41 |
6.93e-02 |
1.22e-01 |
0.2080 |
NA |
0.205000 |
0.038500 |
2.33e-02 |
6.69e-01 |
| MAPK family signaling cascades |
236 |
2.84e-07 |
4.04e-06 |
0.2080 |
NA |
-0.178000 |
0.108000 |
2.59e-06 |
4.23e-03 |
| CDT1 association with the CDC6:ORC:origin complex |
56 |
2.63e-02 |
5.79e-02 |
0.2080 |
NA |
-0.187000 |
-0.090700 |
1.54e-02 |
2.40e-01 |
| Metabolism of amino acids and derivatives |
315 |
1.77e-09 |
3.45e-08 |
0.2080 |
NA |
-0.090400 |
-0.187000 |
5.90e-03 |
1.17e-08 |
| TCF dependent signaling in response to WNT |
163 |
2.72e-05 |
2.25e-04 |
0.2080 |
NA |
-0.179000 |
-0.106000 |
8.12e-05 |
2.02e-02 |
| FOXO-mediated transcription |
56 |
2.71e-02 |
5.93e-02 |
0.2080 |
NA |
-0.207000 |
0.009770 |
7.28e-03 |
8.99e-01 |
| Fatty acid metabolism |
134 |
1.93e-04 |
1.16e-03 |
0.2070 |
NA |
0.207000 |
-0.006470 |
3.56e-05 |
8.97e-01 |
| Post-translational protein phosphorylation |
88 |
3.55e-03 |
1.26e-02 |
0.2070 |
NA |
-0.061100 |
-0.198000 |
3.22e-01 |
1.35e-03 |
| RNA Polymerase III Transcription Initiation |
36 |
9.87e-02 |
1.61e-01 |
0.2070 |
NA |
-0.155000 |
-0.137000 |
1.07e-01 |
1.56e-01 |
| GABA synthesis, release, reuptake and degradation |
13 |
4.37e-01 |
5.27e-01 |
0.2070 |
NA |
-0.141000 |
0.151000 |
3.77e-01 |
3.47e-01 |
| Syndecan interactions |
18 |
3.18e-01 |
4.12e-01 |
0.2070 |
NA |
-0.166000 |
0.123000 |
2.24e-01 |
3.64e-01 |
| Thromboxane signalling through TP receptor |
13 |
4.38e-01 |
5.28e-01 |
0.2060 |
NA |
-0.175000 |
0.109000 |
2.75e-01 |
4.95e-01 |
| Interleukin-37 signaling |
16 |
3.62e-01 |
4.57e-01 |
0.2060 |
NA |
-0.031000 |
-0.203000 |
8.30e-01 |
1.59e-01 |
| MAPK1/MAPK3 signaling |
199 |
4.22e-06 |
4.81e-05 |
0.2050 |
NA |
-0.176000 |
0.106000 |
1.97e-05 |
9.94e-03 |
| Telomere Maintenance |
50 |
4.28e-02 |
8.48e-02 |
0.2050 |
NA |
0.188000 |
0.080700 |
2.13e-02 |
3.24e-01 |
| Sphingolipid de novo biosynthesis |
38 |
9.33e-02 |
1.55e-01 |
0.2050 |
NA |
-0.175000 |
0.106000 |
6.17e-02 |
2.59e-01 |
| Respiratory electron transport |
101 |
1.81e-03 |
7.31e-03 |
0.2040 |
NA |
-0.058800 |
-0.196000 |
3.08e-01 |
6.77e-04 |
| Prolactin receptor signaling |
11 |
5.02e-01 |
5.91e-01 |
0.2040 |
NA |
-0.040300 |
-0.200000 |
8.17e-01 |
2.50e-01 |
| Class A/1 (Rhodopsin-like receptors) |
83 |
5.83e-03 |
1.80e-02 |
0.2040 |
NA |
-0.003900 |
0.204000 |
9.51e-01 |
1.34e-03 |
| Plasma lipoprotein clearance |
31 |
1.46e-01 |
2.22e-01 |
0.2040 |
NA |
-0.203000 |
0.013300 |
5.01e-02 |
8.98e-01 |
| Signaling by ERBB2 |
44 |
6.66e-02 |
1.18e-01 |
0.2030 |
NA |
-0.193000 |
0.062200 |
2.65e-02 |
4.75e-01 |
| Interleukin-7 signaling |
17 |
3.53e-01 |
4.49e-01 |
0.2030 |
NA |
0.144000 |
-0.143000 |
3.06e-01 |
3.07e-01 |
| Signaling by NOTCH1 |
68 |
1.56e-02 |
3.87e-02 |
0.2030 |
NA |
-0.190000 |
0.071500 |
6.86e-03 |
3.08e-01 |
| G-protein beta:gamma signalling |
18 |
3.31e-01 |
4.26e-01 |
0.2030 |
NA |
-0.192000 |
0.065000 |
1.59e-01 |
6.33e-01 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins |
72 |
1.21e-02 |
3.20e-02 |
0.2020 |
NA |
-0.016500 |
-0.202000 |
8.09e-01 |
3.08e-03 |
| Synthesis of substrates in N-glycan biosythesis |
52 |
4.19e-02 |
8.35e-02 |
0.2020 |
NA |
-0.185000 |
0.081900 |
2.10e-02 |
3.07e-01 |
| RHO GTPases activate IQGAPs |
11 |
5.14e-01 |
6.02e-01 |
0.2010 |
NA |
-0.101000 |
0.174000 |
5.61e-01 |
3.18e-01 |
| Positive epigenetic regulation of rRNA expression |
61 |
2.46e-02 |
5.47e-02 |
0.2010 |
NA |
-0.122000 |
-0.160000 |
9.95e-02 |
3.09e-02 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint |
69 |
1.56e-02 |
3.87e-02 |
0.2010 |
NA |
-0.035700 |
-0.198000 |
6.08e-01 |
4.56e-03 |
| Transcriptional regulation by RUNX1 |
170 |
3.63e-05 |
2.91e-04 |
0.2010 |
NA |
-0.129000 |
-0.154000 |
3.85e-03 |
5.39e-04 |
| ECM proteoglycans |
35 |
1.21e-01 |
1.91e-01 |
0.2010 |
NA |
0.054000 |
0.193000 |
5.80e-01 |
4.79e-02 |
| FGFR2 alternative splicing |
26 |
2.10e-01 |
2.99e-01 |
0.2000 |
NA |
-0.149000 |
-0.133000 |
1.87e-01 |
2.42e-01 |
| Signaling by FGFR2 in disease |
30 |
1.69e-01 |
2.51e-01 |
0.1990 |
NA |
-0.114000 |
0.163000 |
2.79e-01 |
1.21e-01 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) |
34 |
1.33e-01 |
2.06e-01 |
0.1990 |
NA |
-0.198000 |
0.021000 |
4.57e-02 |
8.32e-01 |
| Rho GTPase cycle |
118 |
9.65e-04 |
4.30e-03 |
0.1990 |
NA |
-0.073000 |
0.185000 |
1.71e-01 |
5.14e-04 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 |
69 |
1.66e-02 |
4.08e-02 |
0.1990 |
NA |
-0.054300 |
-0.192000 |
4.36e-01 |
5.95e-03 |
| Estrogen-dependent gene expression |
98 |
2.97e-03 |
1.09e-02 |
0.1990 |
NA |
-0.154000 |
-0.126000 |
8.36e-03 |
3.16e-02 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs |
77 |
1.04e-02 |
2.85e-02 |
0.1990 |
NA |
-0.175000 |
-0.093600 |
7.81e-03 |
1.56e-01 |
| Transcriptional regulation of white adipocyte differentiation |
76 |
1.18e-02 |
3.12e-02 |
0.1970 |
NA |
-0.148000 |
-0.130000 |
2.55e-02 |
4.99e-02 |
| Membrane Trafficking |
543 |
5.55e-14 |
1.85e-12 |
0.1970 |
NA |
-0.178000 |
0.083700 |
1.36e-12 |
8.97e-04 |
| Formation of Incision Complex in GG-NER |
43 |
8.35e-02 |
1.42e-01 |
0.1970 |
NA |
0.137000 |
-0.142000 |
1.21e-01 |
1.08e-01 |
| Dissolution of Fibrin Clot |
12 |
4.99e-01 |
5.89e-01 |
0.1970 |
NA |
0.196000 |
-0.006050 |
2.39e-01 |
9.71e-01 |
| Intra-Golgi and retrograde Golgi-to-ER traffic |
173 |
5.33e-05 |
3.90e-04 |
0.1960 |
NA |
-0.187000 |
0.058500 |
2.23e-05 |
1.85e-01 |
| Cyclin E associated events during G1/S transition |
80 |
1.00e-02 |
2.76e-02 |
0.1960 |
NA |
-0.150000 |
-0.126000 |
2.06e-02 |
5.13e-02 |
| Post NMDA receptor activation events |
51 |
5.49e-02 |
1.04e-01 |
0.1950 |
NA |
0.011700 |
0.195000 |
8.85e-01 |
1.62e-02 |
| Signaling by FGFR2 |
58 |
3.72e-02 |
7.62e-02 |
0.1950 |
NA |
-0.194000 |
0.021500 |
1.07e-02 |
7.77e-01 |
| VEGFR2 mediated cell proliferation |
18 |
3.61e-01 |
4.57e-01 |
0.1950 |
NA |
-0.170000 |
0.095400 |
2.12e-01 |
4.83e-01 |
| ESR-mediated signaling |
152 |
1.86e-04 |
1.13e-03 |
0.1950 |
NA |
-0.188000 |
-0.052400 |
6.72e-05 |
2.66e-01 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression |
31 |
1.73e-01 |
2.54e-01 |
0.1940 |
NA |
-0.087500 |
-0.173000 |
3.99e-01 |
9.52e-02 |
| PECAM1 interactions |
10 |
5.69e-01 |
6.53e-01 |
0.1940 |
NA |
-0.015900 |
0.193000 |
9.31e-01 |
2.90e-01 |
| APC/C:Cdc20 mediated degradation of mitotic proteins |
71 |
1.86e-02 |
4.42e-02 |
0.1940 |
NA |
-0.025100 |
-0.192000 |
7.14e-01 |
5.14e-03 |
| PCP/CE pathway |
83 |
9.63e-03 |
2.67e-02 |
0.1940 |
NA |
-0.193000 |
0.010700 |
2.34e-03 |
8.66e-01 |
| Cytosolic sulfonation of small molecules |
20 |
3.25e-01 |
4.20e-01 |
0.1940 |
NA |
0.193000 |
0.012800 |
1.35e-01 |
9.21e-01 |
| Metabolic disorders of biological oxidation enzymes |
24 |
2.65e-01 |
3.62e-01 |
0.1930 |
NA |
0.143000 |
-0.130000 |
2.26e-01 |
2.72e-01 |
| BBSome-mediated cargo-targeting to cilium |
23 |
2.79e-01 |
3.74e-01 |
0.1930 |
NA |
-0.013500 |
0.192000 |
9.11e-01 |
1.11e-01 |
| Base Excision Repair |
59 |
3.82e-02 |
7.78e-02 |
0.1920 |
NA |
0.192000 |
-0.011400 |
1.07e-02 |
8.79e-01 |
| Triglyceride catabolism |
12 |
5.17e-01 |
6.05e-01 |
0.1920 |
NA |
-0.143000 |
0.128000 |
3.91e-01 |
4.42e-01 |
| Recruitment of NuMA to mitotic centrosomes |
79 |
1.30e-02 |
3.39e-02 |
0.1920 |
NA |
0.187000 |
0.040000 |
3.98e-03 |
5.39e-01 |
| Signaling by Interleukins |
314 |
4.06e-08 |
6.19e-07 |
0.1920 |
NA |
-0.188000 |
-0.035700 |
1.02e-08 |
2.78e-01 |
| Sphingolipid metabolism |
75 |
1.68e-02 |
4.09e-02 |
0.1910 |
NA |
-0.176000 |
0.075100 |
8.45e-03 |
2.61e-01 |
| Glycosaminoglycan metabolism |
96 |
5.38e-03 |
1.70e-02 |
0.1910 |
NA |
-0.023900 |
0.190000 |
6.86e-01 |
1.33e-03 |
| Metabolism of proteins |
1653 |
2.13e-36 |
8.99e-34 |
0.1910 |
NA |
-0.160000 |
-0.104000 |
7.67e-27 |
4.09e-12 |
| rRNA processing in the mitochondrion |
32 |
1.75e-01 |
2.57e-01 |
0.1910 |
NA |
0.013800 |
-0.190000 |
8.93e-01 |
6.26e-02 |
| Developmental Biology |
686 |
2.92e-16 |
1.28e-14 |
0.1910 |
NA |
-0.184000 |
0.049500 |
2.87e-16 |
2.81e-02 |
| DNA Double-Strand Break Repair |
132 |
8.13e-04 |
3.75e-03 |
0.1900 |
NA |
0.189000 |
-0.023200 |
1.79e-04 |
6.46e-01 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) |
96 |
5.57e-03 |
1.74e-02 |
0.1900 |
NA |
-0.022400 |
-0.189000 |
7.05e-01 |
1.39e-03 |
| RHO GTPases Activate NADPH Oxidases |
16 |
4.23e-01 |
5.14e-01 |
0.1900 |
NA |
-0.103000 |
0.160000 |
4.75e-01 |
2.69e-01 |
| Platelet sensitization by LDL |
14 |
4.71e-01 |
5.59e-01 |
0.1900 |
NA |
-0.152000 |
0.113000 |
3.23e-01 |
4.62e-01 |
| p75 NTR receptor-mediated signalling |
83 |
1.15e-02 |
3.07e-02 |
0.1900 |
NA |
-0.188000 |
0.025100 |
3.03e-03 |
6.93e-01 |
| Cellular responses to external stimuli |
424 |
1.79e-10 |
3.97e-09 |
0.1900 |
NA |
-0.166000 |
-0.092000 |
5.02e-09 |
1.20e-03 |
| Tight junction interactions |
20 |
3.39e-01 |
4.35e-01 |
0.1900 |
NA |
0.022500 |
0.188000 |
8.62e-01 |
1.45e-01 |
| Metabolism of polyamines |
77 |
1.57e-02 |
3.89e-02 |
0.1900 |
NA |
-0.157000 |
-0.106000 |
1.72e-02 |
1.08e-01 |
| Neurotransmitter release cycle |
35 |
1.55e-01 |
2.34e-01 |
0.1890 |
NA |
-0.116000 |
0.149000 |
2.36e-01 |
1.26e-01 |
| Interferon alpha/beta signaling |
52 |
6.14e-02 |
1.12e-01 |
0.1890 |
NA |
0.127000 |
0.140000 |
1.13e-01 |
8.09e-02 |
| Vesicle-mediated transport |
568 |
2.10e-13 |
6.82e-12 |
0.1890 |
NA |
-0.173000 |
0.075200 |
2.21e-12 |
2.29e-03 |
| TNFR2 non-canonical NF-kB pathway |
76 |
1.74e-02 |
4.21e-02 |
0.1890 |
NA |
-0.173000 |
-0.074700 |
9.11e-03 |
2.61e-01 |
| Rab regulation of trafficking |
115 |
2.38e-03 |
9.26e-03 |
0.1880 |
NA |
-0.163000 |
0.094900 |
2.62e-03 |
7.90e-02 |
| Formation of RNA Pol II elongation complex |
54 |
5.70e-02 |
1.07e-01 |
0.1880 |
NA |
-0.177000 |
-0.064700 |
2.49e-02 |
4.11e-01 |
| RNA Polymerase II Transcription Elongation |
54 |
5.70e-02 |
1.07e-01 |
0.1880 |
NA |
-0.177000 |
-0.064700 |
2.49e-02 |
4.11e-01 |
| Binding and Uptake of Ligands by Scavenger Receptors |
28 |
2.25e-01 |
3.18e-01 |
0.1880 |
NA |
-0.116000 |
-0.148000 |
2.87e-01 |
1.76e-01 |
| Toll-like Receptor Cascades |
127 |
1.29e-03 |
5.45e-03 |
0.1880 |
NA |
-0.184000 |
0.035800 |
3.38e-04 |
4.86e-01 |
| CDK-mediated phosphorylation and removal of Cdc6 |
68 |
2.74e-02 |
5.97e-02 |
0.1880 |
NA |
-0.105000 |
-0.156000 |
1.36e-01 |
2.64e-02 |
| Arachidonic acid metabolism |
35 |
1.57e-01 |
2.36e-01 |
0.1870 |
NA |
0.153000 |
0.108000 |
1.17e-01 |
2.69e-01 |
| Platelet homeostasis |
52 |
6.59e-02 |
1.18e-01 |
0.1870 |
NA |
-0.048300 |
0.181000 |
5.47e-01 |
2.41e-02 |
| Thrombin signalling through proteinase activated receptors (PARs) |
20 |
3.52e-01 |
4.48e-01 |
0.1870 |
NA |
-0.165000 |
0.088500 |
2.02e-01 |
4.93e-01 |
| Vitamin D (calciferol) metabolism |
10 |
5.93e-01 |
6.73e-01 |
0.1870 |
NA |
-0.040000 |
0.183000 |
8.27e-01 |
3.17e-01 |
| Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon |
15 |
4.60e-01 |
5.50e-01 |
0.1860 |
NA |
-0.177000 |
0.056800 |
2.34e-01 |
7.04e-01 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 |
17 |
4.12e-01 |
5.03e-01 |
0.1860 |
NA |
-0.133000 |
-0.130000 |
3.41e-01 |
3.54e-01 |
| Mitochondrial Fatty Acid Beta-Oxidation |
31 |
2.01e-01 |
2.87e-01 |
0.1860 |
NA |
0.183000 |
-0.033200 |
7.77e-02 |
7.49e-01 |
| Cell surface interactions at the vascular wall |
84 |
1.34e-02 |
3.47e-02 |
0.1860 |
NA |
-0.115000 |
0.146000 |
6.89e-02 |
2.06e-02 |
| SUMOylation of transcription factors |
16 |
4.35e-01 |
5.25e-01 |
0.1860 |
NA |
-0.091700 |
-0.162000 |
5.25e-01 |
2.63e-01 |
| Regulation of localization of FOXO transcription factors |
12 |
5.39e-01 |
6.23e-01 |
0.1860 |
NA |
-0.083800 |
0.166000 |
6.15e-01 |
3.20e-01 |
| Signaling by NOTCH4 |
79 |
1.67e-02 |
4.09e-02 |
0.1860 |
NA |
-0.157000 |
-0.099000 |
1.58e-02 |
1.28e-01 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein |
67 |
3.14e-02 |
6.69e-02 |
0.1860 |
NA |
-0.181000 |
-0.040500 |
1.03e-02 |
5.67e-01 |
| Viral Messenger RNA Synthesis |
43 |
1.08e-01 |
1.74e-01 |
0.1860 |
NA |
-0.058600 |
-0.176000 |
5.07e-01 |
4.55e-02 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex |
13 |
5.11e-01 |
5.99e-01 |
0.1860 |
NA |
0.182000 |
0.037200 |
2.57e-01 |
8.16e-01 |
| Mitotic Spindle Checkpoint |
105 |
4.74e-03 |
1.56e-02 |
0.1850 |
NA |
0.171000 |
-0.072200 |
2.53e-03 |
2.02e-01 |
| Downstream signal transduction |
28 |
2.37e-01 |
3.30e-01 |
0.1850 |
NA |
-0.185000 |
-0.006660 |
9.00e-02 |
9.51e-01 |
| G1/S DNA Damage Checkpoints |
64 |
3.72e-02 |
7.62e-02 |
0.1850 |
NA |
-0.146000 |
-0.113000 |
4.31e-02 |
1.17e-01 |
| Protein-protein interactions at synapses |
55 |
5.92e-02 |
1.10e-01 |
0.1850 |
NA |
0.088900 |
0.162000 |
2.54e-01 |
3.75e-02 |
| Diseases of glycosylation |
108 |
4.11e-03 |
1.39e-02 |
0.1850 |
NA |
0.017600 |
0.184000 |
7.52e-01 |
9.74e-04 |
| GAB1 signalosome |
13 |
5.19e-01 |
6.06e-01 |
0.1840 |
NA |
-0.180000 |
0.037600 |
2.62e-01 |
8.15e-01 |
| Signaling by FGFR2 IIIa TM |
18 |
4.03e-01 |
4.95e-01 |
0.1830 |
NA |
-0.004720 |
0.183000 |
9.72e-01 |
1.78e-01 |
| Diseases of signal transduction |
332 |
7.94e-08 |
1.18e-06 |
0.1830 |
NA |
-0.182000 |
0.015100 |
1.19e-08 |
6.38e-01 |
| Post-translational modification: synthesis of GPI-anchored proteins |
44 |
1.11e-01 |
1.78e-01 |
0.1820 |
NA |
0.146000 |
0.110000 |
9.48e-02 |
2.08e-01 |
| G alpha (i) signalling events |
195 |
6.83e-05 |
4.88e-04 |
0.1820 |
NA |
0.013600 |
0.182000 |
7.44e-01 |
1.27e-05 |
| Metabolism of vitamins and cofactors |
157 |
4.51e-04 |
2.34e-03 |
0.1820 |
NA |
0.061600 |
-0.171000 |
1.83e-01 |
2.16e-04 |
| Signaling by WNT |
236 |
1.00e-05 |
9.93e-05 |
0.1820 |
NA |
-0.182000 |
-0.003090 |
1.61e-06 |
9.35e-01 |
| G beta:gamma signalling through CDC42 |
11 |
5.82e-01 |
6.64e-01 |
0.1810 |
NA |
-0.045900 |
0.176000 |
7.92e-01 |
3.13e-01 |
| Mitotic Prophase |
95 |
9.34e-03 |
2.60e-02 |
0.1810 |
NA |
-0.043500 |
-0.176000 |
4.64e-01 |
3.03e-03 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins |
13 |
5.29e-01 |
6.16e-01 |
0.1810 |
NA |
0.102000 |
-0.150000 |
5.23e-01 |
3.50e-01 |
| tRNA processing in the mitochondrion |
35 |
1.80e-01 |
2.63e-01 |
0.1810 |
NA |
0.102000 |
-0.150000 |
2.96e-01 |
1.25e-01 |
| COPI-dependent Golgi-to-ER retrograde traffic |
77 |
2.34e-02 |
5.32e-02 |
0.1810 |
NA |
-0.136000 |
0.120000 |
3.91e-02 |
6.97e-02 |
| Glycosphingolipid metabolism |
37 |
1.63e-01 |
2.43e-01 |
0.1810 |
NA |
-0.176000 |
0.043200 |
6.41e-02 |
6.50e-01 |
| Mitotic Prometaphase |
177 |
1.85e-04 |
1.13e-03 |
0.1810 |
NA |
0.179000 |
-0.027400 |
4.10e-05 |
5.31e-01 |
| Cargo trafficking to the periciliary membrane |
48 |
9.60e-02 |
1.57e-01 |
0.1810 |
NA |
0.000417 |
0.181000 |
9.96e-01 |
3.04e-02 |
| Gap-filling DNA repair synthesis and ligation in GG-NER |
25 |
2.94e-01 |
3.88e-01 |
0.1810 |
NA |
0.176000 |
0.039600 |
1.27e-01 |
7.32e-01 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription |
31 |
2.22e-01 |
3.13e-01 |
0.1800 |
NA |
-0.141000 |
-0.111000 |
1.73e-01 |
2.86e-01 |
| Platelet activation, signaling and aggregation |
192 |
1.09e-04 |
7.23e-04 |
0.1790 |
NA |
-0.118000 |
0.136000 |
5.02e-03 |
1.22e-03 |
| activated TAK1 mediates p38 MAPK activation |
19 |
4.01e-01 |
4.94e-01 |
0.1790 |
NA |
-0.178000 |
0.021800 |
1.80e-01 |
8.69e-01 |
| MASTL Facilitates Mitotic Progression |
10 |
6.18e-01 |
6.96e-01 |
0.1790 |
NA |
-0.053400 |
-0.171000 |
7.70e-01 |
3.50e-01 |
| HSF1 activation |
26 |
2.89e-01 |
3.82e-01 |
0.1780 |
NA |
-0.165000 |
-0.066900 |
1.45e-01 |
5.55e-01 |
| DCC mediated attractive signaling |
13 |
5.42e-01 |
6.26e-01 |
0.1780 |
NA |
-0.052700 |
0.170000 |
7.42e-01 |
2.90e-01 |
| G2/M DNA damage checkpoint |
67 |
4.27e-02 |
8.48e-02 |
0.1770 |
NA |
0.175000 |
0.026400 |
1.31e-02 |
7.08e-01 |
| HuR (ELAVL1) binds and stabilizes mRNA |
10 |
6.25e-01 |
7.02e-01 |
0.1770 |
NA |
-0.016500 |
-0.176000 |
9.28e-01 |
3.34e-01 |
| Centrosome maturation |
80 |
2.42e-02 |
5.42e-02 |
0.1760 |
NA |
0.170000 |
0.046600 |
8.62e-03 |
4.72e-01 |
| Recruitment of mitotic centrosome proteins and complexes |
80 |
2.42e-02 |
5.42e-02 |
0.1760 |
NA |
0.170000 |
0.046600 |
8.62e-03 |
4.72e-01 |
| Cyclin A:Cdk2-associated events at S phase entry |
82 |
2.19e-02 |
5.08e-02 |
0.1760 |
NA |
-0.136000 |
-0.112000 |
3.28e-02 |
8.11e-02 |
| Interleukin-2 family signaling |
29 |
2.65e-01 |
3.62e-01 |
0.1750 |
NA |
-0.139000 |
0.107000 |
1.96e-01 |
3.17e-01 |
| Transcriptional regulation by small RNAs |
61 |
6.03e-02 |
1.11e-01 |
0.1750 |
NA |
-0.064800 |
-0.163000 |
3.81e-01 |
2.80e-02 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest |
18 |
4.38e-01 |
5.28e-01 |
0.1750 |
NA |
0.032200 |
-0.172000 |
8.13e-01 |
2.06e-01 |
| Extracellular matrix organization |
190 |
1.74e-04 |
1.07e-03 |
0.1750 |
NA |
0.053500 |
0.167000 |
2.04e-01 |
7.63e-05 |
| Resolution of Sister Chromatid Cohesion |
101 |
1.02e-02 |
2.79e-02 |
0.1750 |
NA |
0.159000 |
-0.073600 |
5.89e-03 |
2.01e-01 |
| VLDLR internalisation and degradation |
12 |
5.80e-01 |
6.62e-01 |
0.1740 |
NA |
-0.166000 |
0.051800 |
3.18e-01 |
7.56e-01 |
| Synaptic adhesion-like molecules |
15 |
5.05e-01 |
5.94e-01 |
0.1740 |
NA |
0.145000 |
0.095400 |
3.30e-01 |
5.22e-01 |
| Meiotic recombination |
36 |
1.96e-01 |
2.81e-01 |
0.1740 |
NA |
0.166000 |
0.051800 |
8.51e-02 |
5.91e-01 |
| RNA Polymerase III Chain Elongation |
18 |
4.43e-01 |
5.32e-01 |
0.1740 |
NA |
-0.173000 |
-0.018900 |
2.05e-01 |
8.90e-01 |
| MHC class II antigen presentation |
84 |
2.33e-02 |
5.29e-02 |
0.1740 |
NA |
-0.113000 |
0.132000 |
7.36e-02 |
3.68e-02 |
| Neddylation |
210 |
8.05e-05 |
5.63e-04 |
0.1740 |
NA |
-0.102000 |
-0.140000 |
1.06e-02 |
4.72e-04 |
| Beta-catenin independent WNT signaling |
123 |
4.06e-03 |
1.39e-02 |
0.1740 |
NA |
-0.171000 |
0.030300 |
1.07e-03 |
5.62e-01 |
| Transport of small molecules |
540 |
7.91e-11 |
1.89e-09 |
0.1730 |
NA |
-0.157000 |
0.071600 |
5.03e-10 |
4.61e-03 |
| VEGFR2 mediated vascular permeability |
26 |
3.14e-01 |
4.09e-01 |
0.1720 |
NA |
-0.171000 |
-0.022900 |
1.31e-01 |
8.40e-01 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta |
59 |
7.24e-02 |
1.25e-01 |
0.1720 |
NA |
-0.167000 |
-0.043100 |
2.67e-02 |
5.67e-01 |
| Termination of translesion DNA synthesis |
31 |
2.50e-01 |
3.45e-01 |
0.1720 |
NA |
0.121000 |
0.123000 |
2.45e-01 |
2.36e-01 |
| Asymmetric localization of PCP proteins |
59 |
7.27e-02 |
1.26e-01 |
0.1720 |
NA |
-0.155000 |
-0.074100 |
3.92e-02 |
3.25e-01 |
| Transcriptional regulation by RUNX2 |
102 |
1.13e-02 |
3.03e-02 |
0.1720 |
NA |
-0.172000 |
0.002570 |
2.74e-03 |
9.64e-01 |
| Sialic acid metabolism |
22 |
3.80e-01 |
4.76e-01 |
0.1720 |
NA |
-0.151000 |
0.082500 |
2.21e-01 |
5.03e-01 |
| Late Phase of HIV Life Cycle |
129 |
3.38e-03 |
1.20e-02 |
0.1720 |
NA |
-0.095800 |
-0.143000 |
6.06e-02 |
5.22e-03 |
| Signaling by NTRK3 (TRKC) |
14 |
5.38e-01 |
6.23e-01 |
0.1720 |
NA |
-0.163000 |
-0.053500 |
2.91e-01 |
7.29e-01 |
| Signaling by Hedgehog |
122 |
4.83e-03 |
1.59e-02 |
0.1720 |
NA |
-0.165000 |
0.048200 |
1.70e-03 |
3.58e-01 |
| MAP2K and MAPK activation |
35 |
2.18e-01 |
3.08e-01 |
0.1710 |
NA |
-0.154000 |
0.074100 |
1.15e-01 |
4.48e-01 |
| IKK complex recruitment mediated by RIP1 |
21 |
4.01e-01 |
4.94e-01 |
0.1700 |
NA |
-0.166000 |
-0.039100 |
1.89e-01 |
7.57e-01 |
| Branched-chain amino acid catabolism |
21 |
4.03e-01 |
4.95e-01 |
0.1700 |
NA |
0.163000 |
-0.047500 |
1.95e-01 |
7.07e-01 |
| Signaling by NTRK2 (TRKB) |
21 |
4.06e-01 |
4.97e-01 |
0.1700 |
NA |
-0.095700 |
0.140000 |
4.48e-01 |
2.66e-01 |
| Regulation of beta-cell development |
30 |
2.76e-01 |
3.72e-01 |
0.1700 |
NA |
0.079600 |
-0.150000 |
4.51e-01 |
1.55e-01 |
| Regulation of TNFR1 signaling |
30 |
2.76e-01 |
3.72e-01 |
0.1690 |
NA |
-0.155000 |
-0.068000 |
1.43e-01 |
5.19e-01 |
| Base-Excision Repair, AP Site Formation |
31 |
2.69e-01 |
3.65e-01 |
0.1690 |
NA |
0.158000 |
-0.060100 |
1.29e-01 |
5.62e-01 |
| NOTCH1 Intracellular Domain Regulates Transcription |
45 |
1.47e-01 |
2.23e-01 |
0.1690 |
NA |
-0.162000 |
-0.046300 |
6.00e-02 |
5.91e-01 |
| TNFR1-induced proapoptotic signaling |
12 |
6.01e-01 |
6.80e-01 |
0.1680 |
NA |
-0.003530 |
-0.168000 |
9.83e-01 |
3.13e-01 |
| Cellular responses to stress |
341 |
6.83e-07 |
9.39e-06 |
0.1680 |
NA |
-0.117000 |
-0.120000 |
2.05e-04 |
1.44e-04 |
| Diseases of carbohydrate metabolism |
30 |
2.82e-01 |
3.77e-01 |
0.1680 |
NA |
-0.014500 |
-0.167000 |
8.91e-01 |
1.13e-01 |
| Signaling by cytosolic FGFR1 fusion mutants |
18 |
4.69e-01 |
5.57e-01 |
0.1670 |
NA |
-0.164000 |
-0.034800 |
2.29e-01 |
7.98e-01 |
| Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. |
108 |
1.09e-02 |
2.95e-02 |
0.1670 |
NA |
-0.044300 |
-0.161000 |
4.27e-01 |
3.78e-03 |
| APC/C-mediated degradation of cell cycle proteins |
82 |
3.30e-02 |
6.95e-02 |
0.1670 |
NA |
0.000978 |
-0.167000 |
9.88e-01 |
8.99e-03 |
| Regulation of mitotic cell cycle |
82 |
3.30e-02 |
6.95e-02 |
0.1670 |
NA |
0.000978 |
-0.167000 |
9.88e-01 |
8.99e-03 |
| HIV Infection |
215 |
1.43e-04 |
9.02e-04 |
0.1660 |
NA |
-0.127000 |
-0.107000 |
1.35e-03 |
6.74e-03 |
| Olfactory Signaling Pathway |
11 |
6.34e-01 |
7.12e-01 |
0.1660 |
NA |
0.092400 |
0.138000 |
5.96e-01 |
4.29e-01 |
| Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) |
116 |
8.72e-03 |
2.51e-02 |
0.1650 |
NA |
-0.061800 |
-0.153000 |
2.51e-01 |
4.35e-03 |
| Neutrophil degranulation |
354 |
7.66e-07 |
1.04e-05 |
0.1650 |
NA |
-0.130000 |
0.102000 |
2.81e-05 |
1.04e-03 |
| HIV Life Cycle |
141 |
3.24e-03 |
1.16e-02 |
0.1650 |
NA |
-0.074600 |
-0.147000 |
1.26e-01 |
2.58e-03 |
| Keratan sulfate biosynthesis |
18 |
4.83e-01 |
5.71e-01 |
0.1650 |
NA |
-0.125000 |
0.107000 |
3.58e-01 |
4.32e-01 |
| Activation of BH3-only proteins |
29 |
3.09e-01 |
4.04e-01 |
0.1650 |
NA |
-0.161000 |
0.036100 |
1.35e-01 |
7.36e-01 |
| Signaling by high-kinase activity BRAF mutants |
31 |
2.87e-01 |
3.81e-01 |
0.1640 |
NA |
-0.162000 |
0.029000 |
1.19e-01 |
7.80e-01 |
| PPARA activates gene expression |
114 |
1.02e-02 |
2.79e-02 |
0.1640 |
NA |
-0.059400 |
-0.153000 |
2.73e-01 |
4.83e-03 |
| Golgi-to-ER retrograde transport |
108 |
1.35e-02 |
3.48e-02 |
0.1640 |
NA |
-0.138000 |
0.087700 |
1.30e-02 |
1.16e-01 |
| ER-Phagosome pathway |
79 |
4.23e-02 |
8.42e-02 |
0.1630 |
NA |
-0.153000 |
-0.057800 |
1.88e-02 |
3.75e-01 |
| Global Genome Nucleotide Excision Repair (GG-NER) |
84 |
3.56e-02 |
7.38e-02 |
0.1630 |
NA |
0.075500 |
-0.145000 |
2.32e-01 |
2.17e-02 |
| Synthesis of PC |
25 |
3.67e-01 |
4.62e-01 |
0.1630 |
NA |
-0.161000 |
-0.030100 |
1.64e-01 |
7.95e-01 |
| Nucleotide salvage |
20 |
4.49e-01 |
5.39e-01 |
0.1630 |
NA |
0.103000 |
0.126000 |
4.25e-01 |
3.28e-01 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 |
16 |
5.31e-01 |
6.17e-01 |
0.1630 |
NA |
0.155000 |
-0.050000 |
2.84e-01 |
7.29e-01 |
| NRIF signals cell death from the nucleus |
15 |
5.53e-01 |
6.36e-01 |
0.1630 |
NA |
-0.155000 |
0.049600 |
2.99e-01 |
7.39e-01 |
| Formation of the beta-catenin:TCF transactivating complex |
45 |
1.69e-01 |
2.50e-01 |
0.1630 |
NA |
-0.162000 |
-0.007060 |
5.95e-02 |
9.35e-01 |
| Antigen processing-Cross presentation |
89 |
2.97e-02 |
6.39e-02 |
0.1620 |
NA |
-0.155000 |
-0.047800 |
1.14e-02 |
4.36e-01 |
| Signaling by NOTCH |
177 |
1.00e-03 |
4.44e-03 |
0.1620 |
NA |
-0.160000 |
-0.025800 |
2.47e-04 |
5.54e-01 |
| Plasma lipoprotein remodeling |
27 |
3.51e-01 |
4.47e-01 |
0.1610 |
NA |
0.094400 |
-0.131000 |
3.96e-01 |
2.39e-01 |
| Regulation of pyruvate dehydrogenase (PDH) complex |
15 |
5.57e-01 |
6.40e-01 |
0.1610 |
NA |
-0.001460 |
0.161000 |
9.92e-01 |
2.79e-01 |
| Activation of HOX genes during differentiation |
70 |
6.61e-02 |
1.18e-01 |
0.1610 |
NA |
-0.159000 |
-0.023900 |
2.13e-02 |
7.30e-01 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis |
70 |
6.61e-02 |
1.18e-01 |
0.1610 |
NA |
-0.159000 |
-0.023900 |
2.13e-02 |
7.30e-01 |
| Apoptosis induced DNA fragmentation |
10 |
6.80e-01 |
7.50e-01 |
0.1610 |
NA |
0.141000 |
-0.076500 |
4.39e-01 |
6.76e-01 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal |
89 |
3.30e-02 |
6.95e-02 |
0.1600 |
NA |
0.158000 |
-0.027500 |
9.99e-03 |
6.54e-01 |
| Amplification of signal from the kinetochores |
89 |
3.30e-02 |
6.95e-02 |
0.1600 |
NA |
0.158000 |
-0.027500 |
9.99e-03 |
6.54e-01 |
| SLC-mediated transmembrane transport |
176 |
1.35e-03 |
5.67e-03 |
0.1590 |
NA |
-0.134000 |
0.086500 |
2.21e-03 |
4.80e-02 |
| Antigen processing: Ubiquitination & Proteasome degradation |
281 |
3.10e-05 |
2.55e-04 |
0.1580 |
NA |
-0.103000 |
-0.120000 |
3.08e-03 |
5.65e-04 |
| Regulation of FOXO transcriptional activity by acetylation |
10 |
6.87e-01 |
7.56e-01 |
0.1580 |
NA |
-0.122000 |
-0.100000 |
5.06e-01 |
5.82e-01 |
| Hemostasis |
420 |
2.63e-07 |
3.79e-06 |
0.1570 |
NA |
-0.077800 |
0.137000 |
6.41e-03 |
1.62e-06 |
| Factors involved in megakaryocyte development and platelet production |
106 |
2.04e-02 |
4.78e-02 |
0.1570 |
NA |
-0.030500 |
0.154000 |
5.88e-01 |
6.15e-03 |
| Surfactant metabolism |
12 |
6.43e-01 |
7.18e-01 |
0.1570 |
NA |
-0.101000 |
0.120000 |
5.44e-01 |
4.71e-01 |
| TRAF6 mediated IRF7 activation |
14 |
5.96e-01 |
6.76e-01 |
0.1570 |
NA |
-0.141000 |
-0.068200 |
3.60e-01 |
6.59e-01 |
| Gene Silencing by RNA |
83 |
4.70e-02 |
9.17e-02 |
0.1570 |
NA |
-0.071600 |
-0.139000 |
2.60e-01 |
2.82e-02 |
| Zinc transporters |
14 |
5.99e-01 |
6.79e-01 |
0.1570 |
NA |
-0.152000 |
0.038800 |
3.26e-01 |
8.01e-01 |
| Signaling by RAS mutants |
51 |
1.57e-01 |
2.36e-01 |
0.1560 |
NA |
-0.142000 |
0.065800 |
8.06e-02 |
4.16e-01 |
| Visual phototransduction |
72 |
7.27e-02 |
1.26e-01 |
0.1560 |
NA |
0.065200 |
0.142000 |
3.39e-01 |
3.80e-02 |
| Listeria monocytogenes entry into host cells |
18 |
5.22e-01 |
6.09e-01 |
0.1560 |
NA |
-0.131000 |
0.084400 |
3.37e-01 |
5.35e-01 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus |
11 |
6.72e-01 |
7.43e-01 |
0.1550 |
NA |
-0.053800 |
0.146000 |
7.57e-01 |
4.02e-01 |
| Endosomal Sorting Complex Required For Transport (ESCRT) |
31 |
3.25e-01 |
4.20e-01 |
0.1550 |
NA |
-0.101000 |
-0.118000 |
3.31e-01 |
2.56e-01 |
| Molecules associated with elastic fibres |
19 |
5.04e-01 |
5.92e-01 |
0.1550 |
NA |
0.053700 |
0.145000 |
6.85e-01 |
2.73e-01 |
| ISG15 antiviral mechanism |
72 |
7.56e-02 |
1.30e-01 |
0.1550 |
NA |
-0.087900 |
-0.127000 |
1.98e-01 |
6.21e-02 |
| Apoptotic factor-mediated response |
16 |
5.66e-01 |
6.49e-01 |
0.1540 |
NA |
-0.054700 |
0.144000 |
7.05e-01 |
3.17e-01 |
| Non-integrin membrane-ECM interactions |
37 |
2.69e-01 |
3.65e-01 |
0.1540 |
NA |
-0.118000 |
0.099700 |
2.15e-01 |
2.94e-01 |
| Innate Immune System |
740 |
1.32e-11 |
3.55e-10 |
0.1540 |
NA |
-0.140000 |
0.065000 |
1.28e-10 |
2.77e-03 |
| Plasma lipoprotein assembly |
17 |
5.49e-01 |
6.33e-01 |
0.1530 |
NA |
-0.005610 |
-0.153000 |
9.68e-01 |
2.74e-01 |
| Signaling by Nuclear Receptors |
184 |
1.60e-03 |
6.53e-03 |
0.1530 |
NA |
-0.146000 |
-0.047700 |
6.62e-04 |
2.65e-01 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain |
21 |
4.78e-01 |
5.66e-01 |
0.1530 |
NA |
-0.089200 |
-0.124000 |
4.79e-01 |
3.25e-01 |
| Death Receptor Signalling |
123 |
1.38e-02 |
3.54e-02 |
0.1530 |
NA |
-0.147000 |
-0.042500 |
5.00e-03 |
4.16e-01 |
| G beta:gamma signalling through PI3Kgamma |
14 |
6.13e-01 |
6.92e-01 |
0.1530 |
NA |
-0.143000 |
-0.053000 |
3.54e-01 |
7.32e-01 |
| GRB2 events in ERBB2 signaling |
12 |
6.60e-01 |
7.32e-01 |
0.1520 |
NA |
-0.100000 |
0.115000 |
5.48e-01 |
4.90e-01 |
| Activation of Matrix Metalloproteinases |
16 |
5.72e-01 |
6.55e-01 |
0.1520 |
NA |
0.066900 |
0.137000 |
6.43e-01 |
3.44e-01 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants |
56 |
1.46e-01 |
2.22e-01 |
0.1520 |
NA |
-0.147000 |
0.036400 |
5.67e-02 |
6.38e-01 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants |
56 |
1.46e-01 |
2.22e-01 |
0.1520 |
NA |
-0.147000 |
0.036400 |
5.67e-02 |
6.38e-01 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer |
56 |
1.46e-01 |
2.22e-01 |
0.1520 |
NA |
-0.147000 |
0.036400 |
5.67e-02 |
6.38e-01 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer |
56 |
1.46e-01 |
2.22e-01 |
0.1520 |
NA |
-0.147000 |
0.036400 |
5.67e-02 |
6.38e-01 |
| Signaling by NOTCH1 in Cancer |
56 |
1.46e-01 |
2.22e-01 |
0.1520 |
NA |
-0.147000 |
0.036400 |
5.67e-02 |
6.38e-01 |
| Processing of DNA double-strand break ends |
69 |
9.52e-02 |
1.56e-01 |
0.1510 |
NA |
0.149000 |
0.024700 |
3.26e-02 |
7.23e-01 |
| Class I MHC mediated antigen processing & presentation |
335 |
1.28e-05 |
1.22e-04 |
0.1510 |
NA |
-0.116000 |
-0.096200 |
2.68e-04 |
2.53e-03 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane |
10 |
7.11e-01 |
7.78e-01 |
0.1510 |
NA |
0.147000 |
0.031800 |
4.20e-01 |
8.62e-01 |
| RNA polymerase II transcribes snRNA genes |
72 |
8.93e-02 |
1.50e-01 |
0.1500 |
NA |
-0.140000 |
-0.052400 |
3.98e-02 |
4.43e-01 |
| B-WICH complex positively regulates rRNA expression |
46 |
2.13e-01 |
3.03e-01 |
0.1500 |
NA |
-0.121000 |
-0.087900 |
1.56e-01 |
3.02e-01 |
| Smooth Muscle Contraction |
27 |
4.11e-01 |
5.02e-01 |
0.1490 |
NA |
-0.061800 |
0.135000 |
5.79e-01 |
2.24e-01 |
| Metabolism of nucleotides |
87 |
5.89e-02 |
1.09e-01 |
0.1480 |
NA |
0.111000 |
-0.097600 |
7.26e-02 |
1.16e-01 |
| BMAL1:CLOCK,NPAS2 activates circadian gene expression |
26 |
4.24e-01 |
5.15e-01 |
0.1480 |
NA |
-0.104000 |
-0.105000 |
3.57e-01 |
3.54e-01 |
| RUNX2 regulates bone development |
24 |
4.59e-01 |
5.50e-01 |
0.1470 |
NA |
0.022500 |
0.145000 |
8.49e-01 |
2.18e-01 |
| RNA Polymerase I Promoter Clearance |
65 |
1.23e-01 |
1.94e-01 |
0.1470 |
NA |
-0.028400 |
-0.144000 |
6.92e-01 |
4.47e-02 |
| Disease |
885 |
1.64e-12 |
4.93e-11 |
0.1470 |
NA |
-0.139000 |
-0.045700 |
2.77e-12 |
2.20e-02 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat |
39 |
2.87e-01 |
3.81e-01 |
0.1460 |
NA |
-0.131000 |
-0.064000 |
1.56e-01 |
4.89e-01 |
| HIV Transcription Elongation |
39 |
2.87e-01 |
3.81e-01 |
0.1460 |
NA |
-0.131000 |
-0.064000 |
1.56e-01 |
4.89e-01 |
| Tat-mediated elongation of the HIV-1 transcript |
39 |
2.87e-01 |
3.81e-01 |
0.1460 |
NA |
-0.131000 |
-0.064000 |
1.56e-01 |
4.89e-01 |
| Signaling by NOTCH2 |
29 |
3.97e-01 |
4.92e-01 |
0.1460 |
NA |
-0.013700 |
0.145000 |
8.99e-01 |
1.76e-01 |
| Cleavage of the damaged pyrimidine |
29 |
3.98e-01 |
4.92e-01 |
0.1460 |
NA |
0.143000 |
-0.028300 |
1.83e-01 |
7.92e-01 |
| Depyrimidination |
29 |
3.98e-01 |
4.92e-01 |
0.1460 |
NA |
0.143000 |
-0.028300 |
1.83e-01 |
7.92e-01 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine |
29 |
3.98e-01 |
4.92e-01 |
0.1460 |
NA |
0.143000 |
-0.028300 |
1.83e-01 |
7.92e-01 |
| Epigenetic regulation of gene expression |
102 |
3.90e-02 |
7.91e-02 |
0.1460 |
NA |
-0.089700 |
-0.115000 |
1.18e-01 |
4.54e-02 |
| Post-translational protein modification |
1153 |
1.32e-15 |
5.07e-14 |
0.1460 |
NA |
-0.130000 |
-0.064900 |
1.45e-13 |
2.33e-04 |
| Signaling by FGFR1 in disease |
30 |
3.87e-01 |
4.82e-01 |
0.1460 |
NA |
-0.143000 |
0.026800 |
1.75e-01 |
8.00e-01 |
| Collagen formation |
52 |
1.91e-01 |
2.76e-01 |
0.1450 |
NA |
0.100000 |
0.105000 |
2.11e-01 |
1.89e-01 |
| Caspase-mediated cleavage of cytoskeletal proteins |
11 |
7.08e-01 |
7.75e-01 |
0.1450 |
NA |
0.013800 |
0.144000 |
9.37e-01 |
4.09e-01 |
| DNA methylation |
19 |
5.51e-01 |
6.35e-01 |
0.1440 |
NA |
0.078200 |
0.121000 |
5.55e-01 |
3.60e-01 |
| Peptide hormone metabolism |
50 |
2.14e-01 |
3.03e-01 |
0.1440 |
NA |
-0.126000 |
0.069900 |
1.24e-01 |
3.92e-01 |
| Regulation of RUNX1 Expression and Activity |
18 |
5.70e-01 |
6.53e-01 |
0.1440 |
NA |
-0.108000 |
-0.095200 |
4.27e-01 |
4.85e-01 |
| Nucleotide Excision Repair |
110 |
3.40e-02 |
7.10e-02 |
0.1440 |
NA |
0.016000 |
-0.143000 |
7.72e-01 |
9.72e-03 |
| COPI-independent Golgi-to-ER retrograde traffic |
31 |
3.86e-01 |
4.82e-01 |
0.1430 |
NA |
-0.143000 |
0.007900 |
1.68e-01 |
9.39e-01 |
| Metabolism of steroids |
122 |
2.48e-02 |
5.49e-02 |
0.1430 |
NA |
0.072800 |
-0.123000 |
1.66e-01 |
1.90e-02 |
| G alpha (12/13) signalling events |
60 |
1.64e-01 |
2.44e-01 |
0.1420 |
NA |
-0.121000 |
0.074900 |
1.05e-01 |
3.16e-01 |
| NRAGE signals death through JNK |
49 |
2.29e-01 |
3.21e-01 |
0.1420 |
NA |
-0.125000 |
0.067700 |
1.31e-01 |
4.12e-01 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models |
21 |
5.30e-01 |
6.16e-01 |
0.1420 |
NA |
-0.130000 |
-0.057100 |
3.03e-01 |
6.51e-01 |
| Neurodegenerative Diseases |
21 |
5.30e-01 |
6.16e-01 |
0.1420 |
NA |
-0.130000 |
-0.057100 |
3.03e-01 |
6.51e-01 |
| Apoptosis |
157 |
9.01e-03 |
2.56e-02 |
0.1420 |
NA |
-0.123000 |
-0.070200 |
7.82e-03 |
1.29e-01 |
| G0 and Early G1 |
26 |
4.58e-01 |
5.49e-01 |
0.1410 |
NA |
0.130000 |
0.055500 |
2.51e-01 |
6.25e-01 |
| Formation of HIV elongation complex in the absence of HIV Tat |
41 |
2.94e-01 |
3.88e-01 |
0.1410 |
NA |
-0.119000 |
-0.074900 |
1.86e-01 |
4.07e-01 |
| Golgi Cisternae Pericentriolar Stack Reorganization |
14 |
6.58e-01 |
7.30e-01 |
0.1410 |
NA |
-0.057000 |
-0.129000 |
7.12e-01 |
4.04e-01 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway |
11 |
7.21e-01 |
7.86e-01 |
0.1410 |
NA |
0.049900 |
0.131000 |
7.74e-01 |
4.50e-01 |
| Signaling by WNT in cancer |
31 |
4.00e-01 |
4.94e-01 |
0.1400 |
NA |
-0.139000 |
-0.021900 |
1.82e-01 |
8.33e-01 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes |
29 |
4.26e-01 |
5.17e-01 |
0.1400 |
NA |
-0.129000 |
-0.054900 |
2.30e-01 |
6.09e-01 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane |
50 |
2.34e-01 |
3.26e-01 |
0.1400 |
NA |
-0.112000 |
0.083700 |
1.71e-01 |
3.06e-01 |
| Translesion synthesis by POLK |
17 |
6.09e-01 |
6.89e-01 |
0.1390 |
NA |
0.057300 |
0.127000 |
6.83e-01 |
3.65e-01 |
| Gene expression (Transcription) |
1265 |
1.88e-15 |
7.00e-14 |
0.1390 |
NA |
-0.030700 |
-0.135000 |
6.89e-02 |
1.05e-15 |
| RAB GEFs exchange GTP for GDP on RABs |
83 |
9.31e-02 |
1.55e-01 |
0.1390 |
NA |
-0.118000 |
0.073600 |
6.41e-02 |
2.47e-01 |
| FGFR1 mutant receptor activation |
23 |
5.17e-01 |
6.05e-01 |
0.1390 |
NA |
-0.135000 |
0.031100 |
2.62e-01 |
7.96e-01 |
| Interleukin-35 Signalling |
11 |
7.31e-01 |
7.91e-01 |
0.1380 |
NA |
-0.078600 |
0.114000 |
6.52e-01 |
5.13e-01 |
| Signal Transduction |
1625 |
1.75e-18 |
1.11e-16 |
0.1370 |
NA |
-0.109000 |
0.082300 |
4.77e-13 |
4.79e-08 |
| Translesion synthesis by POLI |
17 |
6.20e-01 |
6.98e-01 |
0.1370 |
NA |
0.071700 |
0.116000 |
6.09e-01 |
4.07e-01 |
| Signaling by Non-Receptor Tyrosine Kinases |
46 |
2.78e-01 |
3.73e-01 |
0.1370 |
NA |
-0.136000 |
0.009730 |
1.10e-01 |
9.09e-01 |
| Signaling by PTK6 |
46 |
2.78e-01 |
3.73e-01 |
0.1370 |
NA |
-0.136000 |
0.009730 |
1.10e-01 |
9.09e-01 |
| RNA Polymerase II Pre-transcription Events |
75 |
1.24e-01 |
1.95e-01 |
0.1360 |
NA |
-0.134000 |
-0.022300 |
4.42e-02 |
7.39e-01 |
| Interleukin-6 family signaling |
19 |
5.94e-01 |
6.74e-01 |
0.1350 |
NA |
-0.116000 |
-0.069200 |
3.82e-01 |
6.01e-01 |
| Cell death signalling via NRAGE, NRIF and NADE |
65 |
1.72e-01 |
2.54e-01 |
0.1350 |
NA |
-0.130000 |
0.034700 |
6.96e-02 |
6.29e-01 |
| Glycolysis |
65 |
1.73e-01 |
2.55e-01 |
0.1340 |
NA |
-0.130000 |
-0.035000 |
7.11e-02 |
6.26e-01 |
| Signaling by NODAL |
14 |
6.85e-01 |
7.54e-01 |
0.1340 |
NA |
-0.092500 |
-0.097000 |
5.49e-01 |
5.30e-01 |
| TNF signaling |
40 |
3.45e-01 |
4.42e-01 |
0.1330 |
NA |
-0.077300 |
-0.108000 |
3.98e-01 |
2.37e-01 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF |
40 |
3.50e-01 |
4.46e-01 |
0.1330 |
NA |
-0.129000 |
0.032400 |
1.59e-01 |
7.23e-01 |
| Signaling by moderate kinase activity BRAF mutants |
40 |
3.50e-01 |
4.46e-01 |
0.1330 |
NA |
-0.129000 |
0.032400 |
1.59e-01 |
7.23e-01 |
| TRAF3-dependent IRF activation pathway |
12 |
7.30e-01 |
7.91e-01 |
0.1320 |
NA |
-0.124000 |
0.047100 |
4.58e-01 |
7.77e-01 |
| RNA Polymerase I Transcription |
66 |
1.78e-01 |
2.60e-01 |
0.1320 |
NA |
-0.034500 |
-0.127000 |
6.28e-01 |
7.35e-02 |
| Josephin domain DUBs |
11 |
7.50e-01 |
8.07e-01 |
0.1320 |
NA |
-0.017300 |
-0.131000 |
9.21e-01 |
4.53e-01 |
| Mitotic Anaphase |
173 |
1.18e-02 |
3.12e-02 |
0.1320 |
NA |
0.045100 |
-0.124000 |
3.07e-01 |
5.03e-03 |
| Mitotic Metaphase and Anaphase |
174 |
1.15e-02 |
3.08e-02 |
0.1320 |
NA |
0.042100 |
-0.125000 |
3.39e-01 |
4.58e-03 |
| Programmed Cell Death |
160 |
1.66e-02 |
4.07e-02 |
0.1310 |
NA |
-0.114000 |
-0.063800 |
1.26e-02 |
1.64e-01 |
| RHO GTPases activate PKNs |
45 |
3.17e-01 |
4.12e-01 |
0.1310 |
NA |
-0.106000 |
0.076800 |
2.18e-01 |
3.73e-01 |
| Regulation of PLK1 Activity at G2/M Transition |
86 |
1.12e-01 |
1.79e-01 |
0.1300 |
NA |
0.127000 |
0.029300 |
4.17e-02 |
6.38e-01 |
| Cytochrome c-mediated apoptotic response |
13 |
7.20e-01 |
7.86e-01 |
0.1300 |
NA |
-0.099000 |
0.084400 |
5.37e-01 |
5.98e-01 |
| Deactivation of the beta-catenin transactivating complex |
40 |
3.62e-01 |
4.58e-01 |
0.1300 |
NA |
-0.127000 |
-0.029600 |
1.66e-01 |
7.46e-01 |
| Phospholipid metabolism |
167 |
1.56e-02 |
3.87e-02 |
0.1300 |
NA |
-0.112000 |
0.065800 |
1.27e-02 |
1.43e-01 |
| Growth hormone receptor signaling |
20 |
6.06e-01 |
6.86e-01 |
0.1300 |
NA |
0.098800 |
-0.084000 |
4.44e-01 |
5.16e-01 |
| Retinoid metabolism and transport |
38 |
3.86e-01 |
4.82e-01 |
0.1290 |
NA |
0.108000 |
0.070300 |
2.48e-01 |
4.53e-01 |
| Heme biosynthesis |
10 |
7.79e-01 |
8.31e-01 |
0.1290 |
NA |
0.045200 |
0.121000 |
8.05e-01 |
5.09e-01 |
| Glycogen metabolism |
25 |
5.38e-01 |
6.23e-01 |
0.1280 |
NA |
-0.078200 |
-0.102000 |
4.99e-01 |
3.79e-01 |
| eNOS activation |
11 |
7.64e-01 |
8.19e-01 |
0.1280 |
NA |
0.071000 |
-0.107000 |
6.84e-01 |
5.40e-01 |
| Dual Incision in GG-NER |
41 |
3.66e-01 |
4.61e-01 |
0.1280 |
NA |
0.127000 |
-0.019200 |
1.61e-01 |
8.32e-01 |
| Hedgehog ‘off’ state |
92 |
1.06e-01 |
1.72e-01 |
0.1280 |
NA |
-0.123000 |
0.035600 |
4.17e-02 |
5.56e-01 |
| Intrinsic Pathway for Apoptosis |
49 |
3.08e-01 |
4.03e-01 |
0.1270 |
NA |
-0.122000 |
0.034400 |
1.39e-01 |
6.77e-01 |
| Oncogenic MAPK signaling |
72 |
1.82e-01 |
2.65e-01 |
0.1260 |
NA |
-0.107000 |
0.067100 |
1.17e-01 |
3.25e-01 |
| Separation of Sister Chromatids |
162 |
2.31e-02 |
5.28e-02 |
0.1250 |
NA |
0.051100 |
-0.114000 |
2.62e-01 |
1.20e-02 |
| Interleukin-20 family signaling |
15 |
7.02e-01 |
7.71e-01 |
0.1250 |
NA |
0.125000 |
0.002050 |
4.01e-01 |
9.89e-01 |
| Antiviral mechanism by IFN-stimulated genes |
80 |
1.53e-01 |
2.32e-01 |
0.1250 |
NA |
-0.106000 |
-0.066700 |
1.02e-01 |
3.03e-01 |
| Interleukin-6 signaling |
10 |
7.91e-01 |
8.41e-01 |
0.1250 |
NA |
-0.125000 |
0.006050 |
4.94e-01 |
9.74e-01 |
| Translesion Synthesis by POLH |
19 |
6.40e-01 |
7.18e-01 |
0.1250 |
NA |
0.075200 |
0.099700 |
5.71e-01 |
4.52e-01 |
| Inflammasomes |
17 |
6.73e-01 |
7.43e-01 |
0.1250 |
NA |
-0.002260 |
0.125000 |
9.87e-01 |
3.73e-01 |
| DNA Replication |
122 |
5.97e-02 |
1.10e-01 |
0.1250 |
NA |
0.125000 |
-0.000644 |
1.76e-02 |
9.90e-01 |
| VxPx cargo-targeting to cilium |
18 |
6.61e-01 |
7.32e-01 |
0.1240 |
NA |
-0.091600 |
0.084000 |
5.01e-01 |
5.37e-01 |
| p130Cas linkage to MAPK signaling for integrins |
13 |
7.42e-01 |
7.99e-01 |
0.1240 |
NA |
0.019700 |
-0.122000 |
9.02e-01 |
4.45e-01 |
| RNA Polymerase II Transcription |
1138 |
2.72e-11 |
7.03e-10 |
0.1240 |
NA |
-0.026800 |
-0.121000 |
1.31e-01 |
1.04e-11 |
| Cytochrome P450 - arranged by substrate type |
41 |
3.94e-01 |
4.89e-01 |
0.1230 |
NA |
0.090100 |
-0.084500 |
3.18e-01 |
3.50e-01 |
| SLC transporter disorders |
68 |
2.12e-01 |
3.01e-01 |
0.1230 |
NA |
-0.063300 |
-0.106000 |
3.67e-01 |
1.32e-01 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks |
46 |
3.52e-01 |
4.49e-01 |
0.1230 |
NA |
-0.034100 |
-0.118000 |
6.89e-01 |
1.66e-01 |
| Cell Cycle Checkpoints |
254 |
3.80e-03 |
1.31e-02 |
0.1220 |
NA |
0.116000 |
-0.037100 |
1.45e-03 |
3.09e-01 |
| TP53 Regulates Transcription of DNA Repair Genes |
58 |
2.75e-01 |
3.71e-01 |
0.1220 |
NA |
-0.064500 |
-0.103000 |
3.96e-01 |
1.74e-01 |
| Signaling by Hippo |
20 |
6.42e-01 |
7.18e-01 |
0.1220 |
NA |
-0.118000 |
-0.027800 |
3.60e-01 |
8.30e-01 |
| Cytokine Signaling in Immune system |
478 |
3.59e-05 |
2.89e-04 |
0.1210 |
NA |
-0.120000 |
-0.016500 |
7.51e-06 |
5.37e-01 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) |
14 |
7.35e-01 |
7.94e-01 |
0.1210 |
NA |
-0.078000 |
-0.092300 |
6.13e-01 |
5.50e-01 |
| DNA Repair |
286 |
2.23e-03 |
8.76e-03 |
0.1210 |
NA |
0.102000 |
-0.063900 |
2.97e-03 |
6.34e-02 |
| Transcriptional Regulation by TP53 |
345 |
6.41e-04 |
3.09e-03 |
0.1200 |
NA |
-0.093400 |
-0.075600 |
2.94e-03 |
1.62e-02 |
| Immune System |
1388 |
2.11e-12 |
6.21e-11 |
0.1190 |
NA |
-0.115000 |
0.031500 |
1.44e-12 |
5.21e-02 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells |
15 |
7.29e-01 |
7.91e-01 |
0.1190 |
NA |
0.031100 |
-0.115000 |
8.35e-01 |
4.43e-01 |
| Peptide ligand-binding receptors |
47 |
3.73e-01 |
4.69e-01 |
0.1190 |
NA |
-0.044200 |
0.110000 |
6.00e-01 |
1.92e-01 |
| Transport of bile salts and organic acids, metal ions and amine compounds |
58 |
2.98e-01 |
3.92e-01 |
0.1180 |
NA |
-0.118000 |
-0.011400 |
1.22e-01 |
8.81e-01 |
| Adaptive Immune System |
565 |
1.61e-05 |
1.44e-04 |
0.1160 |
NA |
-0.113000 |
0.026000 |
4.55e-06 |
2.92e-01 |
| Apoptotic cleavage of cellular proteins |
32 |
5.30e-01 |
6.16e-01 |
0.1150 |
NA |
-0.114000 |
-0.014800 |
2.64e-01 |
8.85e-01 |
| STING mediated induction of host immune responses |
12 |
7.88e-01 |
8.37e-01 |
0.1150 |
NA |
-0.028800 |
-0.111000 |
8.63e-01 |
5.04e-01 |
| Interleukin-15 signaling |
14 |
7.59e-01 |
8.15e-01 |
0.1150 |
NA |
-0.071600 |
0.090000 |
6.43e-01 |
5.60e-01 |
| Switching of origins to a post-replicative state |
86 |
1.85e-01 |
2.67e-01 |
0.1150 |
NA |
-0.002350 |
-0.115000 |
9.70e-01 |
6.61e-02 |
| Organelle biogenesis and maintenance |
248 |
7.91e-03 |
2.34e-02 |
0.1150 |
NA |
0.080100 |
0.082000 |
3.02e-02 |
2.65e-02 |
| Oxidative Stress Induced Senescence |
77 |
2.27e-01 |
3.19e-01 |
0.1140 |
NA |
-0.112000 |
-0.018800 |
8.96e-02 |
7.76e-01 |
| The citric acid (TCA) cycle and respiratory electron transport |
152 |
5.42e-02 |
1.03e-01 |
0.1140 |
NA |
-0.018000 |
-0.112000 |
7.02e-01 |
1.72e-02 |
| DNA Double Strand Break Response |
47 |
4.04e-01 |
4.95e-01 |
0.1130 |
NA |
-0.047700 |
-0.103000 |
5.72e-01 |
2.23e-01 |
| SLBP independent Processing of Histone Pre-mRNAs |
10 |
8.27e-01 |
8.64e-01 |
0.1130 |
NA |
0.082300 |
-0.077100 |
6.52e-01 |
6.73e-01 |
| Reproduction |
72 |
2.54e-01 |
3.49e-01 |
0.1130 |
NA |
0.085400 |
0.073500 |
2.11e-01 |
2.81e-01 |
| M Phase |
322 |
2.54e-03 |
9.75e-03 |
0.1130 |
NA |
0.058600 |
-0.096100 |
7.12e-02 |
3.10e-03 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function |
51 |
3.81e-01 |
4.76e-01 |
0.1120 |
NA |
-0.104000 |
-0.043500 |
2.01e-01 |
5.91e-01 |
| RUNX3 regulates NOTCH signaling |
14 |
7.69e-01 |
8.23e-01 |
0.1120 |
NA |
-0.111000 |
0.012100 |
4.71e-01 |
9.38e-01 |
| Orc1 removal from chromatin |
67 |
2.83e-01 |
3.78e-01 |
0.1120 |
NA |
-0.061500 |
-0.093600 |
3.84e-01 |
1.85e-01 |
| Triglyceride biosynthesis |
11 |
8.13e-01 |
8.59e-01 |
0.1120 |
NA |
0.097000 |
0.055900 |
5.77e-01 |
7.48e-01 |
| Synthesis of PE |
11 |
8.15e-01 |
8.60e-01 |
0.1110 |
NA |
-0.100000 |
-0.047900 |
5.65e-01 |
7.83e-01 |
| Interconversion of nucleotide di- and triphosphates |
26 |
6.21e-01 |
6.98e-01 |
0.1110 |
NA |
0.032100 |
-0.106000 |
7.77e-01 |
3.49e-01 |
| Synthesis of DNA |
115 |
1.24e-01 |
1.95e-01 |
0.1100 |
NA |
0.107000 |
-0.026200 |
4.70e-02 |
6.28e-01 |
| Oncogene Induced Senescence |
34 |
5.38e-01 |
6.23e-01 |
0.1100 |
NA |
-0.042500 |
-0.102000 |
6.68e-01 |
3.05e-01 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template |
38 |
5.01e-01 |
5.91e-01 |
0.1100 |
NA |
0.047400 |
0.099300 |
6.13e-01 |
2.90e-01 |
| Transport of vitamins, nucleosides, and related molecules |
33 |
5.53e-01 |
6.36e-01 |
0.1090 |
NA |
0.106000 |
0.028800 |
2.94e-01 |
7.75e-01 |
| Stimuli-sensing channels |
58 |
3.56e-01 |
4.52e-01 |
0.1090 |
NA |
-0.094800 |
0.054600 |
2.12e-01 |
4.72e-01 |
| SIRT1 negatively regulates rRNA expression |
23 |
6.65e-01 |
7.35e-01 |
0.1090 |
NA |
-0.025500 |
-0.106000 |
8.32e-01 |
3.80e-01 |
| Signaling by FGFR in disease |
50 |
4.14e-01 |
5.05e-01 |
0.1090 |
NA |
-0.101000 |
0.040600 |
2.17e-01 |
6.20e-01 |
| Formation of apoptosome |
11 |
8.24e-01 |
8.64e-01 |
0.1080 |
NA |
-0.104000 |
0.031500 |
5.51e-01 |
8.56e-01 |
| Regulation of the apoptosome activity |
11 |
8.24e-01 |
8.64e-01 |
0.1080 |
NA |
-0.104000 |
0.031500 |
5.51e-01 |
8.56e-01 |
| Detoxification of Reactive Oxygen Species |
27 |
6.25e-01 |
7.02e-01 |
0.1080 |
NA |
-0.066200 |
-0.084900 |
5.52e-01 |
4.45e-01 |
| Regulation of IFNG signaling |
13 |
8.01e-01 |
8.48e-01 |
0.1070 |
NA |
0.092200 |
-0.054500 |
5.65e-01 |
7.34e-01 |
| Signaling by BRAF and RAF fusions |
58 |
3.75e-01 |
4.71e-01 |
0.1070 |
NA |
-0.073800 |
0.077100 |
3.31e-01 |
3.10e-01 |
| Cell Cycle |
555 |
1.19e-04 |
7.70e-04 |
0.1060 |
NA |
0.102000 |
-0.029000 |
4.21e-05 |
2.45e-01 |
| Synthesis of IP2, IP, and Ins in the cytosol |
13 |
8.05e-01 |
8.52e-01 |
0.1050 |
NA |
0.080900 |
0.067200 |
6.13e-01 |
6.75e-01 |
| Caspase activation via extrinsic apoptotic signalling pathway |
22 |
6.94e-01 |
7.62e-01 |
0.1050 |
NA |
-0.043500 |
-0.095700 |
7.24e-01 |
4.37e-01 |
| Degradation of the extracellular matrix |
68 |
3.27e-01 |
4.22e-01 |
0.1050 |
NA |
-0.049400 |
0.092800 |
4.81e-01 |
1.86e-01 |
| Translesion synthesis by REV1 |
16 |
7.67e-01 |
8.21e-01 |
0.1050 |
NA |
0.029300 |
0.101000 |
8.39e-01 |
4.85e-01 |
| Formation of the Early Elongation Complex |
33 |
5.79e-01 |
6.62e-01 |
0.1050 |
NA |
-0.103000 |
-0.019500 |
3.05e-01 |
8.46e-01 |
| Formation of the HIV-1 Early Elongation Complex |
33 |
5.79e-01 |
6.62e-01 |
0.1050 |
NA |
-0.103000 |
-0.019500 |
3.05e-01 |
8.46e-01 |
| Pyruvate metabolism |
25 |
6.62e-01 |
7.33e-01 |
0.1050 |
NA |
0.058500 |
0.086800 |
6.13e-01 |
4.53e-01 |
| Interleukin-4 and Interleukin-13 signaling |
65 |
3.46e-01 |
4.43e-01 |
0.1040 |
NA |
-0.099000 |
-0.033100 |
1.68e-01 |
6.45e-01 |
| Transcriptional Regulation by MECP2 |
46 |
4.76e-01 |
5.64e-01 |
0.1040 |
NA |
-0.103000 |
0.015500 |
2.28e-01 |
8.56e-01 |
| Xenobiotics |
15 |
7.85e-01 |
8.36e-01 |
0.1030 |
NA |
0.067900 |
0.078000 |
6.49e-01 |
6.01e-01 |
| IL-6-type cytokine receptor ligand interactions |
13 |
8.13e-01 |
8.59e-01 |
0.1030 |
NA |
-0.092100 |
-0.045600 |
5.65e-01 |
7.76e-01 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter |
28 |
6.42e-01 |
7.18e-01 |
0.1030 |
NA |
-0.091200 |
-0.047000 |
4.04e-01 |
6.67e-01 |
| RNA Polymerase I Transcription Termination |
31 |
6.14e-01 |
6.93e-01 |
0.1030 |
NA |
0.011000 |
-0.102000 |
9.16e-01 |
3.26e-01 |
| Generic Transcription Pathway |
1019 |
3.51e-07 |
4.93e-06 |
0.1020 |
NA |
-0.011200 |
-0.101000 |
5.51e-01 |
6.09e-08 |
| Cell Cycle, Mitotic |
461 |
9.95e-04 |
4.42e-03 |
0.1020 |
NA |
0.091700 |
-0.043700 |
7.70e-04 |
1.09e-01 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) |
78 |
3.02e-01 |
3.96e-01 |
0.1010 |
NA |
-0.038500 |
-0.093600 |
5.57e-01 |
1.53e-01 |
| Ca2+ pathway |
47 |
5.03e-01 |
5.91e-01 |
0.0991 |
NA |
-0.045900 |
0.087900 |
5.86e-01 |
2.97e-01 |
| Collagen degradation |
23 |
7.13e-01 |
7.79e-01 |
0.0990 |
NA |
-0.011200 |
-0.098300 |
9.26e-01 |
4.14e-01 |
| Integrin alphaIIb beta3 signaling |
24 |
7.04e-01 |
7.71e-01 |
0.0989 |
NA |
-0.097900 |
0.013800 |
4.06e-01 |
9.07e-01 |
| Integrin signaling |
24 |
7.04e-01 |
7.71e-01 |
0.0989 |
NA |
-0.097900 |
0.013800 |
4.06e-01 |
9.07e-01 |
| Metalloprotease DUBs |
22 |
7.28e-01 |
7.91e-01 |
0.0982 |
NA |
0.021000 |
-0.096000 |
8.65e-01 |
4.36e-01 |
| Cellular Senescence |
139 |
1.37e-01 |
2.12e-01 |
0.0979 |
NA |
-0.038800 |
-0.089900 |
4.31e-01 |
6.75e-02 |
| Triglyceride metabolism |
23 |
7.20e-01 |
7.86e-01 |
0.0978 |
NA |
-0.028200 |
0.093600 |
8.15e-01 |
4.37e-01 |
| Signaling by Rho GTPases |
346 |
8.74e-03 |
2.51e-02 |
0.0968 |
NA |
-0.033700 |
0.090700 |
2.82e-01 |
3.84e-03 |
| Regulation of TP53 Activity through Phosphorylation |
86 |
3.01e-01 |
3.95e-01 |
0.0968 |
NA |
0.096700 |
-0.001060 |
1.21e-01 |
9.86e-01 |
| Metal ion SLC transporters |
22 |
7.38e-01 |
7.95e-01 |
0.0963 |
NA |
-0.084200 |
0.046800 |
4.94e-01 |
7.04e-01 |
| Metabolism of steroid hormones |
22 |
7.36e-01 |
7.94e-01 |
0.0962 |
NA |
0.082700 |
0.049200 |
5.02e-01 |
6.90e-01 |
| NOD1/2 Signaling Pathway |
31 |
6.56e-01 |
7.29e-01 |
0.0952 |
NA |
-0.088700 |
-0.034400 |
3.93e-01 |
7.40e-01 |
| Negative regulators of DDX58/IFIH1 signaling |
33 |
6.42e-01 |
7.18e-01 |
0.0949 |
NA |
-0.044700 |
0.083700 |
6.57e-01 |
4.05e-01 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) |
11 |
8.65e-01 |
8.96e-01 |
0.0940 |
NA |
-0.033200 |
0.088000 |
8.49e-01 |
6.13e-01 |
| Laminin interactions |
21 |
7.59e-01 |
8.15e-01 |
0.0937 |
NA |
0.000923 |
0.093700 |
9.94e-01 |
4.57e-01 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression |
14 |
8.36e-01 |
8.70e-01 |
0.0923 |
NA |
-0.030700 |
-0.087000 |
8.42e-01 |
5.73e-01 |
| Downregulation of ERBB2 signaling |
24 |
7.37e-01 |
7.95e-01 |
0.0919 |
NA |
-0.086100 |
-0.032400 |
4.66e-01 |
7.84e-01 |
| Protein ubiquitination |
70 |
4.16e-01 |
5.07e-01 |
0.0913 |
NA |
-0.077700 |
-0.048100 |
2.61e-01 |
4.87e-01 |
| Transcriptional Regulation by E2F6 |
34 |
6.56e-01 |
7.29e-01 |
0.0912 |
NA |
0.011300 |
-0.090500 |
9.09e-01 |
3.62e-01 |
| Citric acid cycle (TCA cycle) |
21 |
7.71e-01 |
8.25e-01 |
0.0908 |
NA |
-0.029900 |
-0.085700 |
8.12e-01 |
4.97e-01 |
| Plasma lipoprotein assembly, remodeling, and clearance |
63 |
4.64e-01 |
5.54e-01 |
0.0903 |
NA |
-0.089800 |
-0.009210 |
2.18e-01 |
8.99e-01 |
| Gluconeogenesis |
30 |
6.94e-01 |
7.62e-01 |
0.0900 |
NA |
0.017400 |
0.088300 |
8.69e-01 |
4.02e-01 |
| G2/M Checkpoints |
137 |
1.97e-01 |
2.82e-01 |
0.0894 |
NA |
0.087700 |
-0.017200 |
7.65e-02 |
7.28e-01 |
| Assembly of the pre-replicative complex |
65 |
4.60e-01 |
5.50e-01 |
0.0891 |
NA |
-0.063900 |
-0.062200 |
3.73e-01 |
3.86e-01 |
| Pre-NOTCH Expression and Processing |
64 |
4.68e-01 |
5.57e-01 |
0.0890 |
NA |
-0.088500 |
-0.009870 |
2.21e-01 |
8.91e-01 |
| E3 ubiquitin ligases ubiquitinate target proteins |
51 |
5.46e-01 |
6.30e-01 |
0.0889 |
NA |
-0.058500 |
-0.066900 |
4.70e-01 |
4.08e-01 |
| Amyloid fiber formation |
53 |
5.38e-01 |
6.23e-01 |
0.0884 |
NA |
0.012600 |
0.087500 |
8.74e-01 |
2.71e-01 |
| S Phase |
155 |
1.70e-01 |
2.52e-01 |
0.0879 |
NA |
0.067000 |
-0.056900 |
1.50e-01 |
2.22e-01 |
| Meiosis |
63 |
4.84e-01 |
5.72e-01 |
0.0878 |
NA |
0.087600 |
0.005510 |
2.29e-01 |
9.40e-01 |
| Transcription of the HIV genome |
64 |
4.80e-01 |
5.68e-01 |
0.0875 |
NA |
-0.086900 |
-0.010300 |
2.29e-01 |
8.87e-01 |
| RNA Polymerase I Promoter Escape |
46 |
5.91e-01 |
6.73e-01 |
0.0873 |
NA |
-0.012300 |
-0.086500 |
8.85e-01 |
3.11e-01 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways |
47 |
5.90e-01 |
6.72e-01 |
0.0868 |
NA |
-0.079200 |
0.035400 |
3.48e-01 |
6.75e-01 |
| Diseases associated with glycosylation precursor biosynthesis |
18 |
8.22e-01 |
8.64e-01 |
0.0854 |
NA |
-0.036700 |
0.077200 |
7.88e-01 |
5.71e-01 |
| Regulation of TP53 Activity through Association with Co-factors |
12 |
8.78e-01 |
9.07e-01 |
0.0854 |
NA |
-0.066000 |
0.054100 |
6.92e-01 |
7.46e-01 |
| Formation of tubulin folding intermediates by CCT/TriC |
23 |
7.81e-01 |
8.32e-01 |
0.0847 |
NA |
0.005680 |
0.084500 |
9.62e-01 |
4.83e-01 |
| Synthesis of glycosylphosphatidylinositol (GPI) |
17 |
8.34e-01 |
8.69e-01 |
0.0845 |
NA |
0.084200 |
-0.006660 |
5.48e-01 |
9.62e-01 |
| Regulation of MECP2 expression and activity |
29 |
7.33e-01 |
7.93e-01 |
0.0843 |
NA |
-0.060200 |
-0.059000 |
5.75e-01 |
5.82e-01 |
| Gap-filling DNA repair synthesis and ligation in TC-NER |
64 |
5.14e-01 |
6.02e-01 |
0.0834 |
NA |
-0.009990 |
-0.082800 |
8.90e-01 |
2.52e-01 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 |
19 |
8.25e-01 |
8.64e-01 |
0.0822 |
NA |
-0.077800 |
-0.026500 |
5.57e-01 |
8.41e-01 |
| Apoptotic execution phase |
43 |
6.48e-01 |
7.23e-01 |
0.0819 |
NA |
-0.065600 |
-0.049000 |
4.57e-01 |
5.79e-01 |
| Metabolism of fat-soluble vitamins |
42 |
6.57e-01 |
7.29e-01 |
0.0816 |
NA |
0.044400 |
0.068500 |
6.19e-01 |
4.43e-01 |
| AKT phosphorylates targets in the nucleus |
10 |
9.06e-01 |
9.27e-01 |
0.0815 |
NA |
-0.045400 |
0.067700 |
8.04e-01 |
7.11e-01 |
| RHO GTPases Activate Formins |
115 |
3.30e-01 |
4.24e-01 |
0.0804 |
NA |
0.078600 |
0.017000 |
1.46e-01 |
7.54e-01 |
| PI3K events in ERBB2 signaling |
12 |
8.92e-01 |
9.18e-01 |
0.0797 |
NA |
-0.053100 |
-0.059400 |
7.50e-01 |
7.22e-01 |
| The NLRP3 inflammasome |
13 |
8.87e-01 |
9.16e-01 |
0.0781 |
NA |
0.055700 |
0.054700 |
7.28e-01 |
7.33e-01 |
| Glycerophospholipid biosynthesis |
97 |
4.26e-01 |
5.17e-01 |
0.0768 |
NA |
-0.002250 |
0.076800 |
9.69e-01 |
1.92e-01 |
| Regulation of TP53 Activity |
150 |
2.68e-01 |
3.64e-01 |
0.0767 |
NA |
-0.051000 |
-0.057300 |
2.82e-01 |
2.26e-01 |
| Platelet Aggregation (Plug Formation) |
28 |
7.84e-01 |
8.35e-01 |
0.0759 |
NA |
-0.060100 |
-0.046400 |
5.82e-01 |
6.71e-01 |
| Prefoldin mediated transfer of substrate to CCT/TriC |
27 |
7.97e-01 |
8.45e-01 |
0.0750 |
NA |
-0.071100 |
0.023800 |
5.22e-01 |
8.31e-01 |
| ERBB2 Regulates Cell Motility |
11 |
9.11e-01 |
9.31e-01 |
0.0749 |
NA |
-0.074200 |
-0.010200 |
6.70e-01 |
9.53e-01 |
| Condensation of Prophase Chromosomes |
27 |
8.00e-01 |
8.47e-01 |
0.0743 |
NA |
-0.003350 |
-0.074200 |
9.76e-01 |
5.04e-01 |
| Pentose phosphate pathway |
13 |
9.01e-01 |
9.24e-01 |
0.0731 |
NA |
0.069500 |
0.022400 |
6.64e-01 |
8.89e-01 |
| Cleavage of the damaged purine |
24 |
8.28e-01 |
8.64e-01 |
0.0724 |
NA |
0.072200 |
-0.005490 |
5.41e-01 |
9.63e-01 |
| Depurination |
24 |
8.28e-01 |
8.64e-01 |
0.0724 |
NA |
0.072200 |
-0.005490 |
5.41e-01 |
9.63e-01 |
| Recognition and association of DNA glycosylase with site containing an affected purine |
24 |
8.28e-01 |
8.64e-01 |
0.0724 |
NA |
0.072200 |
-0.005490 |
5.41e-01 |
9.63e-01 |
| Downregulation of ERBB2:ERBB3 signaling |
13 |
9.03e-01 |
9.25e-01 |
0.0723 |
NA |
-0.045100 |
-0.056500 |
7.78e-01 |
7.24e-01 |
| Signaling by BMP |
18 |
8.69e-01 |
9.00e-01 |
0.0723 |
NA |
0.018200 |
-0.069900 |
8.94e-01 |
6.07e-01 |
| Cyclin D associated events in G1 |
42 |
7.31e-01 |
7.91e-01 |
0.0708 |
NA |
-0.032000 |
0.063200 |
7.19e-01 |
4.79e-01 |
| G1 Phase |
42 |
7.31e-01 |
7.91e-01 |
0.0708 |
NA |
-0.032000 |
0.063200 |
7.19e-01 |
4.79e-01 |
| NoRC negatively regulates rRNA expression |
61 |
6.52e-01 |
7.27e-01 |
0.0686 |
NA |
-0.064400 |
0.023600 |
3.84e-01 |
7.50e-01 |
| Negative epigenetic regulation of rRNA expression |
64 |
6.43e-01 |
7.18e-01 |
0.0679 |
NA |
-0.067300 |
-0.008870 |
3.52e-01 |
9.02e-01 |
| Dual incision in TC-NER |
65 |
6.54e-01 |
7.29e-01 |
0.0660 |
NA |
-0.019000 |
-0.063200 |
7.92e-01 |
3.78e-01 |
| Senescence-Associated Secretory Phenotype (SASP) |
62 |
6.76e-01 |
7.46e-01 |
0.0649 |
NA |
-0.010700 |
-0.064100 |
8.84e-01 |
3.83e-01 |
| Metabolism of carbohydrates |
242 |
2.27e-01 |
3.19e-01 |
0.0644 |
NA |
-0.011400 |
0.063400 |
7.60e-01 |
8.99e-02 |
| G2/M Transition |
177 |
3.41e-01 |
4.37e-01 |
0.0642 |
NA |
0.026900 |
-0.058200 |
5.37e-01 |
1.82e-01 |
| Mitotic G2-G2/M phases |
179 |
3.39e-01 |
4.35e-01 |
0.0639 |
NA |
0.032100 |
-0.055300 |
4.59e-01 |
2.03e-01 |
| Nuclear signaling by ERBB4 |
19 |
8.93e-01 |
9.18e-01 |
0.0629 |
NA |
-0.041400 |
-0.047300 |
7.55e-01 |
7.21e-01 |
| IRF3-mediated induction of type I IFN |
10 |
9.42e-01 |
9.58e-01 |
0.0628 |
NA |
-0.062000 |
-0.010400 |
7.34e-01 |
9.55e-01 |
| DNA Damage/Telomere Stress Induced Senescence |
43 |
7.79e-01 |
8.31e-01 |
0.0624 |
NA |
0.007490 |
-0.061900 |
9.32e-01 |
4.82e-01 |
| DNA Damage Bypass |
47 |
7.61e-01 |
8.17e-01 |
0.0623 |
NA |
0.006200 |
0.061900 |
9.41e-01 |
4.63e-01 |
| TNFs bind their physiological receptors |
11 |
9.40e-01 |
9.57e-01 |
0.0611 |
NA |
0.059100 |
-0.015600 |
7.34e-01 |
9.29e-01 |
| RNA Pol II CTD phosphorylation and interaction with CE |
27 |
8.64e-01 |
8.96e-01 |
0.0602 |
NA |
-0.049100 |
0.034900 |
6.59e-01 |
7.53e-01 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection |
27 |
8.64e-01 |
8.96e-01 |
0.0602 |
NA |
-0.049100 |
0.034900 |
6.59e-01 |
7.53e-01 |
| Signaling by Retinoic Acid |
32 |
8.45e-01 |
8.79e-01 |
0.0594 |
NA |
0.053900 |
-0.024800 |
5.98e-01 |
8.08e-01 |
| RHO GTPase Effectors |
237 |
2.94e-01 |
3.88e-01 |
0.0592 |
NA |
-0.022000 |
0.055000 |
5.60e-01 |
1.46e-01 |
| Response to elevated platelet cytosolic Ca2+ |
107 |
5.90e-01 |
6.72e-01 |
0.0576 |
NA |
-0.007750 |
0.057100 |
8.90e-01 |
3.08e-01 |
| Metabolism |
1715 |
6.29e-04 |
3.07e-03 |
0.0566 |
NA |
0.002030 |
-0.056500 |
8.91e-01 |
1.24e-04 |
| Class I peroxisomal membrane protein import |
18 |
9.17e-01 |
9.37e-01 |
0.0566 |
NA |
0.009000 |
-0.055800 |
9.47e-01 |
6.82e-01 |
| Metabolism of nitric oxide: eNOS activation and regulation |
15 |
9.31e-01 |
9.49e-01 |
0.0563 |
NA |
-0.055500 |
0.009550 |
7.10e-01 |
9.49e-01 |
| PRC2 methylates histones and DNA |
28 |
8.76e-01 |
9.07e-01 |
0.0561 |
NA |
-0.006450 |
0.055800 |
9.53e-01 |
6.10e-01 |
| HIV Transcription Initiation |
45 |
8.28e-01 |
8.64e-01 |
0.0530 |
NA |
-0.020400 |
0.049000 |
8.13e-01 |
5.70e-01 |
| RNA Polymerase II HIV Promoter Escape |
45 |
8.28e-01 |
8.64e-01 |
0.0530 |
NA |
-0.020400 |
0.049000 |
8.13e-01 |
5.70e-01 |
| RNA Polymerase II Promoter Escape |
45 |
8.28e-01 |
8.64e-01 |
0.0530 |
NA |
-0.020400 |
0.049000 |
8.13e-01 |
5.70e-01 |
| RNA Polymerase II Transcription Initiation |
45 |
8.28e-01 |
8.64e-01 |
0.0530 |
NA |
-0.020400 |
0.049000 |
8.13e-01 |
5.70e-01 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance |
45 |
8.28e-01 |
8.64e-01 |
0.0530 |
NA |
-0.020400 |
0.049000 |
8.13e-01 |
5.70e-01 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening |
45 |
8.28e-01 |
8.64e-01 |
0.0530 |
NA |
-0.020400 |
0.049000 |
8.13e-01 |
5.70e-01 |
| Notch-HLH transcription pathway |
27 |
8.93e-01 |
9.18e-01 |
0.0530 |
NA |
0.000537 |
-0.053000 |
9.96e-01 |
6.33e-01 |
| Recognition of DNA damage by PCNA-containing replication complex |
30 |
8.87e-01 |
9.16e-01 |
0.0515 |
NA |
0.035000 |
0.037800 |
7.40e-01 |
7.20e-01 |
| Chaperonin-mediated protein folding |
81 |
7.31e-01 |
7.91e-01 |
0.0509 |
NA |
-0.050900 |
0.003000 |
4.29e-01 |
9.63e-01 |
| Depolymerisation of the Nuclear Lamina |
15 |
9.52e-01 |
9.67e-01 |
0.0464 |
NA |
-0.028200 |
-0.036900 |
8.50e-01 |
8.05e-01 |
| ADP signalling through P2Y purinoceptor 1 |
13 |
9.63e-01 |
9.75e-01 |
0.0443 |
NA |
-0.032400 |
0.030200 |
8.39e-01 |
8.50e-01 |
| mRNA Capping |
29 |
9.22e-01 |
9.41e-01 |
0.0433 |
NA |
-0.025300 |
0.035100 |
8.14e-01 |
7.43e-01 |
| Transcription of E2F targets under negative control by DREAM complex |
19 |
9.50e-01 |
9.65e-01 |
0.0424 |
NA |
0.042400 |
0.000454 |
7.49e-01 |
9.97e-01 |
| Platelet degranulation |
102 |
7.73e-01 |
8.26e-01 |
0.0412 |
NA |
-0.013400 |
0.038900 |
8.15e-01 |
4.97e-01 |
| Pre-NOTCH Transcription and Translation |
48 |
8.90e-01 |
9.18e-01 |
0.0402 |
NA |
-0.040200 |
-0.001450 |
6.30e-01 |
9.86e-01 |
| NOTCH4 Intracellular Domain Regulates Transcription |
18 |
9.58e-01 |
9.71e-01 |
0.0397 |
NA |
0.034700 |
0.019300 |
7.99e-01 |
8.87e-01 |
| Pyruvate metabolism and Citric Acid (TCA) cycle |
48 |
9.02e-01 |
9.24e-01 |
0.0380 |
NA |
0.037100 |
-0.008150 |
6.56e-01 |
9.22e-01 |
| Interferon Signaling |
156 |
7.23e-01 |
7.87e-01 |
0.0374 |
NA |
0.035800 |
0.010800 |
4.41e-01 |
8.16e-01 |
| RNA Polymerase I Promoter Opening |
18 |
9.64e-01 |
9.76e-01 |
0.0370 |
NA |
-0.030500 |
0.021000 |
8.23e-01 |
8.77e-01 |
| TP53 Regulates Transcription of Cell Cycle Genes |
48 |
9.09e-01 |
9.30e-01 |
0.0364 |
NA |
0.007630 |
-0.035600 |
9.27e-01 |
6.69e-01 |
| G1/S Transition |
127 |
7.94e-01 |
8.42e-01 |
0.0350 |
NA |
0.012800 |
-0.032600 |
8.04e-01 |
5.26e-01 |
| Protein folding |
87 |
8.57e-01 |
8.90e-01 |
0.0344 |
NA |
-0.033800 |
-0.006590 |
5.86e-01 |
9.15e-01 |
| Prostacyclin signalling through prostacyclin receptor |
10 |
9.83e-01 |
9.89e-01 |
0.0343 |
NA |
-0.032100 |
0.012100 |
8.61e-01 |
9.47e-01 |
| Amino acid synthesis and interconversion (transamination) |
27 |
9.56e-01 |
9.69e-01 |
0.0336 |
NA |
-0.031800 |
0.010900 |
7.75e-01 |
9.22e-01 |
| Cytosolic iron-sulfur cluster assembly |
11 |
9.83e-01 |
9.89e-01 |
0.0322 |
NA |
0.025200 |
-0.020000 |
8.85e-01 |
9.09e-01 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes |
23 |
9.66e-01 |
9.77e-01 |
0.0319 |
NA |
0.024600 |
-0.020300 |
8.39e-01 |
8.66e-01 |
| Packaging Of Telomere Ends |
20 |
9.72e-01 |
9.81e-01 |
0.0309 |
NA |
-0.010700 |
0.029000 |
9.34e-01 |
8.23e-01 |
| Interleukin-27 signaling |
10 |
9.86e-01 |
9.90e-01 |
0.0302 |
NA |
-0.026500 |
0.014500 |
8.85e-01 |
9.37e-01 |
| Glucose metabolism |
84 |
8.95e-01 |
9.20e-01 |
0.0297 |
NA |
-0.029700 |
-0.000616 |
6.38e-01 |
9.92e-01 |
| Mitotic G1-G1/S phases |
144 |
8.47e-01 |
8.81e-01 |
0.0278 |
NA |
0.027600 |
-0.003730 |
5.68e-01 |
9.38e-01 |
| Diseases associated with the TLR signaling cascade |
19 |
9.79e-01 |
9.86e-01 |
0.0275 |
NA |
0.024200 |
-0.013100 |
8.55e-01 |
9.21e-01 |
| Diseases of Immune System |
19 |
9.79e-01 |
9.86e-01 |
0.0275 |
NA |
0.024200 |
-0.013100 |
8.55e-01 |
9.21e-01 |
| Regulation of innate immune responses to cytosolic DNA |
13 |
9.88e-01 |
9.91e-01 |
0.0251 |
NA |
-0.015000 |
0.020100 |
9.26e-01 |
9.00e-01 |
| DNA Replication Pre-Initiation |
81 |
9.35e-01 |
9.52e-01 |
0.0236 |
NA |
0.023100 |
-0.004890 |
7.19e-01 |
9.39e-01 |
| Signaling by PDGF |
44 |
9.69e-01 |
9.79e-01 |
0.0220 |
NA |
0.012200 |
-0.018300 |
8.89e-01 |
8.34e-01 |
| Meiotic synapsis |
42 |
9.75e-01 |
9.84e-01 |
0.0201 |
NA |
-0.018200 |
0.008390 |
8.38e-01 |
9.25e-01 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding |
30 |
9.85e-01 |
9.89e-01 |
0.0187 |
NA |
-0.013300 |
0.013100 |
9.00e-01 |
9.01e-01 |
| Nucleobase catabolism |
29 |
9.90e-01 |
9.92e-01 |
0.0155 |
NA |
0.009960 |
-0.011800 |
9.26e-01 |
9.12e-01 |
| Aflatoxin activation and detoxification |
16 |
9.96e-01 |
9.97e-01 |
0.0131 |
NA |
-0.010100 |
0.008420 |
9.44e-01 |
9.53e-01 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs |
11 |
9.97e-01 |
9.97e-01 |
0.0127 |
NA |
-0.003180 |
-0.012300 |
9.85e-01 |
9.44e-01 |
| Glycogen breakdown (glycogenolysis) |
15 |
9.97e-01 |
9.97e-01 |
0.0113 |
NA |
-0.010500 |
0.004190 |
9.44e-01 |
9.78e-01 |
| Metabolism of lipids |
595 |
8.98e-01 |
9.22e-01 |
0.0112 |
NA |
-0.011000 |
-0.001930 |
6.48e-01 |
9.36e-01 |